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Summary 
 
Considerable progress has been made to increase the success rate of bringing new 
therapeutics to the market by implementation of drug metabolism and pharmacokinetics 
(DMPK) screening strategies in early drug discovery. DMPK screenings help to select leads 
with good oral bioavailability, low clearance, optimal half-life, and a desirable metabolic 
profile. 
 
In previous studies with natural products, the flavonoids kaempferol and quercetin, and the 
alkaloid piperine have been characterized in vivo as central nervous system (CNS) acting 
compounds. To gain a better understanding of anxiolytic effects reported for the flavonoids, 
PK studies after oral and intravenous administrations in rats were conducted. UHPLC-
MS/MS methods for quantification of the compounds of interest in rat plasma were 
developed and validated according to the principles of regulatory guidelines for industry to 
support PK studies. The validated methods were successfully applied to determine the 
concentration levels of the analytes in rat plasma, and PK parameters were calculated with 
the aid of the industry standard software WinNonlin. The findings suggest that poor oral 
bioavailability and extensive first-pass metabolism limit plasma exposure of kaempferol. 
After oral administration, the compound was found as phase II conjugates in plasma. Upon 
intravenous application, kaempferol was rapidly cleared (4-6 l/h/kg), demonstrating an 
extremely short half-life of around 4 min. Based on the results, it is more likely that the 
anxiolytic effect reported for this flavonoid is rather attributed to its metabolites. The major 
colonic metabolites of kaempferol and quercetin are 4-hydroxyphenylacetic acid (4-HPAA), 
3-hydroxyphenylacetic acid (3-HPAA), and 3,4-dihydroxyphenylacetic acid (DOPAC). 
Moreover, anxiolytic activity has been reported for 4-HPAA and DOPAC. Thus, we aimed to 
obtain PK profiles of the metabolites upon intravenous application. It has been found that the 
metabolites were rapidly eliminated with a half-life of 20-30 min, so that effective 
concentrations in the brain do not appear to be reached. Taken together, it is not clear at this 
moment how the anxiolytic-like properties can be explained. 
 
During a screening of natural products for γ-aminobutyric acid type A (GABAA) receptor 
activity, piperine was characterized as a positive allosteric modulator targeting a 
benzodiazepine-independent binding site. Due to pharmacological promiscuity of piperine, its 
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structure was systematically modified, and a library of piperine analogs was prepared. The 
most potent and efficacious analogs were identified from in vitro and in vivo studies. The 
information on metabolically labile sites of the selected analogs was needed to guide further 
lead optimization process. Thus, the objective of the second part of the PhD thesis was to 
investigate metabolism of the selected analogs. UHPLC-MS/MS methods for quantification 
of piperine and its analogs were initially developed to support in vitro metabolism studies. 
Microsomal stability assays revealed piperine as the metabolically most stable compound, 
whereas its analogs demonstrated high metabolic liability. To obtain metabolite profiles of 
the test compounds after incubation with human microsomes, UHPLC-Q-TOF-MS methods 
were developed. The high resolution accurate mass data were further processed with the aid 
of MetID software Mass-MetaSite. The principal routes of oxidative metabolism were found 
to be aliphatic hydroxylation, and N- and O-dealkylation. Additionally, CYP450 reaction 
phenotyping was performed to determine which CYP isozymes are involved in the 
metabolism of piperine and its analogs. It appeared that piperine was exclusively metabolized 
by CYP1A2, whereas CYP2C9 contributed significantly in the oxidative metabolism of all 
analogs. Moreover, extensive binding to blood constituents was observed for all compounds. 
Our findings showed that analogs were rapidly metabolized and demonstrated strong binding 
to blood constituents due to increased lipophilicity. The next cycle of medicinal chemistry 
optimizations should, therefore, be focused on reducing lipophilicity to lower metabolic 
liability and extensive binding of analogs. 
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Zusammenfassung 
 
Es wurden beträchtliche Fortschritte gemacht, um die Erfolgschancen bei der Einführung 
neuer Therapeutika auf den Markt zu erhöhen indem schon bei dem Screening von 
Leitstrukturen der Arzneimittel-Metabolismus und die Pharmakokinetik (DMPK) untersucht 
werden. DMPK Screenings sind geeignet, Leads, mit einer guten oralen Bioverfügbarkeit, 
niedrigerer Clearance, optimaler Halbwertszeit und einem wünschenswerten metabolischen 
Profil zu identifizieren. 
 
In früheren Studien mit Naturstoffen wurden die Flavonoide Kaempferol und Quercetin, 
sowie das Alkaloid Piperin in vivo als auf das Zentralnervensystem (ZNS) wirkende 
Verbindungen charakterisiert. Um ein besseres Verständnis von anxiolytischen Effekten der 
Flavonoide gewinnen zu können, wurden pharmakokinetische (PK) Studien nach oraler und 
intravenöser Verabreichung bei Ratten durchgeführt. Die UHPLC-MS/MS-Verfahren zur 
Quantifizierung der Verbindungen in Rattenplasma wurden für PK Studien nach 
regulatorischen Vorgaben der Industrie entwickelt und validiert. Die validierten Verfahren 
wurden erfolgreich angewendet, um die Konzentrationen der Analyten in Rattenplasma zu 
bestimmen. Die PK Parameter wurden nachfolgend mit Hilfe der Industrie Standard Software 
WinNonlin berechnet. Die Ergebnisse weisen darauf hin, dass eine schlechte orale 
Bioverfügbarkeit zusammen mit einem ausgeprägten First-Pass Metabolismus die 
Plasmakonzentration von Kaempferol begrenzt. Nach oraler Verabreichung wurde die 
Verbindung als Phase-II Konjugat im Plasma nachgewiesen. Bei intravenöser Verabreichung 
wurde eine sehr hohe Clearance beobachtet (4-6 l/h/kg), was in einer extrem kurzen 
Halbwertszeit von etwa 4 min resultierte. Basierend auf den Ergebnissen ist es 
wahrscheinlicher, dass die anxiolytische Wirkung nicht durch das Flavonoid selbst, sondern 
durch seine Metaboliten bedingt ist. Die Flavonoide Kaempferol und Quercetin werden durch 
die Darmflora in 4-Hydroxyphenylessigsäure (4-HPAA), 3-Hydroxyphenylessigsäure (3-
HPAA) und 3,4-Dihydroxyphenylessigsäure (DOPAC) umgewandelt. Daneben, wurde die 
anxiolytische Aktivität für 4-HPAA und DOPAC berichtet. Dementsprechend, wurde es 
notwendig PK Profile von den Metaboliten nach intravenöser Verabreichung zu erhalten. Es 
wurde herausgefunden, dass die entsprechenden Metaboliten mit einer Halbwertszeit von 20-
30 min eliminiert wurden, so dass pharmakologisch wirksame Konzentrationen im Gehirn 
15
unwahrscheinlich sind. Es ist daher noch nicht klar, wie die beobachteten anxiolytischen 
Effekte der Flavonoide erklärt werden können. 
In einem Screening von Naturstoffen mit γ-Aminobuttersäure Typ A (GABAA) Rezeptor-
aktivierenden Eigenschaften wurde Piperin als positiver allosterischer Modulator 
charakteriziert, der mit einer Benzodiazepin-unabhängigen Bindungsstelle interagiert. 
Aufgrund der promiskuitiven Pharmakologie von Piperin wurde die Struktur systematisch 
verändert und eine Bibliothek von Piperin-Derivaten hergestellt. Die wirksamsten Analoga 
wurden durch verschiedene in vitro und in vivo Studien identifiziert. Weitere Informationen 
in Bezug auf metabolisch labile Stellen der ausgewählten Analoga wurden benötigt, um 
weitere Schritte in der Lead-Optimierung zu planen. Aus diesem Grund war das Ziel des 
zweiten Teils der Dissertation, den Metabolismus von ausgewählten Analoga zu untersuchen. 
Zunächst wurden UHPLC-MS/MS-Verfahren zur Quantifizierung von Piperin und seiner 
Analoga entwickelt, um in vitro-Metabolismus-Studien durchführen zu können. In 
mikrosomalen Stabilitätsassays erwies sich Piperin als metabolisch stabilste Verbindung, 
während seine Analoga hohe metabolische Anfälligkeit zeigten. Nach der Inkubation von 
Test-Verbindungen mit humanen Mikrosomen wurden ihre Metabolitprofile mittels UHPLC-
Q-TOF-MS aufgenommen. Die somit erhaltenen Daten wurden mit Hilfe der MetID Software 
Mass-MetaSite verarbeitet. Im oxidativen Stoffwechsel wurden drei Hauptwege identifiziert: 
aliphatische Hydroxylierung, N- und O-Dealkylierung. Zusätzlich wurde eine 
Phänotypisierung der CYP450-Reaktion durchgeführt um festzustellen, welche CYP-
Isoenzyme am Stoffwechsel von Piperin und der Piperin-Analoga beteiligt sind. Es zeigte 
sich, dass Piperin ausschließlich durch CYP1A2 metabolisiert wird, während CYP2C9 
deutlich zum oxidativen Stoffwechsel aller Piperin-Analoga beiträgt. Darüber hinaus wurde 
für alle getesteten Verbindungen eine starke Bindung an Blutbestandteile beobachtet. Unsere 
Ergebnisse zeigten, dass Piperin-Analoga schnell metabolisiert wurden und aufgrund der 
höheren Lipophilie eine starke Bindung an Blutbestandteile  aufweisen. Der nächste Schritt in 
der medizinalchemischen Strukturoptimierung sollte daher auf eine Verringerung der 
Lipophilie fokussieren, um die Metabolisierung und die Bindung an Blutbestandteile der 
Piperin-Analoga zu verringern. 
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In previous studies with natural products, the flavonoids kaempferol and quercetin, and the 
alkaloid piperine have been characterized in vivo as central nervous system (CNS) acting 
compounds. It has been shown that kaempferol and quercetin exert anxiolytic activity in mice 
upon oral administration, while no behavioral changes were observed upon intraperitoneal 
administration, or upon oral administration in gut sterilized animals (1). Thus, it appeared that 
these flavonoids have to undergo metabolic transformations to pharmacologically active 
metabolites. The major colonic metabolites of kaempferol and quercetin are 4-
hydroxyphenylacetic acid (4-HPAA), 3-hydroxyphenylacetic acid (3-HPAA), and 3,4-
dihydroxyphenylacetic acid (DOPAC) (2, 3). Anxiolytic activity upon intraperitoneal 
administration has been reported for 4-HPAA and DOPAC (1). Knowledge of 
pharmacokinetic (PK) profiles of all compounds was required for a better understanding of 
their pharmacological effects, and thus PK studies in rats were conducted with the aim to 
evaluate PK properties of the compounds after oral and intravenous administrations. 
 
At first, we aimed to develop UHPLC-MS/MS methods for quantification of the compounds 
of interest in lithium heparinized Sprague-Dawley rat plasma. Thereafter, bioanalytical 
methods were validated following the principles of regulatory guidelines for industry to 
demonstrate reliability, reproducibility, and robustness for quantitative measurements in a 
given matrix (4, 5). The validated methods were later applied to determine the concentration 
levels of the analytes in rat plasma, and PK parameters were calculated for each compound 
with the industry standard software WinNonlin using non-compartmental and compartmental 
analyses. 
 
Furthermore, during a screening of natural products for γ-aminobutyric acid type A (GABAA) 
receptor activity, piperine was identified as a positive allosteric modulator targeting a 
benzodiazepine-independent binding site (6). However, piperine is also an activator of 
TRPV1 receptors (transient receptor potential vanilloid type 1) involved in pain signaling and 
thermoregulation. Therefore, the structure of piperine was systematically modified to dissect 
GABAA and TRPV1 activating properties, and a library of piperine analogs was prepared (7, 
8). The most potent and efficacious analogs were selected from in vitro and in vivo studies (8, 
9). The information on metabolically labile sites of the selected analogs was needed to guide 
further lead optimization process. Thus, the objective of the second part of the PhD thesis 
was to investigate metabolism of the selected analogs. 
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In a first step, we aimed to develop specific and robust UHPLC-MS/MS methods for 
quantification of the compounds of interest in potassium phosphate buffer. These methods 
were later applied to support microsomal stability assays with the analogs, and the generated 
data were used for calculation of in vitro intrinsic clearances. In a second step, we developed 
UHPLC-Q-TOF-MS methods for qualitative analysis of metabolite profiles obtained after 
incubation of the analogs with human liver microsomes, and identified the metabolites with 
the aid of MetID software Mass-MetaSite. 
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2.1 The current state of CNS drug discovery and development 
 
Disorders of the central nervous system (CNS) continue to be the most devastating illnesses 
afflicting humanity. According to the World Health Organization (WHO), neurological 
disorders affect up to one billion people worldwide (1). In Europe, the economic cost of 
neurological disorders was estimated at €798 billion in 2010 (2). The WHO estimates that 
over 18 million people in the world suffer from Alzheimer's disease, and projections are for 
34 million cases by 2025 (3). Parkinson’s disease affects about 5 million people (4), while 2.5 
million have been diagnosed with multiple sclerosis (5), and 120 million suffer from 
depression (6). The extremely high impact of mental illnesses at the personal, social, and 
economic levels underscores the urgent need for development of new, and better CNS drugs. 
CNS drug discovery and development is a long, complex and financially risky process. The 
low probability of success for CNS drugs is attributable to the complexity of the brain, and to 
the blood-brain barrier (BBB) with its active drug efflux transporters (e.g. P- glycoprotein). 
Only 2% of small molecules can cross the BBB and achieve effective therapeutic 
concentrations in the brain (7). The time to get a new CNS drug to the market takes 13-16 
years, whereas for a non-CNS drug it takes 10-12 years (8). Development of CNS drugs costs 
more than for drugs in any other therapeutic area, yet it has the highest attrition rate. More 
than 90% of the CNS drug candidates are abandoned during phases I or II of clinical trials. 
Despite this, the CNS therapeutic area comprises approximately 15% of total pharmaceutical 
sales, representing about $50 billion per annum globally (9). Current CNS medicines can 
relieve symptoms in people with various CNS disorders, but a large number of individuals 
either do not respond to existing therapies, or the level of improvement from medicinal 
treatment does not significantly enhance their quality of life. Therefore, new generations of 
CNS drugs providing higher benefits to patients are urgently needed. 
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2.2 Natural products as a source of CNS-active compounds 
 
 
„It is clear Nature will continue to be  
a major source of new structural leads (...)” 
-Gordon M. Cragg and David J. Newman, BBA General Subjects, p. 3670 
 
Mankind has always relied on Nature to fulfill their basic needs, one of which is remedies for 
the treatment of a wide variety of illnesses (10). In particular, plants as remedies have been 
used over thousands of years and have formed the basis of sophisticated traditional medical 
systems (10). The first records on medicinal properties of plants, written on Assyrian clay 
tablets, are dated from about 2000 B.C. In Europe, the use of plants for medicinal purposes 
was described in the works of Hippocrates (5
th
 century B.C.), Dioscorides (1
st
 century A.D.) 
and Galen (2
nd
 century A.D.) (11). Centuries later, Paracelsus (1493-1541) developed the first 
idea of active principles contained in a medicinal plant (the so-called Arcanum, which he 
considered as an immaterial principle), and the concept of dose dependency for drug action 
and toxicity (sola dosis facit venenum) (11, 12). 
The use of natural products as psychoactive agents probably dates from the dawn of 
humankind, when shamans experimented with mind-altering plants (13). Therefore, it is 
notable that the psychoactive analgesic morphine was the first alkaloid to be purified from a 
plant (1805) (13). Modern societies have extensively produced and broadly consumed 
psychoactive drugs such as coffee, alcohol, and tobacco (14). Natural product screening 
programs have led to the discovery of a number of CNS active molecules. Most common 
examples of natural products acting in the brain are summarized in Table 1. 
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Table 1. Selected CNS-active natural products. 
Compound Source Type Mechanism of action Psychoactivity type Ref. 
Arecoline Areca catechu P M1- and M2-muscarinic 
receptor agonist 
anti-Alzheimer’s (15) 
Bicuculline Dicentra cucullaria P GABAA antagonist convulsant (16) 
Caffeine Coffea arabica P adenosine receptor 
antagonist 
stimulant (17) 
Cocaine Erythroxylum coca P monoamine reuptake blocker stimulant, analgesic (17) 
Cytisine Fabaceae family P partial nicotinic AChR 
agonist 
stimulant (18) 
Huperzine A Huperzia serrata P AChE inhibitor anti-Alzheimer’s (11) 
Kaempferol Angiospermae families P unknown anxiolytic (19) 
Mescaline Lophophora williamsii P partial serotonin receptor 
agonist 
hallucinogen (20) 
Morphine Papaver somniferum P µ-opioid receptor agonist analgesic (17) 
Muscimol Amanita muscaria F GABAA agonist hallucinogen (17) 
Myristicin Myristica fragrans P dopaminergic hallucinogen (17) 
Nicotine Nicotiana tabacum P nicotinic AChR agonist stimulant (17) 
Piperine Piper nigrum P GABAA agonist anxiolytic, sedative (21) 
Psilocybin Psilocybe genus P partial serotonin receptor 
agonist 
hallucinogen (22) 
Quercetin Angiospermae families P unknown anxiolytic (19) 
Salvinorin A Salvia divinorum P κ-opioid receptor agonist analgesic, hallucinogen, 
dissociative 
(23, 24) 
∆9-Tetrahydrocannabinol Cannabis sativa P non-specific CB1 receptor 
agonist 
analgesic, hallucinogen (11, 25) 
P: plant; F: fungi; CB1: cannabinoid receptor type 1; AChR: acetylcholine receptor; AChE: acetylcholinesterase; GABAA: γ-aminobutyric acid  
receptor type A 
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There are a number of marketed CNS drugs originating from natural sources. 
Dihydroergotamine (Migranal
® 
nasal spray) is a serotonin 5-HT (1D) receptor agonist 
introduced as a semi-synthetic product in 1946 for the treatment of migraine and cluster 
headache. Stoll and Hoffmann prepared it by hydrogenation of the alkaloid ergotamine 
isolated from fungi of the genus Claviceps (26, 27). 
Galantamine (Reminyl
®
) is a competitive AChE inhibitor and nicotinic AChR agonist 
developed by Janssen Pharmaceuticals that was approved in 2001 for the treatment of 
Alzheimer's disease and various other memory impairments. Galantamine was first isolated 
from snowdrop (Galanthus species) (28, 29). 
Another example of an anti-Alzheimer’s drug of natural origin is rivastigmine (Exelon®). It 
was developed by Novartis and approved in 2006. The structure of rivastigmine is inspired 
from the alkaloid physostigmine isolated from Physostigma venenosum (27, 30). 
Varenicline (Chantix
®
 in the USA and Champix
®
 in Canada and Europe) is a partial agonist 
of the 42 nicotinic AChR developed by Pfizer that was approved in 2006 for the treatment 
of nicotine addiction (31, 32). The structure of varenicline is based on the alkaloid cytisine 
which is found in various members of Fabaceae family (31). 
Fingolimod (Gilenya
®
) is a sphingosine-1-phosphate receptor modulator developed by 
Novartis that was approved by the FDA in 2010 for reducing relapses and delaying disability 
progression in patients with multiple sclerosis. The design of fingolimod is based on the 
structure of the fungal metabolite myriocin from Isaria sinclairii (31). 
Several natural compounds are undergoing clinical evaluation at present. ELND005 (scyllo-
inositol) is a naturally occurring inositol stereoisomer found most abundantly in the coconut 
palm (Cocos nucifera). ELND005 is developed by Transition Therapeutics and has been 
evaluated for the treatment of agitation/aggression in patients with moderate Alzheimer's 
disease (completed phase II), and for the treatment of Down syndrome patients without 
dementia (completed phase II) (31, 33). 
Epigallocatechin gallate is a green tea polyphenol that prevents aggregation of -amyloid to 
toxic oligomers and thus has a positive influence on the course of Alzheimer's disease. It is 
being investigated in phase II clinical trials by the Charité Clinic (31, 34). 
GTS-21 is a derivative of the alkaloid anabaseine produced by Pacific nemertine worm 
Paranemertes peregrine. It is being evaluated as a sustained release formulation by the 
University of Colorado in a phase II trial for the treatment of patients with schizophrenia who 
also smoke cigarettes (31, 35). 
28
Natural products represent an invaluable source of bioactive compounds and structural 
diversity, with recognized potential in drug discovery. They complement synthetic molecules 
since about 40% of the chemical scaffolds present in natural products are absent in today’s 
medicinal chemistry (36). Natural products demonstrate advanced binding properties 
compared to synthetics, most probably due to their sterically complex structures (36). 
However, screening of natural products extracts is a time-consuming process because the 
screening step has to be followed by isolation of the active compound from the hit extract and 
structure elucidation. Other challenges related to natural products are the resupply of raw 
material since it is not constantly available in sufficient amounts, and political objections due 
to protection of biological resources (36). Although natural products-based drug discovery is 
associated with some difficulties, a significant number of natural products and their 
derivatives as marketed drugs or in various stages of clinical development emphasize the 
importance of natural products as sources of new drug candidates. 
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 2.3 Drug metabolism and pharmacokinetics (DMPK) 
 
„By far the most complex systems that we have are our own bodies” 
-Stephen Hawking, “The Universe in a Nutshell”, p. 37 
 
High attrition rate in drug development remains one of the key challenges for pharmaceutical 
industry (1). Over the past decades, considerable progress has been made to reduce the 
number of failures caused by a poor DMPK profile of drug substances. DMPK screenings 
incorporated in early drug discovery help to identify leads with favorable DMPK 
characteristics. Numerous in vitro and in vivo models, along with advanced instrumentation, 
are now available to make relatively reliable predictions from in vitro to in vivo, and from 
animals to humans (2). Thus, implementation of DMPK screening strategies in early drug 
discovery has increased the success rate due to the selection of better quality candidates 
moving through the pipeline. 
 
2.3.1 Drug metabolism 
Drug metabolism is the process where drugs are enzymatically altered, typically to more 
water soluble metabolites, to aid excretion from the body (3). Rapidly metabolized drugs may 
require multiple daily dosing or higher doses to maintain a sufficient level needed to produce 
a therapeutic effect. For prodrugs, which are administered as an inactive form and then 
converted into the active drugs in the body, rapid metabolism is beneficial (3). Very slowly 
metabolized drugs may remain in the body for long periods, causing accumulation and 
toxicity. Drug metabolism is generally divided into two groups, termed phase I and phase II 
metabolism. 
2.3.1.1 Phase I metabolism 
Phase I metabolism includes reactions such as oxidation, reduction and hydrolysis (Table 2). 
The major enzymes that catalyze phase I reactions are the cytochrome P450 (CYP450) 
superfamily, the flavin-containing monooxygenases (FMO), the monoamine oxidases 
(MAO), alcohol (ADH) or aldehyde (ALDH) dehydrogenases, reductases, esterases, 
amidases and epoxide hydrolases (3). CYP450 and FMO enzymes are bound to the 
membrane of the smooth endoplasmic reticulum, the fragments of which, after differential 
centrifugation, are associated with the microsomal fractions. Non-microsomal enzymes (e.g. 
MAO, ADH, ALDH) are mainly present in mitochondria and cytoplasm of hepatocytes. 
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Table 2: Phase I metabolic reactions. Modified from Davis, A., 2014 (4). 
Reaction type Pathway 
Oxidation 
Aromatic hydroxylation 
Aliphatic hydroxylation 
Epoxidation 
N-, O-, S-dealkylation 
Alcohol oxidation 
Aldehyde oxidation 
N-, S-oxidation 
Dehydrogenation 
Reduction Nitro-reduction to hydroxylamine, amines 
Carbonyl-, aldehyde-, aldose-reduction to alcohol 
Hydrolysis Ester hydrolysis to acid and alcohol 
Amide hydrolysis to acid and amine 
 
Since most of the marketed drugs are cleared by hepatic CYP-mediated metabolism, CYP450 
enzymes will be further discussed in this subchapter. CYP450 enzymes are a superfamily of 
heme-containing proteins that catalyze the oxidative metabolism of drugs. The CYP-
mediated oxidation proceeds as follows: 
S + O2 + 2e
-
 + 2H
+ 
𝐶𝑌𝑃450
→      SO + H2O 
The oxygen is bound to the heme of the CYP enzyme. Two protons, which are essential for a 
reductive splitting of the molecular oxygen into atoms, are provided by NAD(P)H cofactors. 
CYP450 inserts one oxygen atom to a substrate (S) and reduces the second oxygen to a water 
molecule. CYP450 utilizes two electrons that are provided by NAD(P)H via a reductase 
protein (5). In humans, nearly 60 CYPs have been identified thus far, however only some 
CYP isoforms are relevant to drug metabolism (Fig. 1). 
 
Figure 1: CYP450 nomenclature with the most relevant isoforms to drug metabolism. 
Modified from Nassar, A. F., 2009 (6). 
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 Drugs, food constituents, and environmental chemicals can either induce or inhibit CYP 
enzymatic activity which may cause unanticipated clinical consequences. Enzyme induction 
can lead to a potential reduction in drug efficacy or an increased formation of reactive (toxic) 
metabolites. In the case of enzyme inhibition, decreased metabolism may result in elevated 
plasma levels of the drug and may cause toxicity. A selected list of CYP450 inducers and 
inhibitors appears in Table 3. 
 
Table 3: Selected CYP450 inducers and inhibitors. 
CYP isoform Inducers Inhibitors 
CYP1A2 Broccoli, cigarette smoking, 
omeprazole 
Furafylline, cimetidine, 
amiodarone 
CYP1B1 Polycyclic aromatic hydrocarbons, 
-naphthoflavone 
Coumarins, resveratrol, 
flutamide 
CYP2A6 Phenobarbital, rifampin Tranylcypromine, methoxsalen 
CYP2B6 Phenobarbital, rifampin, 
phenytoin 
Clopidogrel, ticlopidine, 
thiotepa 
CYP2C8 Phenobarbital, rifampin Quercetin, montelukast, 
gemfibrozil 
CYP2C9 Secobarbital, rifampin Sulfaphenazole, fluconazole, 
valproic acid 
CYP2C19 Carbamazepine, rifampin, 
artemisinin 
Fluoxetine, chloramphenicol, 
moclobemide 
CYP2D6 Rifampin Fluoxetine, quinidine, 
Cimetidine, paroxetine 
CYP2E1 Ethanol, acetone, 
isoniazid 
Diethyldithiocarbamate, 
clomethiazole, diallyl disulfide 
CYP3A4/5 Phenobarbital, rifampin, 
carbamazepine 
Ketoconazole, itraconazole, 
verapamil, grapefruit juice 
 
The highest expression of CYP enzymes is found in the liver, while lower levels of CYPs are 
also found in extra-hepatic sites such as intestine, lungs, kidneys, brain, skin, nasal and 
tracheal mucosa, placenta, ovaries, testes, adrenal gland, and pancreas (7). Contribution of 
extra-hepatic CYPs to the overall metabolism of drugs and total body clearance is minor; 
however extra-hepatic CYPs may affect the absorption of drugs into systemic circulation and 
their local disposition, and may therefore modify pharmacological effects of drugs (7). 
2.3.1.2 Phase II metabolism 
Phase II metabolism involves conjugation with an endogenous substance (e.g. glucuronic 
acid, sulfate, glutathione). Phase II reactions can be sequential to Phase I reactions or may 
occur directly if susceptible functional groups such as –OH, –COOH, –NH2, –SH are present 
on the molecule (3). Phase II metabolizing enzymes mainly belong to the class of transferases 
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 (Table 4). Most of phase II enzymes are found in the cytosol of the hepatocytes, except 
uridine diphosphate (UDP)-glucuronosyltransferase which is a microsomal enzyme. 
 
Table 4: Phase II metabolic reactions. Modified from Evans, G., 2004 (8). 
Reaction type Enzyme 
Glucuronidation UDP-glucuronosyltransferase 
Sulfation Sulfotransferase 
Methylation Methyltransferase 
Acetylation Acetyltransferase 
Glutathione conjugation Glutathione-S-transferase 
Amino acid conjugation Acyl-CoA synthetase and  
acyl-CoA: amino acid N-acyltransferase 
 
Generally, the conjugative metabolism diminishes or abolishes biological activities. 
However, in some cases, like with morphine-6-glucuronide and 4-hydroxytriamterene sulfate, 
the conjugated metabolites possess enhanced biological activity (9, 10). Glucuronidation is a 
significant pathway in the phase II metabolism of various exogenous and endogenous 
compounds. The conjugation of glucuronic acid to a substrate is catalyzed by a family of 
enzymes called UDP-glucuronosyltransferases or UGTs (8). The cofactor uridine 
diphosphoglucuronic acid (UDPGA) acts as a donor of glucuronic acid for UGTs. The 
glucuronide conjugates are recognized by the biliary and renal organic anion transporter 
proteins, which enable their excretion into urine and bile. Although the liver is recognized as 
the major site of glucuronidation, many other organs such as nasal mucosa, the gut, kidneys, 
skin, leukocytes, lungs, brain, breast, placenta, prostate, and uterus have also been reported to 
express a panel of UGT isoforms (11). In humans, two subfamilies of UGT1A and UGT2B 
are mainly involved in the metabolism of xenobiotics. 
Another significant phase II detoxification pathway is sulfation. The reactions are catalyzed 
by the family of enzymes called sulfotransferases (SULTs). These enzymes catalyze the 
transfer of sulfonate group (SO3
־
) from the cofactor 3'-phosphoadenosine-5'-phosphosulfate 
(PAPS) to a substrate. In humans four SULT families (SULT1, SULT2, SULT4 and SULT6) 
have been identified. Similar to the glucuronidation reactions, sulfation occurs in various 
tissues, but the main sites are the liver and small intestine (8). 
Methylation is a common but minor metabolic route in the overall metabolism of xenobiotics 
which does not generally increase the aqueous solubility of substrates. It is primarily involved 
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 in the metabolism of endogenous compounds (e.g. neurotransmitters). Methyltransferases 
catalyze the transfer of a methyl group from the co-factor S-adenosylmethionine (SAM) to a 
substrate. 
Acetylation is an important biotransformation pathway for xenobiotics containing either 
aromatic amines or hydrazines, which are converted to aromatic amides and hydrazides (8). 
Acetyltransferases catalyze the transfer of an acetyl group from the cofactor acetyl-coenzyme 
A (acetyl-CoA) to a substrate. 
Conjugation of glutathione with reactive metabolites plays an important role in the 
detoxification mechanism of many xenobiotics. Glutathione is a tripeptide (γ-glutamic acid-
cysteine-glycine) which can be found in every cell of the human body with the highest 
concentration in hepatocytes. Glutathione conjugated metabolites are immediately excreted 
into bile or transported to the kidneys where they are subjected to further metabolism into 
mercapturic acids and excretion into urine (8). 
Xenobiotics with a carboxyl group can undergo conjugation with amino acids, most 
commonly glycine, glutamine and taurine (8). The mechanism of biotransformation includes 
two enzymatic processes: first, formation of a reactive xenobiotic-CoA thioester intermediate 
catalyzed by acyl-CoA synthetase, and second, linkage of the activated acyl group via an 
acyl-CoA: amino acid N-acyltransferase to the amino group of the acceptor amino acid (12). 
2.3.1.3 Factors affecting drug metabolism 
Factors affecting drug metabolism can be divided into three major categories: genetic, 
environmental, and physiological. Individual variability in drug efficacy and safety can be 
explained in some cases by genetic variations (genetic polymorphism) resulting in four 
different phenotypes: poor metabolizers, intermediate metabolizers, extensive metabolizers 
and ultrarapid metabolizers (3). Genetic differences in the expression of metabolizing 
enzymes are more commonly observed in specific ethnic groups. For instance, the CYP2D6 
poor metabolizer phenotype is more frequent in the Caucasian population compared to Asians 
(3). Conversely, the CYP2C19 poor metabolizer phenotype is more frequent in the Asian 
population compared to the Caucasian population (3). Environmental factors include 
environmental chemicals (e.g. heavy metals, industrial pollutants, insecticides, herbicides) 
which may induce and/or inhibit the activity of metabolizing enzymes. Physiological factors 
include those related to age, disease state, and gender (including hormonal cycle) (6). 
Metabolism differs between the very young and the elderly. Newborns lack drug 
metabolizing enzymes except CYP3A7 and SULT (6). In the elderly a decrease in metabolic 
rate is often observed due to the reduced hepatic blood flow (6). Some pathological 
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 conditions like impaired hepatic and renal function can significantly affect drug metabolism 
leading to the risk of adverse effects. 
2.3.2 Strategies to study drug metabolism 
2.3.2.1 In vitro models 
Since the liver is the major metabolic organ, the in vitro models used to investigate drug 
metabolism often focus on hepatocytes or subcellular fractions of the liver where 
concentrations of metabolizing enzymes are high [3]. 
Metabolic stability assessment 
Liver microsomes 
Microsomes are subcellular fractions containing the endoplasmic reticulum-localized 
metabolizing enzymes. Microsomes are the most widely used in vitro system to investigate 
both CYP-mediated and UGT-mediated metabolism. Incubations with microsomes require an 
addition of the appropriate cofactor (NADPH or UDPGA). The advantages of using 
microsomes in metabolism studies are their relatively low cost, easy preparation and storage, 
and applicability to high throughput screening. However, for compounds which are mainly 
eliminated from the body via phase II metabolism, microsomal incubations tend to 
underpredict intrinsic clearance (3). In addition, metabolites formed by cytosolic enzymes 
will not be detected with this system. 
Liver S9 
Liver S9 is the post-mitochondrial supernatant fraction containing both microsomal and 
cytosolic enzymes (3). As with microsomes, incubations with S9 require an addition of the 
appropriate cofactor. Because of the lower enzymatic activity in the S9 fractions compared to 
microsomes, the S9 systems are often used for qualitative purposes to identify if cytosolic 
enzymes are responsible for the formation of a metabolite (3). 
Hepatocytes 
Hepatocytes are whole cells containing the full spectrum of phase I and phase II metabolizing 
enzymes, cofactors, and transporters. Cryopreservation techniques ensure cell viability and 
enable cells to be stored for long periods of time (3). The drawbacks of this system are 
associated with a complicated, time consuming, and costly hepatocyte isolation method, 
inter-lot variability in enzymatic activity, and short incubation time (due to limited viable 
period of hepatocytes) for the experiments. 
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 Reaction phenotyping 
Reaction phenotyping is used to determine which enzymes are involved in the metabolism of 
a test substance (3). The data from these studies can be important for identification of the 
potential drug interactions with common co-medications used in the clinic, and also the 
possible differences in pharmacokinetics caused by genetic polymorphism in certain enzymes 
(3). Several in vitro approaches have been developed to study reaction phenotyping: 
Correlation analysis 
Correlation analysis relies on statistical analysis to establish a correlation between the 
metabolic rates of a test compound and marker substrate for each individual CYP enzyme 
(13). Pools of human liver microsomes (donors ≥ 10) previously characterized for activity 
towards individual probe substrates are used to correlate with the activity towards the test 
compound (3). 
Inhibition of metabolism 
Inhibition of specific enzymatic pathways using selective chemical inhibitors or antibodies is 
another approach for reaction phenotyping. A battery of incubations with various inhibitors 
and a test compound is performed to identify which inhibitor reduces the overall metabolism 
to the greatest extent, and thus uncover the enzymatic pathway that contributes to the 
clearance of a test compound (14). 
Recombinant enzymes 
Recombinant enzymes are manufactured by transfecting a human cDNA of a specific enzyme 
into a vector, with its further transfer into a rapidly growing and easily cultured host (e.g. 
Escherichia coli) (6). A panel of recombinant human CYP and UGT enzymes is available to 
investigate the metabolic pathways of a test compound by substrate-depletion method. 
Silensomes
™
 
Recently, novel systems called Silensomes
™
 have been developed for CYP reaction 
phenotyping. Silensomes
™
 are human pooled liver microsomes in which one specific CYP 
has been chemically and irreversibly inactivated using mechanism based inhibitors. 
Incubations with Silensomes
™
 are accompanied by control incubations in which enzymatic 
activity of all CYPs is preserved. Contribution of each CYP isoform can be determined by 
comparing the substrate disappearance in Silensomes
™
 and the controls. 
CYP450 induction/inhibition assessment 
CYP450 induction assays help to identify a potential of the test compound to increase the 
activity of CYP isoenzymes. Induction of CYP isoenzymes may lead to therapeutic failure of 
the drug caused by a decreased systemic exposure or to toxicity as a result of increased 
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 formation of toxic metabolites. Incubations of a test substance and isoform specific probe 
substrates are conducted with human hepatocytes from at least three donors and compared to 
controls. Increased mRNA levels due to increased transcription of CYP genes, as well as 
increased formation of the isoform specific metabolites in the presence of the test compound 
indicate induction of CYP isoenzymes. 
CYP450 inhibition assays help to identify a potential of the test compound to inhibit a 
specific CYP450 enzyme. Inhibition of a drug’s metabolism may lead to increased plasma 
levels resulting in toxicity. Isoform-specific probe substrates are incubated individually with 
the test compound in the presence of human liver microsomes or recombinant enzymes, and a 
cofactor (3). Ideally, probe substrates should be predominantly metabolized by a single 
isoenzyme with no sequential metabolism (3). Formation of metabolites is monitored in the 
test incubations and compared to the controls. 
2.3.2.2 In vivo models 
Multi-species animal metabolism studies are initially conducted with non-radiolabeled 
compounds to understand the main elimination pathways and systemic metabolite exposure, 
and to find relevant species for preclinical development. Thereafter, mass balance studies 
with 
14
C- or 
3
H-radiolabeled compounds are performed to obtain additional information, 
including (i) mass recovery, (ii) metabolic profile, (iii) abundance of metabolites in excreta 
and circulation, (iv) exposure of parent compound and its metabolites in different organs and 
tissues at different time intervals, and (v) pharmacokinetic properties of parent compound and 
its metabolites (12). The preclinical in vivo data are used to predict human outcomes, and 
select candidates for progression towards phase I clinical studies. Human metabolites can 
differ from those identified in the animal species or be present at disproportionately higher 
levels, and thus can raise safety concerns (15). Radiolabeled human metabolism studies to 
address safety related issues of drug metabolites are mandatory early in clinical development 
before large numbers of patients get enrolled in clinical trials. 
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 2.3.3 Pharmacokinetics 
Pharmacokinetics (PK) is a quantitative study of the time course of drug and metabolite 
concentrations in the body (16). The term PK originates from the ancient Greek words 
pharmakon and kinetikos meaning "drug" and "moving", respectively. PK data are used to 
optimize the dose, dosage regime, and dosage form. Five key PK parameters that are used in 
drug discovery and development will be discussed in more detail below, namely elimination 
half-life, area under the curve, total clearance, apparent volume of distribution, and 
bioavailability. 
2.3.3.1 Pharmacokinetic parameters 
Elimination half-life 
Elimination half-life (t1/2) is the time required to reduce the drug concentration by half (17). 
The unit for t1/2 is typically expressed in min or h. The t1/2 can be calculated as follows: 
t1/2 = 
0.693
𝑘𝑒
 
The ke is the elimination rate constant which can be determined from the slope of the line (so 
called linear regression analysis) fitted to the terminal portion of ln (Fig. 2A) or log (Fig. 2B) 
drug concentrations versus time profile. 
 
Figure 2: Determination of the elimination rate constant (ke) by linear regression analysis for 
ln (A) and log (B) drug concentrations versus time profiles. 
 
The t1/2 depends on volume of distribution (Vd) and clearance (Cl), and thus can be calculated 
using the following equation: 
t1/2 = 0.693 × 
Vd
Cl
 
The t1/2 is used to determine the dosing interval. Drugs with a shorter half-life (higher 
elimination rate) should be generally given more frequently, than drug with a longer half-life 
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 (lower elimination rate) (17). With each subsequent dose, maximum (peak) and minimum 
(trough) concentrations increase until equilibrium is reached (17). When equilibrium occurs, 
peak and trough concentrations remain constant with each subsequent dose (17). The 
condition at which the amount of drug administered over a dosing interval equals the amount 
of drug being eliminated over that same period is called steady state (17). The time of four to 
five half-lives is needed to reach the steady state. 
Area under the curve 
Area under the curve (AUC) is a measure of the total drug exposure over time (18). The AUC 
is expressed as h*mg/l. The most common method for the calculation of AUC is the linear 
trapezoidal rule, where the drug concentrations versus time plot is considered as a sequence 
of trapezoids (Fig. 3). The trapezoidal area between two data points (for example, C1, t1 and 
C2, t2) can be calculated as follows: 
AUCt1→t2 = 0.5 × (C1 + C2) × (t2 - t1) 
The total area of all the trapezoids reflects the AUC. Comparison of AUCs from drug leads 
helps to select the lead with the highest exposure level. Also, the AUC is used to calculate 
other PK parameters, such as clearance and bioavailability. 
 
Figure 3: Area under the drug concentrations versus time curve viewed as a sequence of 
trapezoids. 
 
Total clearance 
Total clearance (Cl) is the volume of body fluid cleared from the drug per unit of time (17). 
Drugs, either in unchanged forms or as metabolites, are eliminated from the body by 
excretion and metabolism. Thus, the total Cl is the sum of all individual organ clearances. 
The unit for Cl is expressed in l/h. The total Cl can be calculated from the expression: 
Cl = 
Dose
AUC
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 If there is no saturation of elimination mechanisms, the Cl is constant over the dose range, 
and the drug follows first-order kinetics. Highly cleared drugs require higher doses or 
frequent administration to maintain a certain level of exposure needed to achieve the 
therapeutic effect. This negatively impacts cost and treatment acceptability. 
Apparent volume of distribution 
Apparent volume of distribution (Vd) indicates how widely the compound is distributed in the 
body (19). The unit for Vd is typically reported in l/kg or ml/kg of body weight. The Vd can 
be calculated using the following expression: 
Vd = 
Dose
C0
 
C0 is the initial drug concentration in plasma after intravenous administration, before 
elimination has started. C0 can be determined on the semi-logarithmic graph of drug 
concentrations versus time by extrapolation back to time zero. The Vd is associated with Cl 
and ke and thus can be calculated as follows: 
Vd = 
Cl
ke
 
Vd is dependent on the properties of the drug. Hydrophilic drugs have small Vd, close to the 
volume of blood (approximately 0.07 l/kg) (19). Those drugs tend to be restricted to the 
bloodstream and do not enter the tissues in significant amounts (19). Moderately lipophilic 
drugs have Vd which is in the range of the volume of body water (approximately 0.7 l/kg) 
(19). Highly lipophilic drugs tend to bind extensively to tissues, and thus have a Vd which 
exceeds the volume of body water. 
Bioavailability 
Bioavailability (F) is a fraction of the administered dose that reaches the systemic circulation 
in the unchanged form (19). It is expressed in %. When a drug is administered intravenously, 
the F is equal to 100%. The F of orally administered (po) drugs can be determined from the 
equation: 
F = 100 × 
AUCpo × Doseiv
AUCiv × Dosepo
 
The F can be affected by several factors, such as incomplete intestinal absorption, first-pass 
metabolism, decomposition of the drug in the lumen, drug formulation, and presence/absence 
of food (food effect). Low bioavailability causes high patient-to-patient variability in plasma 
concentrations and thus may have a negative impact on the treatment outcome. Thereby, for 
orally administered drug candidates to be taken into clinical development, many 
pharmaceutical companies set the F limit of 20% (20). 
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 2.3.3.2 Pharmacokinetic data analysis 
The main PK parameters can be calculated as described above using non-compartmental 
analysis in which a body is considered as a kinetically homogenous unit. Another approach in 
the PK data processing includes compartmental analysis which applies mathematical models 
to describe the changes in drug concentration over time. In compartmental analysis a body is 
considered as subdivided into one, two or multi compartments, each representing a group of 
similar tissues or fluids. Therefore, blood (plasma), heart, lungs, liver, and kidneys are 
combined into one compartment usually referred to as the central compartment (17). The 
adipose tissue, muscles, bones are grouped in the peripheral compartment. In compartmental 
analysis calculation of the PK parameters are based on fitting an appropriate compartmental 
model to the PK data. Specific computer programs (e.g. WinNonlin
®
) are usually used to do 
that. WinNonlin
®
 includes a library of PK compartmental and pharmacodynamic models, 
non-compartmental analysis, and it also supports the creation of custom models. 
2.3.4 Plasma protein binding 
Plasma protein binding is the reversible association of a drug with the plasma proteins (8). 
The interactions of drugs and plasma proteins are electrostatic and hydrophobic (19). 
Common human plasma proteins that drugs bind to are human serum albumin and 1-acid 
glycoprotein. The drug-plasma protein complex cannot diffuse across the cell membranes to 
reach the target tissue. Only free drug passes through membranes, and only free drug is 
available for liver metabolism and renal excretion (19). Drugs that are highly and tightly 
bound to plasma proteins may not be able to exert their therapeutic effect, but if the drug has 
a fast kinetic (high dissociation rate) protein binding may not impact distribution of the drug 
into tissues, its metabolism, excretion, and efficacy (19). Plasma protein binding can 
influence the PK properties of the drug (Vd, Cl, t1/2) and, therefore, the extent of protein 
binding should be determined during the lead optimization process. 
2.3.5 Techniques for measurement of plasma protein binding 
Equilibrium dialysis 
Equilibrium dialysis is the gold standard for measurement of plasma protein binding. As a 
typical example of equilibrium dialysis, the mixture of a drug with plasma proteins is 
separated from a buffer solution by a semi-permeable membrane with a known molecular 
mass cut-off (Da) (8). Diffusion of the drug across the membrane continues until the 
concentration of free drug is equal on both sides of the membrane (equilibrium has been 
reached) (8). After the incubation at the desired temperature, samples from both reservoirs 
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 are taken and analyzed for drug concentrations. The unbound fraction (fu) can be calculated 
as follows: 
fu = 1-( 
CP−CB
CP
) 
CP is the drug concentration in the plasma reservoir; CB is the drug concentration in the 
buffer reservoir. Even though equilibrium dialysis approach has been widely used, it suffers 
from several drawbacks that limit its application in the pharmaceutical industry. The method 
requires a big sample volume, pre-conditioning of the dialysis membrane, long time to reach  
equilibrium (up to 24 h). Such long incubation time may associate with volume shift, 
meaning an increase in plasma volume and decrease in buffer volume due to the difference in 
osmotic pressure between plasma and buffer (21). Also, long incubation time may result in 
drug degradation in plasma. As an alternative to classic dialysis, rapid equilibrium dialysis 
(RED) method has been developed. The RED device represents a 96-well plate with 
equilibrium dialysis membrane inserts. Each insert is comprised of two chambers for sample 
and buffer with a semi-permeable membrane in between. The RED does not require pre-
conditioning of the dialysis membrane. The increased membrane surface-to-volume ratio 
allows achieving equilibrium in 4 h. The base plate of RED device is made from Teflon to 
minimize non-specific binding of test compound. The RED is a fast and reliable technique 
which suitable for high-throughput screening format. 
Ultrafiltration 
Ultrafiltration is based on the physical separation of free drug in plasma from the drug bound 
to proteins, by filtering plasma samples through a semipermeable membrane with a known 
molecular mass cut-off under a positive pressure generated by centrifugation (21). The 
unbound fraction can be calculated from the equation: 
fu = 
Cf
Cp
 
Cf is the concentration of drug in the ultrafiltrate after centrifugation; Cp is the initial 
concentration of drug in plasma before centrifugation. The ultrafiltration technique has 
several advantages over equilibrium dialysis: small sample volume, fast (takes 15-30 min), no 
buffer needed, relative low cost (21). However, a major drawback is non-specific binding of a 
drug to the plastic surfaces or to the ultrafiltration membrane. Although non-specific binding 
can be overcome by pre-treatment of the ultrafiltration membrane with Tween-80, or by 
performing separate studies using water spiked with the drug (used for correction of non-
specific binding), equilibrium dialysis is considered to be a more reliable method for protein 
binding measurements, if non-specific binding is more than 20% (21). 
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 Ultracentrifugation 
In ultracentrifugation, the drug-protein complex is pelleted by using high speed centrifugation 
(e.g. 500000 g), leaving the free drug in the supernatant (8). After centrifugation, an aliquot 
of supernatant is taken to measure the free drug concentration (8). The unbound fraction can 
be calculated as follows: 
fu = 
Cs
Cp
 
Cs is the concentration of drug in the supernatant; Cp is the initial concentration of drug in 
plasma before the experiment. Several factors like costly equipment, long centrifugation time, 
low sample throughput, physical phenomena (sedimentation, back diffusion) limit the 
application of this technique (8). 
2.3.6 Red blood cell binding 
The PK parameters are usually determined by quantification of drug in plasma rather than 
whole blood. Therefore, drug molecules that bind to erythrocytes will not be measured in the 
sample (19). Extensive binding to erythrocytes limits the amount of free drug available for 
metabolizing enzymes and thus reduces the drug clearance. Binding of a drug to erythrocytes 
could be an explanation for low plasma concentrations or unexplained clearance, especially 
from iv dosing (19). Therefore, evaluation of red blood cell binding is important for the 
thorough interpretation of the drug’s PK. 
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2.4 Bioanalysis 
 
„In mass spectrometry there are no problems, only challenges!” 
-Professor Jan van der Greef 
 
Bioanalysis is a sub-discipline of analytical chemistry focusing on the qualitative and 
quantitative determination of xenobiotics (drugs and their metabolites, environmental 
chemicals) and biotics (DNA, proteins) in a given biological matrix, such as blood, plasma, 
serum, or urine (1, 2). The quantitative bioanalysis applies to all stages of the drug discovery 
and development process: from in vitro testing to preclinical and clinical studies.  
 
2.4.1 A brief history of bioanalysis 
In the 1940s paper chromatography has been developed to separate drugs from its 
metabolites. Later, thin-layer chromatography was used to quantify drugs in biological fluids, 
although its main application was in the separation of radiolabeled metabolites (3). However, 
these techniques did not provide sufficient sensitivity to measure the new drugs of the 1950s, 
such as “tricyclics” that had levels of ng/ml (3). In the 1950s, gas chromatography (GC) 
coupled to nitrogen phosphorus detector was widely used in the pharmaceutical industry. 
Thereafter, a wide variety of detectors became commercially available, of which mass 
spectrometric (MS) detectors were the most preferred due to improved sensitivity (3). Since 
the separation for GC is carried out in the gas phase, the analyte of interest should be volatile 
and thermostable. Thus, the major drawback of GC was a time-consuming chemical 
derivatization of nonvolatile compounds prior to the analysis. In the late 1960s and early 
1970s, high pressure liquid chromatography (HPLC) became the most powerful tool in 
analytical chemistry (3). HPLC coupled to ultraviolet (UV), electrochemical, and fluorescent 
detectors were primarily used in bioanalysis before HPLC-MS became the first-choice 
technique. In the 1980s, invention of the atmospheric pressure ionization (API) technique 
improved sensitivity of HPLC-MS systems (3). For quantitative purposes high specificity and 
selectivity were attained with the employment of triple quadrupole (QqQ) or ion trap mass 
analyzers capable of MS/MS fragmentation (4). In 2004, ultra-high performance liquid 
chromatography (UHPLC) was introduced to improve chromatographic separation efficiency. 
UHPLC allowed reduced solvent consumption, ultra-fast analysis, and increased throughput, 
while maintaining resolution. The combination of UHPLC-MS/MS offered benefits in 
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sensitivity, selectivity, specificity, and speed, and thus has obtained widespread application in 
the bioanalysis of small molecules and biologics. Nowadays, high resolution MS (HR-MS) 
based on quadrupole time-of-flight (Q-TOF) or Orbitrap mass analyzers is receiving more 
attention. HR-MS enables accurate mass measurements at high resolving power, and provides 
simultaneous qualitative and quantitative information in a single injection (5). 
2.4.2 Operation principles of the QqQ and Q-TOF mass analyzers 
Before entering a mass analyzer, the sample molecules are converted into ions in the 
ionization source. Among the most used ionization techniques are electrospray ionization 
(ESI) and atmospheric pressure chemical ionization (APCI). In the ESI source, liquid samples 
are pumped through a metal capillary maintained at 3 to 5 kV and nebulized at the tip of the 
capillary to form a fine spray of charged droplets: [M+H]
+
 or [M-H]
-
 (6). Charged droplets 
are further evaporated by the application of heat and nitrogen, and the residual electrical 
charge on the droplets is transferred to the analytes (6). In contrast to ESI, the APCI source 
operates at higher temperatures and includes a corona discharge pin which is responsible for 
ionizing the solvent molecules. These ions then react with the analytes and ionize them via 
charge transfer (6, 7). APCI generates singly charged ions, whereas ESI produces multiple 
charged ions. APCI is applied for thermostable and non-polar molecules, while ESI is used 
for labile and polar analytes (7). Both techniques are considered to be “soft”, meaning that 
little or no fragmentation of the analytes occurs during ionization (6). 
Upon ionization, charged ions are transferred through an octopole ion guide into a mass 
analyzer, where they are separated based on their mass-to-charge ratio (m/z). The QqQ mass 
analyzer consists of three quadrupoles aligned in series, where the first (Q1) and the third 
(Q3) quadrupoles act as selective mass filters, and the middle quadrupole (Q2) is a collision 
cell. Each mass filter contains four parallel metal rods controlled by direct current and radio 
frequency potentials and thus only ions with the certain m/z value can pass through (8). For 
quantitative analysis, the most common mode allowing increased sensitivity and selectivity is 
selected reaction monitoring (SRM) (6, 8). In SRM, Q1 selects ions with a specific m/z 
(precursor ions) and filters out ions with different m/z. In Q2, precursor ions strike collision 
gas molecules (N2 or Ar) generating product ions, so called collision induced dissociation 
(CID). Product ions with a specific m/z are selected in Q3 and are finally detected by an 
electron- or photo-multiplier detector (Fig. 4). Therefore, SRM mode is denoted as a double 
mass filter able to significantly reduce background noise. 
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Figure 4: Schematic representation of a triple quadrupole (QqQ) mass analyzer operating in 
selected reaction monitoring (SRM) mode. 
 
In the Q-TOF mass analyzer, the third quadrupole is replaced by a flight tube (Fig. 5). The 
beam of ions enters the ion pulser, where the ions are accelerated orthogonally by a high 
voltage pulse. The ion mirror reverses the direction of flying ions making them arrive at the 
detector. The flight time for each particular m/z is unique. Ions with small m/z have higher 
velocity and thus arrive at the detector earlier than ions with larger m/z. The time-of-flight 
analysis provides high mass accuracy (mass errors less than 5 ppm) and high resolution (up to 
50000) (9, 10). The Q-TOF mass analyzer allows data acquisition at high speed of around 20 
spectra/s without sacrificing sensitivity and resolution in the full scan and MS/MS modes 
(11). 
 
Figure 5: Schematic representation of a quadrupole time-of-flight (Q-TOF) mass analyzer 
operating simultaneously in the full scan MS and targeted MS/MS modes. 
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2.4.3 Sample preparation 
The primary goal of sample preparation is to isolate the analyte of interest from a wide 
variety of matrix components (e.g. phospholipids, proteins, salts), which can affect (suppress 
or enhance) the ionization of the analyte (12-14). This phenomenon is termed matrix effect, 
and can lead to inaccurate quantification (14). Moreover, sample preparation is performed to 
enrich the sample with respect to the analyte, thus maximizing the sensitivity of LC-MS/MS 
system (13). Prior to analysis, biological samples are processed by using one of the following 
procedures: dilution, protein precipitation (PP), liquid-liquid extraction (LLE), supported-
liquid extraction (SLE), and solid phase extraction (SPE). 
Dilution 
Dilution is a fast and simple technique of sample preparation, only requiring the dilution of 
the sample with water or mobile phase prior to LC-MS/MS analysis. The main disadvantage 
of this technique is that it does not remove any matrix interferences, and dilutes out the 
analyte of interest (12). 
Protein precipitation (PP) 
PP removes proteins present in the biological matrix through denaturation caused by external 
stress such as strong acid/base, heat or, most commonly, organic solvent (methanol, 
acetonitrile) (1). The organic solvent is added to the sample in a ratio of 3:1 (v/v) (15). The 
denatured proteins are then removed by centrifugation, but the desired analyte remains in the 
supernatant liquid (1). PP is an inexpensive, simple, and widely applicable procedure for 
sample preparation. However, it is time-consuming when handled manually for a large 
number of samples, and it does not always provide sufficient sample clean-up (1). 
Liquid-liquid extraction (LLE) 
LLE separates an analyte from matrix interferences based on their different solubility into 
two immiscible phases (polar aqueous and non-polar organic). Low molecular weight 
lipophilic drugs will preferentially reside in the organic phase, while polar matrix 
components remain in the aqueous phase (13). LLE yields cleaner samples than PP, but it has 
several drawbacks: low recovery of polar analytes, relatively large volume of costly solvents 
and biological samples required, labor intensive, and time-consuming (14). 
Supported-liquid extraction (SLE) 
SLE is an alternative to the conventional LLE extraction technique, which is suitable for 96-
well format operation. The SLE cartridge is packed with inert diatomaceous earth sorbent 
material, which absorbs the aqueous sample with the analyte of interest. An immiscible 
solvent is then used to elute the desired analyte (16). SLE provides clean extracts with a high 
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recovery and reproducibility, but it has a limited sample aliquot volume (<400 µl) in order to 
maintain a 96-well plate format (16, 17). 
Solid phase extraction (SPE) 
SPE separates an analyte from matrix interferences based on the affinity of the analyte 
towards a stationary phase. The analyte is retained by the stationary phase through 
hydrophobic (reverse-phase SPE) or electrostatic (ion-exchange SPE) interactions, while 
matrix interferences are washed off (14). The retained analyte is then eluted with an 
appropriate solvent (mobile phase). Different stationary phases have been developed to 
provide the cleanest extract, thus minimizing matrix effect. The main disadvantage of this 
technique is the high cost per sample. 
2.4.4 Method development 
For a robust LC-MS/MS method development, it is important to follow several steps such as: 
(i) Assessment of physicochemical properties: Physicochemical properties of the analyte of 
interest should be initially assessed to select appropriate solvents, and to take the necessary 
precautions during the method development process (e.g. protection from light for 
photosensitive compounds). 
(ii) Selection of internal standard (IS): IS must have the same or similar physicochemical 
properties as the analyte of interest, so that it can mimic closely the performance of the 
analyte in every stage of analysis: from the sample preparation to MS detection (17). For 
quantification, the use of signal ratio of the analyte to the IS (rather than the use of the 
analyte absolute signal) is preferable. The losses and variations of the analyte, which may 
occur during sample preparation or during LC-MS/MS analysis, can thus be corrected (17). 
The best IS is a stable isotopic (e.g. 
2
H, 
13
C, 
15
N)-labeled compound due to its very similar 
physicochemical properties as the analyte. However, the high cost for synthesis of 
isotopically labeled compounds limits their application. As a cheaper alternative, structural 
analogs can be used. 
(iii) Optimization of MS/MS parameters: For successful MS detection and quantification, a 
number of parameters, such as ionization mode, SRM transitions, capillary voltage, cone 
voltage, source temperature, desolvation gas flow, and collision energy should be optimized 
for analyte and corresponding IS. 
(iv) Optimization of LC method: For optimal separation conditions, the composition of 
mobile phase, gradient, flow rate, column type, and temperature (column oven temperature, 
autosampler temperature) should be optimized. 
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(v) Selection of sample preparation procedure: In general, PP extraction is considered to be 
the first choice if the required lower limit of quantification (LLOQ) is in the range of ng/ml 
(17). Because PP extraction does not remove matrix effect, it is recommended that the 
maximal sample aliquot volume should not be more than 100 µl (17). If the target LLOQ is at 
pg/ml, more sophisticated procedures like LLE, SLE and SPE can be employed. 
(vi) Quantification range and carry-over assessment: A quantification range should be 
chosen based on the concentrations expected in a particular study, and should be described by 
the simplest regression model possible (linear or quadratic) (2, 17). 
Carry-over can be assessed by injecting a blank sample immediately after the upper limit of 
quantification (ULOQ). If carry-over is observed, it is critical to determine the source of 
carry-over (autosampler injector carry-over or LC column carry-over) in order to eliminate or 
minimize it. Selection of the appropriate needle wash solvent, addition of acid or base 
modifier to the mobile phase may increase the solubility of the analyte and thus may help to 
overcome autosampler injector carry-over (17). LC column carry-over can be minimized by 
changing the LC method to isocratic conditions or a flat gradient, or by switching to a less 
retentive LC column (17). 
2.4.5 Method validation 
Validation of bioanalytical methods is performed to demonstrate reliability and 
reproducibility of a particular method used for quantification of analytes in a given biological 
matrix (2). Validation should be conducted in compliance with guidelines defined by 
regulatory agencies: the US Food and Drug Administration (FDA) and/or the European 
Medicines Agency (EMA) (2, 18). The main characteristics that ensure performance 
acceptability of the bioanalytical method are: calibration curve and LLOQ, accuracy, 
precision, selectivity, specificity, carry-over, matrix effect, recovery, dilution integrity, and 
stability (2, 18). 
Calibration curve and LLOQ 
The calibration curve describes the relationship between instrument response and known 
concentrations of the analyte (2). A calibration curve comprises a double blank sample 
(matrix without analyte and IS), a calibrator zero sample (matrix without analyte but with IS), 
a minimum of six calibration standards (CALs), and quality controls (QCs) prepared in the 
same biological matrix as the samples (2). Concentrations of CALs should be chosen based 
on the concentration range expected in a particular study (2). The LLOQ is defined by two 
parameters: (i) an experimental concentration within ± 20% of the nominal value (2, 18), and 
(ii) a signal to noise (S/N) ratio, which should be ≥ 10. QCs are prepared at three 
52
concentration levels: low (QCL), medium (QCM), and high (QCH). QCL should be 3 times 
higher than LLOQ, while QCM and QCH should be 50% and 80% of the ULOQ, 
respectively (2, 18). Each analytical run is opened and closed by the set of CALs, while six 
QCs are placed randomly between two sets. The back calculated concentrations of CALs and 
QCs should be within ± 15% of the nominal value, except for the LLOQ for which it should 
be within ± 20% (2, 18). At least 75% of CALs and 67% of QCs should fulfill these criteria 
to obtain a valid run (2, 18). 
Accuracy and precision 
The accuracy describes the closeness of the measured concentrations to the nominal 
concentrations. The accuracy is usually measured in terms of inaccuracy expressed as the 
relative error (RE, %): 
RE = 
Measured conc.−Nominal conc.
Nominal conc.
 × 100 
 
The precision describes the closeness of the repeated individual measures of the analyte, and 
is usually measured in terms of imprecision expressed as the coefficient of variation (CV, %): 
CV = 
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑀𝑒𝑎𝑛 𝑐𝑜𝑛𝑐.
 × 100 
 
The accuracy and precision should be measured using a minimum of five replicates per 
concentration level at LLOQ, QCL, QCM, QCH, and ULOQ (2, 18). Precision and accuracy 
are further subdivided into within-run (accuracy and precision of a single analytical run) and 
between-run (accuracy and precision of at least three runs analyzed on at least two different 
days) (2, 18). According to the guidelines, RE should be ± 15% (± 20% at the LLOQ), and 
CV should not exceed 15% (20% at the LLOQ) (2, 18). 
Selectivity and specificity 
Selectivity and specificity are defined as the ability of an analytical method to differentiate 
and quantify the analyte of interest in the presence of matrix interferences (2). The selectivity 
is tested by spiking at least six sources of the appropriate matrix with the analyte at LLOQ 
(2). The specificity of the method is evaluated by analyzing at least six sources of the blank 
matrix, and confirmed if no interferences are found at the retention time of the analyte (2).  
Carry-over 
Carry-over of the analyte and corresponding IS should be evaluated during the method 
development by injecting a blank sample immediately after ULOQ. According to the EMA 
guideline, carry-over should not be greater than 20% for the analyte and 5% for the IS (18).  
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Matrix effect 
The EMA guideline recommends evaluation of matrix effect with the aid of the matrix factor 
(MF). The MF is the ratio of the peak area in the presence of matrix to the peak area in 
absence of matrix (18). The MF of the analyte should be normalized by the MF of the IS. The 
MF = 1 indicates no matrix effect, MF ˂1 indicates ion suppression, MF >1 indicates ion 
enhancement (15). The CV of the IS-normalized MF calculated for at least 6 sources of 
matrix should not be greater than 15% (18). 
Recovery 
Recovery (= extraction efficiency) of the analyte should be evaluated at three concentration 
levels (QCL, QCM, and QCH). It does not need to be 100%, but the extent of recovery over 
the different concentration levels should be consistent (2). 
Dilution integrity 
Dilution of the study samples is required when the sample concentration is expected to be 
outside the quantification range. To demonstrate that the analyte of interest can be accurately 
measured by the bioanalytical method after dilution, QCs at the concentration above ULOQ 
should be prepared, and then diluted with blank matrix (18).  
Stability 
Evaluation of the analyte stability in the studied matrix should be carried out to ensure that 
the analyte concentration is not affected during storage, sample preparation and analysis 
steps. Stability should be proven after short-term storage (benchtop stability at room 
temperature, autosampler stability) and long-term storage (frozen at the intended storage 
temperature), and after freeze and thaw cycles. Stability of the analyte and the corresponding 
IS in stock solution should also be assessed (2, 18). 
2.4.6 Analysis of study samples 
The validated LC-MS/MS method is further applied for the analysis of study samples. As for 
the method validation, an analytical run should be opened and closed by the set of CALs, in-
between study samples together with six QCs should be placed randomly. An analytical run 
can be considered valid if the back calculated concentrations of at least 75% CALs and 67% 
QCs are within ± 15% of the nominal value (± 20% for LLOQ). 
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2.5 Metabolite identification in early drug discovery 
 
A critical step in early drug discovery is the detection and identification of metabolites of 
drug leads. It provides information on metabolically labile sites of the molecules suggesting 
structural modifications to reduce their clearance, and also allows an early safety assessment 
via the identification of reactive metabolites (1-4). Metabolite profiles for drug leads are 
typically determined using liver fractions (microsomes, S9) or hepatocytes (5, 6). For the 
detection and quantification of metabolites often present at trace levels in a complex matrix, 
MS instruments providing high resolution, high sensitivity, and accurate mass measurements 
(e.g. Q-TOF) are required (7-10). Afterwards, high resolution accurate mass data along with 
MS/MS fragmentation are processed with the aid of metabolite identification (MetID) 
software packages to generate elemental formulae for metabolites and to provide insight 
about metabolite structures (11). There are many MetID tools, such as Mass-MetaSite 
(Molecular Discovery), ACD/Labs MetID (ACD/Labs), MetabolitePilot (AB Sciex), 
MassHunter Metabolite ID (Agilent) available on the market. Data processing with these 
computer programs follow a similar workflow. For a better understanding, Mass-MetaSite 
program will be taken as an example to describe the algorithm used in data processing. The 
initial step imports HR-MS data and the structure of a parent compound into the computer 
program. The next step involves prediction of possible metabolites from the parent structure, 
and calculation of their exact masses. Mass-MetaSite provides an option for selecting the type 
of metabolites (phase I and/or phase II) to be generated. For example, if the metabolic 
stability assay was performed with microsomes, there would be no need to generate phase II 
metabolites, and thus the time for data analysis could be shortened. After mass calculations, 
the program searches for matches in the experimental total ion chromatogram (TIC). 
Metabolite structures are proposed based on the fragmentation pattern, and presented using a 
Markush notation. Hypothetical fragments for each metabolite are produced by breaking each 
bond, excluding aromatic, double, triple bonds, and bonds to hydrogen atoms (12). Fragments 
for a parent compound are generated by breaking a maximum of four bonds (12). Then the 
fragmentation pattern of a metabolite is compared with the parent one, and a score is assigned 
based on the number of matches/mismatches (12). Mass shifts and mass defects also assist in 
structural characterization (13). The predicted metabolites are classified as to whether they 
are related to first-, second- or higher-generation metabolites (12). Generally, three different 
acquisition files are needed for data processing: (i) a blank file for monitoring the background 
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noise which will be subtracted from other files; (ii) a substrate (parent compound) file (t0) for 
analysis of the fragmentation pattern; and (iii) an incubation file (tx) that contains all the 
products after incubation (remaining parent compound and metabolites) (12). Following data 
processing, the biotransformation map will be automatically created. 
A combination of HR-MS and MetID software significantly accelerates the data acquisition 
and interpretation process allowing high-throughput metabolite identification early in the 
drug discovery. The data generated from MetID studies is useful as a guide for medicinal 
chemists during lead optimization, thus transforming metabolic information into rational drug 
design. 
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Previous studies have shown that kaempferol and its major intestinal metabolite 4-
hydroxyphenylacetic acid (4-HPAA) exert anxiolytic activity in mice. To gain a better 
understanding of their pharmacological effects, pharmacokinetic (PK) studies were conducted 
with the aim to evaluate PK properties of the compounds after oral and intravenous 
administrations. At first, UHPLC-MS/MS methods were developed and validated according 
to the principles of current regulatory guidelines for industry. The validated methods were 
later applied for quantification of kaempferol and 4-HPAA in rat plasma. PK parameters were 
calculated with the industry standard software WinNonlin using non-compartmental and 
compartmental analyses. PK studies revealed that kaempferol and its metabolite 4-HPAA are 
highly cleared compounds so that effective concentrations at the site of action do not appear 
to be reached. At present, it is not clear how the anxiolytic-like effects reported for the 
compounds can be explained. 
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Abstract 
Kaempferol is a major flavonoid in the human diet and in medicinal plants. The compound 
exerts anxiolytic activity when administered orally in mice, while no behavioural changes 
were observed upon intraperitoneal administration, or upon oral administration in gut 
sterilized animals. 4-hydroxyphenylacetic acid (4-HPAA), which possesses anxiolytic effects 
when administered intraperitoneally, is a major intestinal metabolite of kaempferol. 
Pharmacokinetic properties of the compounds are currently not clear. 
UHPLC-MS/MS methods were validated to support pharmacokinetic studies of kaempferol 
and 4-HPAA in rats. Non-compartmental and compartmental analyses were performed. After 
intravenous administration, kaempferol followed a one-compartment model, with a rapid 
clearance (4.40-6.44 l/h/kg) and an extremely short half-life of 2.93-3.79 min. After oral 
gavage it was not possible to obtain full plasma concentration-time profiles of kaempferol. 
Pharmacokinetics of 4-HPAA was characterized by a two-compartment model, consisting of 
a quick distribution phase (half-life 3.04-6.20 min) followed by a fast elimination phase (half-
life 19.3-21.1 min). 
Plasma exposure of kaempferol is limited by poor oral bioavailability and extensive 
metabolism. Both compounds are rapidly eliminated, so that effective concentrations at the 
site of action do not appear to be reached. At present, it is not clear how the anxiolytic-like 
effects reported for the compounds can be explained. 
 
Keywords: 4-HPAA, kaempferol, pharmacokinetics, UHPLC-MS/MS. 
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1 Introduction 
Kaempferol occurs in numerous vegetables, fruits and medicinal plants, and is thus a 
commonly ingested flavonoid. The compound reportedly possesses a wide range of biological 
and pharmacological activities [1, 2]. However, flavonoids are extensively metabolized by 
the colonic microflora [3, 4] and activities reported for kaempferol may not necessarily be 
due to the compound itself but possibly to metabolites. Recent in vitro study on the intestinal 
permeability of kaempferol showed that the compound undergoes significant 
biotransformation, with only a small fraction of the unchanged kaempferol able to cross the 
intestinal barrier [5]. A major intestinal metabolite of kaempferol is 4-hydroxyphenylacetic 
acid (4-HPAA) [6, 7]. Anxiolytic activity of kaempferol was shown in behavioural paradigms 
in mice. However, the anxiolytic properties were only seen after oral administration, while no 
behavioural changes were observed upon intraperitoneal (i.p.) administration. In contrast, 4-
HPAA showed anxiolytic affect after i.p. application [8]. In addition, the anxiolytic effect of 
orally administered kaempferol was absent in gut sterilized mice, supporting the hypothesis 
that kaempferol requires metabolic transformation into a pharmacologically active 
compound. In a comparison of kaempferol, quercetin and myricetin, the number of hydroxyl 
groups on the B-ring of flavonols appeared to affect the anxiolytic-like properties of 
flavonoids, as decreasing activity was seen with an increasing number of hydroxyl groups 
[8]. 
4-HPAA is not only an intestinal metabolite of kaempferol, but also an endogenous 
metabolite of the neurotransmitter dopamine. 4-HPAA has been described as a possible 
biological marker for depression, since decreased 4-HPAA concentration has been linked to 
depression and anxiety [9, 10]. To gain a better understanding of the antidepressant effect of 
kaempferol and 4-HPAA we here investigated the pharmacokinetic (PK) properties of 
kaempferol and 4-HPAA after intravenous and oral administration in rats. Several PK and 
metabolism studies with kaempferol have been published, whereby HPLC coupled with 
ultraviolet (UV) [11, 12], electrochemical [13], chemiluminescence [14] and MS [15] 
detection was used for the quantification in rat or human plasma. However, these methods do 
not meet current requirements for bioanalytical methods, and the above mentioned MS 
assays, in our hands, did not meet validation criteria of the FDA and EMA guidelines for 
industry [16, 17]. We here report on the development and validation of UHPLC-MS/MS 
methods for determination of kaempferol and 4-HPAA in Sprague Dawley rat plasma, and on 
the evaluation of the PK properties of the compounds. 
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2 Materials and methods 
2.1 Chemicals and reagents 
Kaempferol (Figure 1A) (purity 97.7%) was purchased from Tokyo Chemical Industry Co. 
(Tokyo, Japan). 4-HPAA (Figure 1C) (purity 98%), solution of glucuronidase/sulfatase from 
Helix pomatia (≥100000 and ≥2000 units/ml, respectively), bovine serum albumin (BSA), 
Cremophor, Tween-80, PEG were from Sigma-Aldrich (St. Louis, MO, USA). Kaempferol-
3-O-glucuronide (Figure 1B) (purity 99.6%) was purchased from Extrasynthese (Genay, 
France). 
13
C15-kaempferol was obtained from IsoLife Company (Wageningen, The 
Netherlands), and 
2
H2-labeled 4-HPAA was from Diverchim (Roissy-en-France, France). 
Methanol (HPLC grade), ammonium formate, formic (FA) and acetic acid (AA) (purity 98-
100%) were from Biosolve BV (Valkenswaard, the Netherlands). ACN, isopropanol (HPLC 
grade) and DMSO were supplied by Scharlau S.L. (Barcelona, Spain). Deionized water was 
obtained from an EASY pure II (Barnstead; Dubuque, IA, USA) water purification system. 
Blank male Sprague-Dawley (SD) lithium heparin rat plasma was purchased from Seralab 
(Haywards Heath, UK). 
2.2 Standards and stock solutions 
Stock solutions (SS) of kaempferol, kaempferol-3-O-glucuronide and 4-HPAA were prepared 
in DMSO by weighing the compounds on a micro balance (Sartorius, Göttingen, Germany). 
Working solutions 1 (WS1) 
at a concentration of 100 µg/ml of the analytes were prepared in methanol. The WS1 of 
13
C15-
labeled kaempferol was prepared in methanol by diluting the SS at a concentration of 500 
µg/ml. For 
13
C15-labeled kaempferol, a second working solution 2 (WS2), at a concentration 
of 200 ng/ml, was prepared daily from WS1. The WS1 of 
2
H2-labeled 4-HPAA was prepared 
in methanol at a concentration of 50 µg/ml. A WS2 (500 ng/ml) was prepared every day from 
WS1. All the SSs and WSs were stored below -65ºC until analysis. 
2.3 Preparation of calibration standards and samples for quality control  
Two sets of calibrators (Cals) over the range of 20.0-2000 ng/ml, and quality controls (QCs) 
at low, medium and high levels (QCL = 60 ng/ml, QCM = 1000 ng/ml, QCH = 1600 ng/ml) 
were prepared in rat plasma (for kaempferol) and in BSA (for 4-HPAA), by serial dilution of 
the WS (100 µg/ml). For kaempferol-3-O-glucuronide, two sets of CALs over the range of 5-
500 ng/ml and QCs (QCL = 15 ng/ml, QCM = 250 ng/ml, QCH = 400 ng/ml) were prepared 
in rat plasma. All samples were aliquoted into polypropylene tubes, and stored below -65ᵒC 
until analysis. 
2.4 Sample processing 
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2.4.1 Kaempferol extraction from rat plasma 
A volume of 75 µl of plasma was loaded onto a 96-well Ostro plate (Waters Corp., Milford, 
MA, USA). 225 µl of WS2 of the internal standard (IS) (200 ng/ml) were added to achieve a 
3:1 solvent/plasma ratio. Samples were eluted into a 96-deepwell plate under a positive 
pressure of 40 psi for 7 min (Pressure + 96, Biotage, Sweden), and dried under a heated 
nitrogen flow (EVX-96, Apricots, Covina, CA, USA). Dried residues were reconstituted with 
200 µL of solvent consisting of 50% A (10 mM ammonium formate + 0.05% FA) and 50% B 
(ACN + 0.05% FA). The plate was shaken (Mixmate, Eppendorf, Hamburg, Germany) for 30 
min at 2000 rpm before injection (5 µl). 
2.4.2 4-HPAA extraction from BSA 
An aliquot of 75 µl of BSA was mixed with 150 µl of WS2 of the corresponding IS (500 
ng/ml) and 300 µl ACN in 1.5 ml tubes. The mixture was briefly vortexed, and centrifuged at 
10ºC for 15 min at 13200 rpm (Centrifuge 5415R, Eppendorf, Schönenbuch, Switzerland). 
Afterwards, 400 µl of supernatant were collected into a 96-deepwell plate. Samples were 
dried under a heated nitrogen flow and reconstituted with 200 µl of 50% A (5 mM aqueous 
AA) and 50% B (ACN + 5 mM AA). The plate was shaken for 30 min at 2000 rpm prior to 
injection (10 µl). 
2.4.3 Extraction of total kaempferol after treatment with glucuronidase/sulfatase 
Buffer was prepared with water, ascorbic acid (0.5%, w/v), and acetic acid (10%, v/v) at a 
1:1:1 ratio. An aliquot (15 μl) of buffer was mixed with 38 μl of plasma samples, and 4 μl of 
enzyme solution were added. The mixture was incubated at 37°C for 1 h. Aliquots (57 µl) of 
the reaction mixture were loaded into a 96-well Ostro plate, and 171 µl of IS (
13
C15-
kaempferol) solution (200 ng/ml) were added for extraction as described in 2.4.1. 
2.4.4 Extraction of kaempferol-3-O-glucuronide from rat plasma 
Aliquots (38 µl) of plasma, and 114 µl of WS2 of the IS (1000 ng/ml) were loaded onto a 96-
well Ostro plate for extraction as described in 2.4.1. 
2.5 LC-MS/MS instrumentation and chromatographic conditions 
An Agilent UHPLC 1290 system consisting of a binary pump, autosampler, column oven, 
and needle wash unit was coupled to an Agilent 6430 triple quadrupole mass spectrometer 
(Agilent Technologies, USA). The instrument was controlled by MassHunter software 
(version 6.0; Agilent Technologies, USA). Nitrogen generated by a nitrogen generator N2-
Mistral (Schmidlin AG, Neuheim, Switzerland) was used for desolvation and nebulization. 
Nitrogen was also used as collision gas. The MS parameters for each compound are 
summarized in Table 1. 
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Chromatography of kaempferol and IS was performed on an Acquity BEH C18 column (1.7 
µm, 2.1 × 50 mm) (Waters Corp., Milford, MA, USA). Column temperature was set at 80ºC, 
and the autosampler temperature at 10ºC. The mobile phase consisting of eluent A (0.1 % 
aqueous FA) and eluent B (ACN with 0.1 % FA) was delivered at a flow rate of 0.6 ml/min. 
Separation was achieved with the following gradient: 0-1 min, 15% B, 1-3 min, 15-60% B, 3-
3.1 min, 60-100% B, 3.1-4 min, 100% B, 4-4.1, 100-15% B, 4.1-5.0 min, 15% B. The total 
run time was 5 min. The needle wash solvent consisted of water and methanol (50:50, v/v). 
Chromatography of 4-HPAA and IS was performed on an Acquity HSS T3 column (1.8 µm, 
2.1 × 100 mm) (Waters Corp., Milford, MA, USA). Column temperature was set at 45ºC, and 
the autosampler temperature at 10ºC. The mobile phase consisting of eluent A (5 mM 
aqueous AA) and eluent B (ACN with 5 mM AA) was delivered at a flow rate of 0.5 ml/min. 
Separation was achieved with the following gradient: 0-1 min, 5% B, 1-3 min, 5-100% B, 3-4 
min, 100% B, 4-4.1 min, 100-5% B, 4.1-5, 5% B. The total run time was 5 min. The needle 
wash solvent consisted of water/methanol/isopropanol/ACN (1:1:1:1, v/v/v/v). The separation 
of kaempferol-3-O-glucuronide and IS was performed on a Kinetex XB column (1.7 µm, 
2.1×100 mm) (Phenomenex, Torrance, CA, USA). Column temperature was set at 55ºC, and 
the autosampler temperature at 10ºC. The mobile phase consisting of eluent A (0.1% FA) and 
eluent B (ACN with 0.1% FA) was delivered at a flow rate 0.5 ml/min. The separation was 
achieved with the following gradient: 0-1 min, 2% B, 1-6 min, 2-50% B, 6.0-6.01 min, 50-
100% B, 6.01-7 min, 100% B, 7-7.01 min, 100-2% B, 7.01-8 min, 2% B. The total run time 
was 8 min. The needle wash solvent consisted of water/methanol/isopropanol/ACN (1:1:1:1, 
v/v/v/v). 
2.6 Method validation 
The regression curves obtained for kaempferol and 4-HPAA from two sets of seven 
calibrators over the range 20.0-2000 ng/ml were validated by six QCs. Carryover was 
assessed by two extracted blank matrices injected immediately after the ULOQ. Selectivity of 
the method was confirmed by six QC samples at the LLOQ, prepared in three different 
batches of rat plasma (for kaempferol), or in three different lots of BSA (for 4-HPAA). Due 
to the endogenous presence of 4-HPAA in blank plasma samples, a BSA solution (60 g/l) was 
used as a surrogate matrix. Specificity of the methods was checked with six blank samples 
(three different batches of rat plasma or BSA in replicates). To fulfill acceptance criteria, the 
peak area measured in the blank samples had to be within 20% of the analyte peak area at 
LLOQ. The intra-day imprecision (CV) and inaccuracy (RE) were estimated by performing 
six replicates of LLOQ, QCL, QCM, QCH and ULOQ. The inter-run CV and RE were 
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assessed by the same QCs on three different days. Extraction yields of analytes and the 
corresponding IS were evaluated at three levels before extraction, and spiked with the IS after 
extraction, in comparison to six blank samples spiked after extraction. The dilution QC 
samples (10 000 ng/ml) were prepared and diluted at 10- and 100-fold. Short-term (three 
overnight freeze-thaw cycles, 4 h benchtop stability at RT, 48 h autosampler stability at 10ºC) 
and long-term stability tests were performed. Stability of the SS of kaempferol after 180 days 
of storage below -65ºC and stability of the SS of 4-HPAA after 35 days of storage below -
65ºC were confirmed by comparison with freshly prepared SSs. 
2.7 PK studies 
2.7.1 Animals 
Male SD rats (body weight 320-350 g) were purchased from Charles River (Wilmington, 
MA, USA) The animals were individually housed in plastic cages and maintained under a 12 
h/12 h light/dark cycle. The rats received water ad libitum and a standard chow. Before being 
used in experiments, the animals were allowed to acclimate to their environment for one 
week. All animal experiments were performed according to the policies and guidelines of the 
Institutional Animal Care and Use Committee (IACUC) of the University of Florida, 
Gainesville, USA, study protocol # 200903448. 
2.7.2 Design of PK studies in rats 
Rats (n = 8 per group) were randomly divided into six groups and used for oral (p.o) and 
intravenous (i.v.) studies. Kaempferol was given by i.v. bolus injection in the doses of 1, 2 
and 4 mg/kg body weight (b.w.). After a one week washout period the same rats received 
kaempferol at 5, 10, 20 mg/kg b.w. p.o. 4-HPAA was administered i.v. at 1, 2 and 4 mg/kg 
b.w. Both compounds were dissolved in a vehicle consisting of Cremophor/Tween-
80/PEG/ethanol/water (2:1:1:1:5, v/v/v/v/v) for p.o. and i.v. administrations. Blood samples 
(500 μl) were collected from the sublingual vein into heparinized tubes at 0 (prior to dosing), 
2, 5, 10, 20, 30 min, 1, 2, 4, 6, 8 and 12 h. The loss of blood volume was replaced with 1 ml 
normal saline. Plasma samples were obtained by centrifugation at 4000 rpm for 15 min at 
4ºC, then transferred into 1.5 ml tubes and stored at below -65ºC until analysis. 
2.8 PK data analysis 
Mean plasma concentrations of kaempferol and 4-HPAA versus time were plotted in 
Graphpad Prism (version 5.01; San Diego, CA, USA). PK parameters were determined by 
non-compartmental (NCA) and compartmental (CA) analyses using WinNonlin
®
 software 
(version 5.2.1; Pharsight Corporation, St. Louis, MO, USA). 
 
70
2.8.1 Non-compartmental analysis 
The PK parameters included the extrapolated concentration at time 0 (C0), terminal 
elimination rate constant (ke), terminal half-life (t½), area under the concentration-time curve 
(AUC), area under the first moment curve (AUMC), mean residence time (MRT), volume of 
distribution at terminal phase (Vd), and the plasma clearance (CL). The slope of the terminal 
phase was estimated by log-linear regression using the “best fit” method and uniform 
weighting. The ke was derived from the slope. The t½ was calculated as 0.693/ke. The linear 
trapezoidal rule was applied for determination of the area under the curve from time 0 to the 
last measurable concentration (AUC0-last) and extrapolated to infinity (AUC0-). The CL 
following the i.v. dosing was calculated as Dose/AUC0-. The Vd was calculated as CL/ke. 
2.8.2 Compartmental analysis 
A one-compartment body model with different weighting factors was fitted to the kaempferol 
data, and a two-compartment body model with different weighting factors was fitted to the 4-
HPAA data. The goodness of fit was estimated by Akaike's information criterion (AIC), 
Schwarz's Bayesian criterion (SBC), and weighted sum of squared residuals (WSSR). The 
equation for the i.v. bolus one-compartment model was as follows: Cp(t)=C0×exp
-ke×t
, where 
Cp(t) is a concentration of a drug in plasma at time t; C0 is the extrapolated concentration at 
time 0; ke is an elimination rate constant; and t is the time after drug administration. The 
equation for the i.v. bolus two-compartment model was as follows: Cp(t)=A×exp
-×t
 + B×exp
-
×t
, where A and B were mathematical coefficients,  the distribution rate constant and  the 
elimination rate constant. 
2.9 Statistics 
The analytical data were calculated in Excel and presented as mean ± SD with CV and RE. 
 
3 Results 
3.1 Validation of the bioanalytical methods for kaempferol and 4-HPAA 
Detection and quantification of kaempferol and 4-HPAA were performed by UHPLC-
MS/MS. Figure 2 shows extracted multiple reaction monitoring (MRM) chromatograms of 
kaempferol in rat plasma and 4-HPAA in BSA, and their corresponding ISs. Two UHPLC-
MS/MS methods were fully validated according to industry guidelines for bioanalytical 
methods [16, 17]. CV was within 15%, and RE did not exceed ± 15% of the nominal value, 
except at the LLOQ (20%). Calibration curves were quadratic in the range of 20.0-2000 
ng/ml, with a 1/X weighting factor, and a mean r
2
 of 0.9993 for kaempferol, and 0.9995 for 4-
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HPAA (Supporting information Tables 1 and 2). No carryover was detected (Supporting 
information Tables 3 and 4). Both methods were shown to be selective, with CV and RE 
<20% (Supporting information tables 5 and 6). In the blank samples, no peaks were observed 
at the retention time of analytes, confirming specificity of the methods (Data not shown). 
Results from the intra-and inter-day imprecision and inaccuracy for both compounds are 
summarized in Table 2. The mean extraction recovery of kaempferol from plasma was 61.7% 
(QCL), 60.2% (QCM), and 73.2% (QCH), and recovery of 
13
C15-labeled kaempferol was 
69.2% (Supporting information Table 7). The extraction yield of 4-HPAA from BSA was 
80.2% (QCL), 91.0% (QCM), and 92.3% (QCH), and recovery of 
2
H2-4-HPAA was 112% 
(Supporting information Table 8). To demonstrate that there was no impact of dilution on the 
results, blank samples spiked with the analyte at 10000 ng/ml were prepared and then diluted 
10- and 100-fold. For both dilution factors, the CV was below 2.22%, and RE was between -
1.48% and 7.63% (Supporting information Tables 9 and 10). 
Kaempferol and 4-HPAA were stable in biological samples during sample collection and 
handling, after three freeze and thaw cycles, after 4 h storage at RT, and after 48 h storage in 
the autosampler at 10°C (Supporting information Tables 11 and 12). Kaempferol in plasma 
and 4-HPAA in BSA were shown to be stable during a year of storage below -65°C 
(Supporting information Figures 1 and 2). The SS of kaempferol stored below -65°C for 180 
days and kept for 6 h at RT before analysis was shown to be stable. Degradation expressed as 
a percentage of the difference was 3.23% (Supporting information Table 13). Degradation of 
the SS of 4-HPAA (stored below -65°C for 35 days and kept for 6 h at RT) was -0.737% 
(Supporting information Table 14). Hence, the bioanalytical methods were shown to be 
reliable and reproducible for the quantification of kaempferol and 4-HPAA. 
 
3.2 Pharmacokinetics of kaempferol 
Linear and semi-logarithmic plots of mean plasma concentration-time profiles in rats after i.v. 
administration are presented in Figure 3, and main PK parameters of kaempferol after a 
single i.v. dose of 1, 2 and 4 mg/kg were calculated by NCA using WinNonlin
®
 (Table 3). 
For the doses of 1 and 2 mg/kg, the plasma concentration of kaempferol dropped below the 
LLOQ 20 min after injection (Fig. 3). Kaempferol plasma concentrations at time 0, and 
AUC0- increased in a dose-proportional manner over the dose range tested (Fig. 4). The ke 
was high (10.4-13.9 h
-1
), resulting in an extremely short terminal t1/2 of 3.01-4.05 min (Table 
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3). PK studies of kaempferol in rats showed very high plasma CL (4.00-5.77 l/h/kg) and Vd 
of 0.344-0.414 l/kg. 
A one-compartment i.v. bolus model with first-order elimination and 1/Ŷ2 as weighting factor 
was chosen as the best fit model, and goodness of fit was confirmed by the AIC, SBC, and 
WSSR (Supporting information Table 15). The goodness of fit was also shown in a 
comparison of simulated and observed concentrations vs. time profiles using the one-
compartment body model (Fig. 5). PK parameters obtained from a compartmental modeling 
are summarized in Table 4. The values of AUC, MRT, Vd and CL of the compartmental 
analysis were close to those obtained by NCA analysis. 
Individual plasma concentrations vs. time profiles after a single oral dose of 5, 10 and 20 
mg/kg are shown in Figure 6. After oral administration it was not possible to obtain full 
concentration-time profiles needed for an estimation of the AUC, and for calculation of the 
absolute bioavailability (Fig. 6). Plasma samples were then treated with β-
glucuronidase/sulfatase to indirectly detect phase II metabolites of kaempferol, and to 
quantify total kaempferol in plasma (Fig. 7). The data showed that kaempferol was present 
almost exclusively as conjugates, and that phase II metabolites increased very rapidly after 
oral administration of kaempferol to reach maximum concentration at 8 h (7308 ± 2213 µg/l). 
With the aid of a reference compound, one metabolite was identified as kaempferol-3-O-
glucuronide. The second metabolite was either the 7- or 4-O-glucuronide, but the exact 
position of glucuronidation could not be established in this case due to non-availability of 
reference compounds. While plasma concentrations of glucuronides reached a maximum 30 
to 60 min after oral administration and gradually decreased over the sampling period of 12 h, 
the concentration of total sulfate/glururonide conjugates reached its maximum at 8 h, before 
starting to decline slowly. A strong plasma protein binding of sulfate conjugates is probably 
the most reasonable explanation for this behavior. However, this should be further 
substantiated in future investigations. 
 
3.3 Pharmacokinetics of 4-HPAA 
We first determined plasma concentrations of 4-HPAA in the pre-dose samples, and 
concentrations in the range of 31-127 µg/l were found. For each rat the pre-dose values were 
subtracted from all post-dose concentrations prior to PK analysis. Concentration-time profiles 
(linear and semi-logarithmic plots) after a single i.v. administration of 1, 2 and 4 mg/kg of 4-
HPAA are shown in Fig. 8. At the dose of 4 mg/kg the compound was detected for up to 8 h 
(Fig. 8B). For the doses of 1 and 2 mg/kg, in contrast, the plasma concentration of 4-HPAA 
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dropped below the LLOQ after 2 h. The C0 and AUC0- showed a linear increase over the 
range of administered doses, and thus confirmed dose proportionality (Fig. 9). The PK 
parameters obtained from the NCA are given in Table 5. The ke of 4-HPAA ranged from 
1.88-2.45 h
-1
, resulting in a short terminal t1/2 of 18.6-28.3 min. The compound showed high 
plasma CL (0.876-1.13 l/h/kg) and Vd of 0.391-0.666 l/kg. 
A two-compartment i.v. bolus model with first-order elimination and 1/Ŷ2 as weighting factor 
fitted the 4-HPAA data well for the groups of 2 and 4 mg/kg b.w. The goodness of fit was 
confirmed by the AIC, SBC, WSSR (Supporting information Table 16). A comparison of 
simulated and observed concentrations vs. time profiles with the two-compartment body 
model also confirmed goodness of fit (Fig. 10). PK parameters of the two-compartment body 
model are summarized in Table 6. 4-HPAA was quickly distributed from central 
compartment to peripheral tissues (t1/2 = 3.04-6.20 min). The distribution phase 
characterized by rapid decline in 4-HPAA concentrations ( = 10.0-15.4 h-1) followed by 
slower elimination phase ( = 1.47-2.34 h-1) with elimination half-life (t1/2) of 19.3-21.1 min. 
The values of AUC (h×µg/l), AUMC (h×h×µg/l), and MRT (min) were 1884-3914, 554-
1666, 22.7-23.1, respectively, and confirmed results obtained from the NCA. In contrast, the 
two-compartment body model with first-order elimination and 1/Ŷ2 as weighting factor did 
not provide the best fit for the data of the 1 mg/kg dosing group. 
In addition, we determined plasma concentrations of 4-HPAA after oral administration of 
kaempferol (20 mg/kg). The increase of plasma concentration was statistically insignificant in 
comparison to the endogenous level of the compound (Data not shown). 
 
4 Discussion 
After i.v. application, PK of kaempferol followed a one-compartment model. PK study 
revealed that kaempferol had a high clearance, resulting in an extremely short half-life. Upon 
oral administration, kaempferol showed low bioavailability due to extensive pre-systemic 
metabolism. In plasma the compound was present as phase II conjugates. Our findings are 
supported by the results from in vitro intestinal permeability study which demonstrated 
extensive metabolism of kaempferol in Caco-2 cell model [5]. Further, Barrington et al. 
identified biotransformation of kaempferol into glucuronides and sulfates inside the Caco-2 
cells [18]. Several PK studies with kaempferol have been reported in the literature [11, 14, 
15]. From a current perspective, however, they suffered from methodological limitations, 
such as non-specific detection, and/or from inappropriately high dosing of kaempferol in the 
74
animals. Barve et al. [11] evaluated the PK parameters after i.v. application of kaempferol at 
doses of 10 and 25 mg/kg, and after oral doses of 100 and 250 mg/kg. For the quantification 
of kaempferol they used UV-detection, which is insensitive and not sufficiently selective for 
application to PK studies and explains why these extraordinary doses were necessary. In 
another study [14] kaempferol was administered orally at doses of 1250 and 2500 mg/kg. 
Such high doses can result in damage to tight junctions causing an increase in intestinal 
permeability. These examples show the importance of sensitive and validated bioanalytical 
methods, and appropriate dosing in PK studies with natural products. 
For kaempferol a wide range of biological activities have been reported with in vitro assays 
[1, 2], in which the compound was typically tested at micromolar concentrations. Given that 
we found plasma concentrations of free kaempferol that were one to two orders of magnitude 
lower than concentrations used in these in vitro pharmacological studies, the relevance of 
reported activities has to be seriously questioned. Future pharmacological studies with 
kaempferol should, therefore, focus on the properties of the metabolites rather than the parent 
compound. Examples of pharmacologically active phase II drug metabolites include 
morphine-6-glucuronide [19] and 4-hydroxytriamterene sulfate [20]. 
To the best of our knowledge, we determined the first concentration-time profile of 4-HPAA, 
a major intestinal metabolite of kaempferol. PK of 4-HPAA was characterized by a two-
compartment model, with a quick distribution into peripheral tissues as well as a rapid 
elimination from the body. The plasma levels of 4-HPAA did not increase after oral 
administration of kaempferol in rats. This can be explained by inability of 4-HPAA to 
permeate through the intestinal barrier [5]. 
CNS active molecules need to cross the blood-brain barrier (BBB) in order to exert a 
pharmacological effect. BBB permeability of kaempferol and 4-HPAA has been previously 
evaluated in BBB models with rat and human derived cell lines, whereby high permeability 
of kaempferol and no permeability of 4-HPAA was found [5]. Lacking BBB permeation of 4-
HPAA could be due to the negative membrane potential of the BBB, on the one hand, and the 
negatively charged 4-HPAA (clogD7.4 = −1.86) [5, 21], on the other. 
 
4.1 Conclusions 
UHPLC-MS/MS methods for the quantification of kaempferol and 4-HPAA in rat plasma 
were developed and validated in compliance to international regulatory guidelines for 
bioanalytical method validation [16, 17]. Poor oral bioavailability and extensive metabolism 
are the factors limiting the plasma exposure of kaempferol, and the low plasma 
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concentrations found in our study cast a serious doubt on the relevance of numerous in vitro 
pharmacological data with this flavonoid. Kaempferol was mostly present as phase II 
metabolites. Among these, one glucuronide could be identified, and high and persistent levels 
of sulfates were indirectly deduced from the enzymatic treatment of plasma samples. Thus, it 
is not clear whether in vivo pharmacological effects of kaempferol reported in the literature 
are to be attributed to the parent compound or to its phase II metabolites. PK studies revealed 
that kaempferol and its metabolite 4-HPAA are highly cleared compounds so that effective 
concentrations at the site of action do not appear to be reached. Therewith, plasma levels of 
4-HPAA were not significantly increased after oral administration of kaempferol. Hence, it is 
unclear how CNS-related pharmacological effects reported for kaempferol and 4-HPAA are 
to be explained. 
 
Acknowledgements 
Volha Zabela was a recipient of a scholarship from the Swiss Federal Commission. Financial 
support from the Swiss National Science Foundation (project 105320_126888) is gratefully 
acknowledged. Authors thank Orlando Fertig for technical assistance. 
 
Conflict of interest 
The authors declare no conflicts of interest. 
76
5 References 
 
[1] J.M. Calderon-Montano, E. Burgos-Moron, C. Pérez-Guerrero, M. López-Lázaro, A review on the 
dietary flavonoid kaempferol, Mini Rev. Med. Chem. 11 (2011) 298-344. 
[2] A.Y. Chen, Y.C. Chen, A review of the dietary flavonoid, kaempferol on human health and cancer 
chemoprevention, Food Chem. 138 (2013) 2099-2107. 
[3] P.C.H. Hollman, Absorption, bioavailability, and metabolism of flavonoids, Pharm. Biol. 42 
(2004) 74-83. 
[4] J. Van Duynhoven, E.E. Vaughan, D.M. Jacobs, R.A. Kemperman, E.J.J. Van Velzen, G. Gross, 
L.C. Roger, S. Possemiers, A.K. Smilde, J. Doré, J.A. Westerhuis, T. Van de Wiele, Metabolic fate of 
polyphenols in the human superorganism, Proc. Natl. Acad. Sci. USA. 108 (2011) 4531-4538. 
[5] F. Moradi-Afrapoli, M. Oufir, F.R. Walter, M.A. Deli, M. Smiesko, V. Zabela, V. Butterweck, M. 
Hamburger, Validation of UHPLC-MS/MS methods for the determination of kaempferol and its 
metabolite 4-hydroxyphenyl acetic acid, and application to in vitro blood-brain barrier and intestinal 
drug permeability studies, J. Pharm. Biomed. Anal. 128 (2016) 264–274. 
[6] L. Griffiths, G. Smith, Metabolism of apigenin and related compounds in the rat. Metabolite 
formation in vivo and by the intestinal microflora in vitro, Biochem. J. 128 (1972) 901-911. 
[7] J. Winter, M.R. Popoff, P. Grimont, V.D. Bokkenheuser, Clostridium orbiscindens sp. nov., a 
human intestinal bacterium capable of cleaving the flavonoid C-ring, Int. J. Syst. Microbiol. 41 (1991) 
355-357. 
[8] C. Vissiennon, K. Nieber, O. Kelber, V. Butterweck, Route of administration determines the 
anxiolytic activity of the flavonols kaempferol, quercetin and myricetin—are they prodrugs?, J. Nutr. 
Biochem. 23 (2012) 733-740. 
[9] H. Sabelli, J. Kawcett, E. Gusovsky, J. Edwards, H. Jeffriess, J. Javaid, Phenylacetic acid as an 
indicator in bipolar affective disorders, J. Clin. Psychopharmacol. 3 (1983) 268-270. 
[10] B. Davis, D. Durden, R. O'reilly, The effect of age, sex, weight and height on the plasma 
concentrations in healthy subjects of the acidic metabolites of some biogenic monoamines involved in 
psychiatric neurological disoders, Prog. Neuropsychopharmacol. Biol. Psychiatry 15 (1991) 503-512. 
[11] A. Barve, C. Chen, V. Hebbar, J. Desiderio, C. Saw, A. Kong, Metabolism, oral bioavailability 
and pharmacokinetics of chemopreventive kaempferol in rats, Biopharm. Drug Dispos. 30 (2009) 
356-365. 
[12] S. Yodogawa, T. Arakawa, N. Sugihara, K. Furuno, Glucurono-and sulfo-conjugation of 
kaempferol in rat liver subcellular preparations and cultured hepatocytes, Biol. Pharm. Bull. 26 (2003) 
1120-1124. 
[13] A. Bolarinwa, J. Linseisen, Validated application of a new high-performance liquid 
chromatographic method for the determination of selected flavonoids and phenolic acids in human 
plasma using electrochemical detection, J. Chromatogr. B. 823 (2) (2005) 143-151. 
[14] Q. Zhang, Y. Zhang, Z. Zhang, Z. Lu, Sensitive determination of kaempferol in rat plasma by 
high-performance liquid chromatography with chemiluminescence detection and application to a 
pharmacokinetic study, J. Chromatogr. B. 877 (2009) 3595-3600. 
[15] W.-D. Zhang, X.-J. Wang, S.-Y. Zhou, Y. Gu, R. Wang, T.-L. Zhang, H.Q. Gan, Determination 
of free and glucuronidated kaempferol in rat plasma by LC–MS/MS: Application to pharmacokinetic 
study, J. Chromatogr. B. 878 (23) (2010) 2137-2140. 
[16] FDA, Guidance for Industry: Bioanalytical Method Validation, Center for Drug Evaluation and 
Research, Draft Guidance 2013. Available at 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm3681
07.pdf. Accessed February 15, 2016. 
[17] EMA, Guideline on bioanalytical method validation, European Medicines Agency 
(EMEA/CHMP/EWP/192217/2009), 2011. Available at 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC50010968
6.pdf. Accessed February 15, 2016. 
[18] R. Barrington, G. Williamson, R.N. Bennett, B.D. Davis, J.S. Brodbelt, P.A. Kroon, Absorption, 
conjugation and efflux of the flavonoids, kaempferol and galangin, using the intestinal CaCo-2/TC7 
cell model, J. Funct. Foods. 1 (2009) 74-87. 
77
[19] R. Osborne, P. Thompson, S. Joel, D. Trew, N. Patel, M. Slevin, The analgesic activity of 
morphine-6-glucuronide, Br. J. Clin. Pharmacol. 34 (1992) 130-138. 
[20] A.E. Busch, H. Suessbrich, K. Kunzelmann, A. Hipper, R. Greger, S. Waldegger, E. Mutschler, 
B. Lindemann, F. Lang, Blockade of epithelial Na+ channels by triamterenes—Underlying 
mechanisms and molecular basis, Pflügers Archiv. 432 (1996) 760-766. 
[21] L. Di, E.H. Kerns, Drug-like properties: concepts, structure design and methods from ADME to 
toxicity optimization, 2nd ed., Academic Press, New York, 2015. 
 
 
78
Legends for Figures 
Figure 1. Chemical structures of kaempferol (A), kaempferol-3-O-glucuronide (B) and 4-
HPAA (C). 
Figure 2. Typical MRM chromatograms of kaempferol quantifier (A), kaempferol qualifier 
(B), 
13
C15-labeled kaempferol (C) in rat plasma, and 4-HPAA quantifier (D), 4-HPAA 
qualifier (E), and 
2
H2-labeled 4-HPAA (F) in BSA. Both analytes presented at LLOQ (20 
ng/ml). 
Figure 3. Plasma concentrations of kaempferol (mean ± S.D.) after a single intravenous 
administration of 1, 2 and 4 mg/kg b.w., shown as linear (A) and semi-logarithmic (B) plots. 
Figure 4. C0 and AUC0-inf (mean ± S.D.) of kaempferol vs. dosing group (solid line) and fitted 
simple linear regression (dashed line, for visual comparison). 
Figure 5. Observed (mean ± S.D.) and simulated concentration vs. time profiles of 
kaempferol in rats after a single intravenous dose of 1 (A), 2 (B), and 4 (C) mg/kg b.w. 
Figure 6. Plasma concentration vs. time profiles of kaempferol after a single oral dose of 5 
(A), 10 (B), and 20 (C) mg/kg b.w. Data for individual rats are shown. 
Figure 7. Plasma concentration of free kaempferol and its glucuronide conjugates (oral 
dosage = 20 mg/kg) determined after enzymatic treatment (n = 7). Data are shown as mean ± 
SD. 
Figure 8. Plasma concentrations of 4-HPAA (mean ± S.D.) after a single intravenous 
administration of 1, 2 and 4 mg/kg b.w., shown as linear (A) and semi-logarithmic (B) plots. 
Figure 9. C0 and AUC0-inf (mean ± S.D.) of 4-HPAA vs. dosing group (solid lines), and fitted 
simple linear regression (dashed line, for visual comparison). 
Figure 10. Observed (mean ± S.D.) and simulated concentration vs. time profiles of 4-HPAA 
in rats after a single intravenous dose of 2 (A) and 4 (B) mg/kg b.w. 
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TABLES 
 
Table 1: MS/MS parameters of the analytes and the internal standards. 
Compound Precursor 
ion (m/z) 
Product 
ion (m/z) 
Fragmentor 
(V) 
Collision 
energy (V) 
ESI polarity 
Kaempferol quantifier 287.06 69.0 155 54 positive 
Kaempferol qualifier 287.06 152.9 155 34 positive 
Kaempferol-3-O-
glucuronide quantifier 
463.09 287 113 10 positive 
Kaempferol-3-O-
glucuronide qualifier 
463.09 153 113 62 positive 
13
C15-kaempferol 302.0 160.1 167 38 positive 
4-HPAA quantifier 151.0 107.0 102 10 negative 
4-HPAA qualifier 151.0 106.6 102 6 negative 
2
H2-4-HPAA 153.1 109.0 102 10 negative 
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Table 2: Within (n = 6)- and between (n = 18)-run imprecision (expressed as CV%) and inaccuracy (expressed as RE%) of kaempferol QC 
samples in rat plasma and 4-HPAA QC samples in BSA solution, based on 3 series at 5 different levels. 
 Kaempferol 4-HPAA 
Nominal level (ng/ml) 20.0 60.0 1000 1600 2000 20.0 60.0 1000 1600 2000 
Intra-run mean 19.4 60.8 1029 1652 2009 20.4 63.3 1026 1613 1980 
Intra-run S.D. 1.32 2.15 23.3 69.5 39.7 1.83 1.94 13.4 14.0 8.83 
Intra-run CV % 6.82 3.54 2.26 4.21 1.97 9.00 3.06 1.31 0.865 0.446 
Intra-run RE % -3.15 1.39 2.89 3.24 0.448 1.82 5.48 2.55 0.829 -1.01 
Inter-run mean 19.8 62.5 1030 1637 1994 21.0 63.4 1038 1649 2049 
Inter-run S.D. 1.06 1.97 18.9 41.6 36.2 1.21 1.84 14.3 42.1 29.2 
Inter-run CV% 5.35 3.16 1.84 2.53 1.81 5.84 2.93 1.38 2.55 1.43 
Inter-run RE % -1.25 4.11 2.97 2.28 -0.291 4.97 5.70 3.75 3.05 2.44 
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Table 3: PK parameters of kaempferol after a single intravenous administration of 1, 2 and 4 
mg/kg b.w., calculated by non-compartmental analysis (mean ± S.D.). 
Dosing group (mg/kg) 1 2 4 
n 6 6 6 
C0 (µg/l) 3880 ± 1019 5780 ± 2358 13270 ± 2242 
ke (1/h) 11.8 ± 1.13 13.9 ± 1.34 10.4 ± 0.992 
t1/2 (min) 3.56 ± 0.344 3.01 ± 0.280 4.05 ± 0.404 
AUC0-last (h×µg/l) 262 ± 77.0 368 ± 107 992 ± 107 
AUC0- (h×µg/l) 266 ± 76.9 372 ± 108 996 ± 108 
AUMC0-last (h×h×µg/l) 18.7 ± 3.94 20.7 ± 5.19 73.3 ± 16.6 
AUMC0- (h×h×µg/l) 20.0 ± 9.43 22.1 ± 5.75 75.9 ± 17.2 
CL (l/h/kg) 4.00 ± 0.975 5.77 ± 1.60 4.06 ± 0.432 
Vd (l/kg) 0.341 ± 0.0837 0.414 ± 0.109 0.396 ± 0.0624 
MRT (min) 4.39 ± 0.876 3.61 ± 0.437 4.54 ± 0.615 
 
 
82
Table 4: PK parameters of kaempferol after a single intravenous dose of 1, 2 and 4 mg/kg 
b.w., calculated by compartmental analysis
a
 (mean ± S.D.). 
Dosing group (mg/kg) 1 2 4 
n 6 6 6 
Cmax (µg/l) 2928 ± 804 4663 ± 1146 9744 ± 1397 
ke (1/h) 12.1 ± 1.57 14.3 ± 1.23 11.0 ± 0.777 
t1/2 (min) 3.51 ± 0.550 2.93 ± 0.255 3.79 ± 0.266 
AUC (h×µg/l) 250 ± 94.5 328 ± 86.1 887 ± 130 
AUMC (h×h×µg/l) 21.9 ± 12.1 23.3 ± 6.71 81.1 ± 14.8 
CL (l/h/kg) 
Vd (l/kg) 
4.40 ± 1.30 
0.361 ± 0.0855 
6.44 ± 1.63 
0.451 ± 0.109 
4.58 ± 0.621 
0.417 ± 0.0556 
MRT (min) 5.06 ± 0.794 4.23 ± 0.368 5.47 ± 0.384 
a) A one-compartment model with 1/Ŷ2 as weighting factor was fitted to the data. 
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Table 5: PK parameters of 4-HPAA after a single intravenous administration of 1, 2 and 4 
mg/kg b.w., calculated by non-compartmental analysis (mean ± S.D.). 
Dosing group (mg/kg) 1 2 4 
n 5 7 6 
C0 (µg/l) 3651 ± 1333 8763 ± 2415 19788 ± 1643 
ke (1/h) 2.45 ± 1.42 2.42 ± 0.577 1.88 ± 0.860 
t1/2 (min) 20.8 ± 8.84 18.6 ± 6.88 28.3 ± 17.5 
AUC0-last (h×µg/l) 1352 ± 691 1882 ± 739 4095 ± 914 
AUC0- (h×µg/l) 1405 ± 699 1974 ± 759 4134 ± 909 
AUMC0-last (h×h×µg/l) 661 ± 494 600 ± 475 1682 ± 861 
AUMC0- (h×h×µg/l) 784 ± 556 774 ± 639 1978 ± 1000 
CL (l/h/kg) 0.876 ± 0.427 1.13 ± 0.379 1.00 ± 0.179 
Vd (l/kg) 0.391 ± 0.163 0.472 ± 0.114 0.666 ± 0.447 
MRT (min) 29.9 ± 13.6 21.4 ± 8.90 28.1 ± 11.9 
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Table 6: PK parameters of 4-HPAA after a single intravenous dose of 2 and 4 mg/kg b.w., 
calculated by compartmental analysis
a
 (mean ± S.D.). 
Dosing group (mg/kg) 2 4 
n 7 6 
Cmax (µg/l) 9212 ± 2928 17987 ± 4202 
A (µg/l) 5953 ± 2175 13266 ± 906 
B (µg/l) 3259 ± 1177 4721 ± 3412 
 (1/h) 15.4 ± 5.77 10.0 ± 6.46 
 (1/h) 2.34 ± 0.595 1.47 ± 1.13 
t1/2 (min) 3.04 ± 1.15 6.20 ± 4.30 
t1/2 (min) 19.3 ± 7.21 21.1 ± 7.59 
k 10 (1/h) 5.08 ± 1.30 4.41 ± 1.30 
k 12 (1/h) 5.71 ± 3.57 4.62 ± 2.44 
k 21 (1/h) 6.92 ± 2.18 5.68 ± 3.02 
AUC0- (h×µg/l) 1884 ± 710 3914 ± 848 
AUMC (h×h×µg/l) 554 ± 232 1666 ± 1196 
CL (l/h/kg) 
Vc (l/kg) 
1.18 ± 0.390 
0.238 ± 0.0766 
1.06 ± 0.191 
0.253 ± 0.0740 
Vp (l/kg) 0.176 ± 0.0676 0.169 ± 0.0516 
MRT (min) 22.7 ± 9.44 23.1 ± 9.63 
a) A two-compartment model with 1/Ŷ2 as weighting factor was fitted to the data. 
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FIGURES 
 
Figure 1: Chemical structures of kaempferol (A), kaempferol-3-O-glucuronide (B) and 4-
HPAA (C). 
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Figure 2: Typical MRM chromatograms of kaempferol quantifier (A), kaempferol qualifier 
(B), 
13
C15-labeled kaempferol (C) in rat plasma, and 4-HPAA quantifier (D), 4-HPAA 
qualifier (E), and 
2
H2-labeled 4-HPAA (F) in BSA. Both analytes presented at LLOQ (20 
ng/ml). 
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Figure 3: Plasma concentrations of kaempferol (mean ± S.D.) after a single intravenous administration of 1, 2 and 4 mg/kg b.w., shown as linear 
(A) and semi-logarithmic (B) plots. 
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Figure 4: C0 and AUC0-inf (mean ± S.D.) of kaempferol vs. dosing group (solid line) and fitted 
simple linear regression (dashed line, for visual comparison). 
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Figure 5: Observed (mean ± S.D.) and simulated concentration vs. time profiles of kaempferol in rats after a single intravenous dose of 1 (A), 2 
(B), and 4 (C) mg/kg b.w. 
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Figure 6: Plasma concentration vs. time profiles of kaempferol after a single oral dose of 5 (A), 10 (B), and 20 (C) mg/kg b.w. Data for 
individual rats are shown. 
 
 
91
Figure 7: Plasma concentration of free kaempferol and its glucuronide conjugates (oral 
dosage = 20 mg/kg) determined after enzymatic treatment (n = 7). Data are shown as mean ± 
S.D. 
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Figure 8: Plasma concentrations of 4-HPAA (mean ± S.D.) after a single intravenous administration of 1, 2 and 4 mg/kg b.w., shown as linear 
(A) and semi-logarithmic (B) plots. 
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Figure 9: C0 and AUC0-inf (mean ± S.D.) of 4-HPAA vs. dosing group (solid lines), and fitted 
simple linear regression (dashed line, for visual comparison). 
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Figure 10: Observed (mean ± S.D.) and simulated concentration vs. time profiles of 4-HPAA in rats after a single intravenous dose of 2 (A) and 
4 (B) mg/kg b.w. 
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Supporting information Figure 1: Long-term stability of kaempferol in rat plasma stored for 386 
days below -65°C (n=3). 
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Supporting information Figure 2: Long-term stability of 4-HPAA in BSA stored for 367 days 
below -65°C (n=3). 
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Supporting information Table 1: Calibrators and calibration curve parameters of kaempferol (n=8). 
Response: A×Conc.
2
+B×Conc.+C, Quadratic regression, 1/X weighting. 
 
 
 
 
Run 
No. 
Nominal level (ng/ml) Regression parameters 
20.0 50.0 100 250 500 1000 2000 A B C R
2
 
1 19.8 51.9 109 255 474 1052 2053 
0.000000209 0.00413 0.0211 0.9984 
 
18.7 48.2 99.3 256 479 985 1938 
2 20.6 51.5 101 250 507 1005 1987 
0.0000000810 0.00426 0.0133 0.9998 
 
19.4 48.8 99.1 243 509 981 2017 
3 20.2 49.6 106 243 505 983 1997 
0.0000000812 0.00455 0.0204 0.9998 
 
18.8 50.8 100 252 502 1005 2007 
4 18.4 47.4 101 250 494 974 1950 
0.0000000886 0.00409 0.0190 0.9992 
 
21.3 52.1 100 252 522 1000 2058 
Mean 19.7 50.0 102 250 499 998 2001 0.000000115 0.00426 0.0185 0.9993 
S.D. 1.00 1.78 3.63 4.93 16.0 24.6 43.1 0.0000000626 0.000209   
CV% 5.11 3.55 3.56 1.97 3.22 2.46 2.15  
RE% -1.74 0.0493 1.93 0.0880 -0.193 -0.197 0.0513 
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Supporting information Table 2: Calibrators and calibration curve parameters of 4-HPAA (n=8). 
Response: A×Conc.
2
+B×Conc.+C, Quadratic regression, 1/X weighting. 
* > 15% outside acceptance criteria 
 
Run 
No. 
Nominal level (ng/ml) Regression parameters 
20.0 50.0 100 250 500 1000 2000 A B C R
2
 
1 19.5 55.4 111 266 507 987 2003 
0.0000000396 0.00235 0.0591 0.9988 
 
17.1 44.4 103 245 513 944 2024 
2 21.3 51.2 *2719 0.00 506 1004 2013 
0.0000000365 0.00228 0.0513 0.9998 
 
19.1 49.1 100 239 499 1007 1982 
3 22.3 49.3 100 252 494 985 1996 
0.00000000420 0.00225 0.0573 0.9997 
 
18.7 49.9 96.8 246 507 1023 0.00 
4 19.7 52.5 98.6 257 501 1009 2050 
0.0000000104 0.00231 0.0675 0.9995 
 
20.8 48.2 96.5 241 507 989 1950 
Mean 19.8 50.0 101 249 504 993 2002 0.0000000227 0.00230 0.0588 0.9995 
S.D. 1.65 3.22 5.12 9.51 5.92 23.7 31.5 0.0000000180 0.0000414   
CV% 8.31 6.44 5.08 3.81 1.17 2.39 1.57  
RE% -0.948 0.0215 0.928 -0.205 0.837 -0.654 0.124 
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Supporting information Table 3: Carry-over assessment of the analyte kaempferol and the 
internal standard (IS) 
13
C15-labeled kaempferol (n=8). 
 
 
Run 
No. 
Replicate Peak response (counts) Carry-over (%) Mean Carry-over 
(%) 
  Blank sample LLOQ   
  Analyte IS Analyte IS Analyte IS Analyte IS 
1 1 0.00 0.00 332 3223 0.00 0.00 0.00 0.00 
 2 0.00 0.00 385 3904 0.00 0.00 
2 1 0.00 0.00 399 3953 0.00 0.00 0.00 0.00 
 2 0.00 0.00 394 4103 0.00 0.00 
3 1 0.00 0.00 467 4157 0.00 0.00 0.00 0.00 
 2 0.00 0.00 487 4604 0.00 0.00 
4 1 0.00 0.00 469 4972 0.00 0.00 0.00 0.00 
 2 0.00 0.00 452 4262 0.00 0.00  
     Mean   0.00   0.00 
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Supporting information Table 4: Carry-over assessment of the analyte 4-HPAA and the 
internal standard (IS) 
2
H2-labeled 4-HPAA (n=8). 
 
 
Run 
No. 
Replicate Peak response (counts) Carry-over (%) Mean Carry-over 
(%) 
  Blank sample LLOQ   
  Analyte IS Analyte IS Analyte IS Analyte IS 
1 1 0.00 0.00 1892 18022 0.00 0.00 0.00 0.00 
 2 0.00 0.00 1449 14601 0.00 0.00 
2 1 0.00 0.00 2420 24206 0.00 0.00 0.00 0.00 
 2 0.00 0.00 2815 29673 0.00 0.00 
3 1 0.00 0.00 2459 22877 0.00 0.00 0.00 0.00 
 2 0.00 0.00 2944 29612 0.00 0.00 
4 1 0.00 0.00 2610 23094 0.00 0.00 0.00 0.00 
 2 0.00 0.00 3110 26920 0.00 0.00  
     Mean   0.00   0.00 
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Supporting information Table 5: Selectivity test of kaempferol, based on three different 
plasma lots spiked at LLOQ (n=6). 
 
 
 
Supporting information Table 6: Selectivity test of 4-HPAA, based on three different BSA 
lots spiked at LLOQ (n=6). 
 
 
Nominal level (ng/ml) 20.0 
Mean 21.2 
S.D. 1.21 
CV% 5.70 
RE% 1.94 
Nominal level (ng/ml) 20.0 
Mean 21.5 
S.D. 2.95 
CV% 13.7 
RE% -1.93 
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Supporting information Table 7: Absolute recovery of kaempferol and the IS 
13
C15-labeled 
kaempferol from rat plasma (n=6). 
Kaempferol nominal level (ng/ml) 60.0 1000 1600 
Absolute recovery (%) 61.7 60.2 73.2 
CV% 8.62 12.9 2.87 
SD 5.32 7.78 2.10 
 
 
IS nominal level (ng/ml) 225 
Absolute recovery (%) 69.2 
CV% 9.58 
SD 6.63 
 
 
 
Supporting information Table 8: Absolute recovery of 4-HPAA and the IS 
2
H2-labeled 4-
HPAA from BSA (n=6). 
4-HPAA nominal level (ng/ml) 60.0 1000 1600 
Absolute recovery (%) 80.2 91.0 92.3 
CV% 6.62 2.17 3.11 
SD 5.31 1.98 2.87 
 
 
IS nominal level (ng/ml) 286 
Absolute recovery (%) 112 
CV% 9.75 
SD 10.9 
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Supporting information Table 9: Dilution test of kaempferol in rat plasma at nominal 
concentration of 10000 ng/ml (n=6). 
Nominal level (ng/ml) 10000 
Dilution factor 10X 100X 
Mean 9852 10639 
S.D. 163 186 
CV% 1.66 1.75 
RE% -1.48 6.39 
 
 
 
Supporting information Table 10: Dilution test of 4-HPAA in BSA solution at nominal 
concentration of 10000 ng/ml (n=6). 
 
 
 
 
 
Nominal level (ng/ml) 10000 
Dilution factor 10X 100X 
Mean 10744 10763 
S.D. 135 239 
CV% 1.26 2.22 
RE% 7.44 7.63 
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Supporting information Table 11: Short-term stabilities of kaempferol, expressed as RE% 
(n=6). 
Nominal level (ng/ml) 60.0 1600 
Three successive freeze/thaw cycles 
below -65°C 
2.74 -0.483 
Benchtop at RT for 4 h 2.60 0.164 
Autosampler at 10°C for 48 h 12.1 6.93 
 
 
 
Supporting information Table 12: Short-term stabilities of 4-HPAA, expressed as RE% (n=6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nominal level (ng/ml) 60.0 1600 
Three successive freeze/thaw cycles 
below -65°C 
-1.81 5.52 
Benchtop at RT for 4 h -8.38 2.04 
Autosampler at 10°C for 48 h -13.2 4.01 
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Supporting information Table 13: Stock solution (SS) stability of kaempferol in DMSO, 
stored below -65°C for 180 days (n=6). 
 
Kaempferol SS stored below -65°C 
for 180 days with freshly prepared 
IS SS 
Freshly prepared kaempferol SS 
with freshly prepared IS SS 
Mean peak  
area ratio 
2.70 2.61 
S.D. 0.0122 0.0118 
CV% 0.454 0.453 
Difference% 3.23 
 
 
 
Supporting information Table 14: Stock solution (SS) stability of 4-HPAA in DMSO, stored 
below -65°C for 35 days (n=6). 
 
4-HPAA SS stored below -65°C for 
35 days with freshly prepared IS SS 
Freshly prepared 4-HPAA SS with 
freshly prepared IS SS 
Mean peak 
area ratio 
628 632 
S.D. 15.3 30.1 
CV% 2.43 4.76 
Difference% -0.737 
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Supporting information Table 15: Diagnostic table for a one-compartment model with 1/Ŷ2 as 
weighting factor fitted to the kaempferol data. 
Dosing 
group (mg/kg) 
Goodness of fit 
AIC SBC WSSR 
1 -6.79 -7.87 0.229 
2 -6.77 -8.00 0.247 
4 -7.73 -8.51 0.122 
 
 
 
Supporting information Table 16: Diagnostic table for a two-compartment model with 1/Ŷ2 as 
weighting factor fitted to the 4-HPAA data. 
Dosing 
group (mg/kg) 
Goodness of fit 
AIC SBC WSSR 
2 -22.2 -22.8 0.0133 
4 -10.7 -10.4 0.214 
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3.2 Single dose pharmacokinetics of intravenous 3,4-dihydroxyphenylacetic acid and 3-
hydroxyphenylacetic acid in rats 
 
Volha Zabela, Chethan Sampath, Mouhssin Oufir, Veronika Butterweck, and Matthias 
Hamburger 
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3,4-Dihydroxyphenylacetic acid (DOPAC) and 3-hydroxyphenylacetic acid (3-HPAA) are 
intestinal metabolites of the dietary flavonoid quercetin. DOPAC reportedly showed 
anxiolytic activity after intraperitoneal administration in rats. In this study, we aimed to 
evaluate PK properties of the compounds after intravenous administration. At first, UHPLC-
MS/MS methods were developed and validated according to the principles of current 
regulatory guidelines for industry. The validated methods were later applied for 
quantification of DOPAC and 3-HPAA in rat plasma. PK parameters were calculated with the 
industry standard software WinNonlin using non-compartmental and compartmental 
analyses. PK studies revealed that DOPAC and 3-HPAA are quickly distributed into 
peripheral tissues, as well as rapidly cleared from the body. 
 
 
 
 
 
 
 
 
 
My contributions to this publication: development and validation of UHPLC-MS/MS 
quantification methods according to the principles of current regulatory guidelines for 
industry, plasma sample preparation and analysis, non-compartmental and compartmental 
pharmacokinetic data analysis, writing the manuscript draft, and preparation of figures and 
tables. 
Volha Zabela 
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Abbreviations 
AIC, Akaike’s information criterion 
AUC, area under the curve 
AUMC, area under the first moment curve 
BBB, blood-brain barrier 
BSA, bovine serum albumin 
b.w., body weight 
C0, concentration at time 0 
CA, compartmental analysis 
Cals, calibrators 
CL, clearance 
Cmax, maximal concentration 
CV, coefficient of variation 
DMSO, dimethyl sulfoxide 
DOPAC, 3, 4-dihydroxyphenylacetic acid 
3-HPAA, 3-hydroxyphenylacetic acid 
IS, internal standard 
ke, elimination rate constant 
LLOQ, lower limit of quantification 
MRM, multiple reaction monitoring 
MRT, mean residence time 
NCA, non-compartmental analysis 
PEG, polyethylene glycol 
PK, pharmacokinetic 
QCH, quality control at a high level 
QCL, quality control at a low level 
QCM, quality control at a medium level 
QCs, quality controls 
RE, relative error 
RT, room temperature 
SBC, Schwarz’s Bayesian criterion 
SS, stock solution 
t1/2, half-life 
Vd, volume of distribution during the 
terminal phase 
WS1, working solution 1 
WS2, working solution 2 
WSSR, weighted sum of squared residuals 
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Abstract 
3,4-Dihydroxyphenylacetic acid (DOPAC) and 3-hydroxyphenylacetic acid (3-HPAA) are 
intestinal metabolites of the dietary flavonoid quercetin. DOPAC reportedly showed 
anxiolytic activity after i.p. administration in rats. The fate of these metabolites after 
consumption, and the pharmacological properties of 3-HPAA in the body are largely 
unknown. The aim of the current study was to characterize pharmacokinetic properties of 
DOPAC and 3-HPAA after intravenous bolus application in rats. UHPLC-MS/MS methods 
for quantification of DOPAC and 3-HPAA levels in lithium heparin Sprague Dawley rat 
plasma were developed and validated according to international regulatory guidelines. Non-
compartmental and compartmental analyses were performed. Pharmacokinetic profiles of 
DOPAC and 3-HPAA followed a two-compartment body model, with a fast distribution into 
peripheral tissues (half-lives of 3.27-5.26 min) and rapid elimination from the body (half-
lives of 18.4-33.3 min).  
 
Keywords: DOPAC, 3-HPAA, pharmacokinetics, UHPLC-MS/MS, validation. 
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1. Introduction 
3,4-Dihydroxyphenylacetic acid (DOPAC) and 3-hydroxyphenylacetic acid (3-HPAA) are 
small phenolic acids which are formed by the intestinal microflora as metabolites of the 
flavonoid quercetin (Booth et al., 1956; Aura et al., 2002; Blaut et al., 2003). Quercetin has 
been shown to possess anxiolytic-like activity in mice, but only after oral administration. No 
anxiolytic properties were observed when the compound was given intraperitoneally (i.p.), or 
orally administered to gut sterilized mice. However, the metabolite DOPAC showed 
anxiolytic-like activity after i.p. administration (Vissiennon et al., 2012). These data 
suggested that quercetin requires metabolic transformation into pharmacologically active 
compounds. 
Oral bioavailability of quercetin is poor, and low plasma concentrations of free quercetin 
have been reported in rats and humans after oral administration (Manach et al., 1997; Cai et 
al., 2013). In plasma, quercetin predominantly occurs in conjugated forms (glucuronides, 
sulfates, and as O-methyl derivatives) (Manach et al., 1998; Morand et al., 1998; Mullen et 
al., 2006), which are subsequently eliminated via renal and biliary excretion (Ueno et al., 
1983; Crespy et al., 1999; Mullen et al., 2006). When excreted in the bile, conjugates of 
quercetin are released into the small intestine, where they can be converted by intestinal β-
glucuronidases and sulfatases back to aglycones which are then transformed by the gut 
microbiota into phenolic acids. DOPAC and 3-HPAA are recovered in urine of rats and 
humans after oral consumption of quercetin (Booth et al., 1956; Hong and Mitchell, 2006; 
Gasperotti et al., 2015). DOPAC is not only an intestinal metabolite of quercetin, but also an 
endogenous metabolite of the neurotransmitter dopamine. Studies showed that reduced 
striatal levels of dopamine and DOPAC are associated with CNS disorders such as 
Parkinson’s disease and schizophrenia (Cohrs et al., 2004; Ravenstijn et al., 2012). 
Anxiolytic-like effects in rodents were also observed with oral administration of kaempferol, 
another commonly ingested flavonoid (Vissiennon et al., 2012). However, a pharmacokinetic 
(PK) study in rats showed low bioavailability of kaempferol, and extensive pre-systemic 
metabolism (Zabela et al., 2016). We here report on the PK properties of the major intestinal 
metabolites of quercetin, DOPAC and 3-HPAA. 
 
2. Materials and methods 
2.1. Chemicals and reagents 
DOPAC (Fig. 1-1) (purity 99.8%) was purchased from Sigma-Aldrich (Buchs, Switzerland), 
and [
2
H]5-DOPAC with isotopic enrichment of 98% (Fig. 1-2) as internal standard (IS) was 
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from Cambridge Isotope Laboratories, Inc. (Andover, MA, USA). 3-HPAA (Fig. 1-3) (purity 
99.2%), bovine serum albumin (BSA) as a surrogate matrix, Cremophor, Tween-80, and 
polyethylene glycol (PEG) were from Sigma-Aldrich (Steinheim, Germany). [
2
H]2-3-HPAA 
with isotopic enrichment of 96% (Fig. 1-4) was purchased from Diverchim (Roissy-en-
France, France). Methanol (HPLC grade), and acetic acid (purity 98-100%) were from 
Biosolve BV (Valkenswaard, the Netherlands). Acetonitrile, isopropanol (HPLC grade), and 
dimethyl sulfoxide (DMSO) were supplied by Scharlau (Barcelona, Spain). Tween-20 was 
from Fluka (Buchs, Switzerland). HPLC grade water was obtained by a Milli-Q integral 
water purification system (Millipore Merck, Darmstadt, Germany). 
2.2. Standards and stock solutions 
Stock solutions (SS) of DOPAC, [
2
H]5-DOPAC, 3-HPAA and [
2
H]2-3-HPAA were prepared 
in DMSO by weighing compounds on a Sartorius micro balance (Göttingen, Germany). 
Appropriate dilution in methanol were prepared to obtain working solutions 1 (WS1) of 
DOPAC (200 µg/ml) and 3-HPAA (100 µg/ml). WS1 of [
2
H]5-DOPAC and [
2
H]2-3-HPAA 
were prepared in methanol at a concentration of 50 µg/ml. A daily WS2 was prepared from 
WS1 to obtain a concentration of 250 ng/ml. All the SSs and WSs were stored below -65ºC 
until use. 
2.3. Preparation of calibration standards and quality control samples 
To prevent adsorption of DOPAC to the container surfaces, polypropylene tubes were pre-
treated with 0.2% Tween-20 before preparation of calibrators (Cals) and quality controls 
(QCs). Two sets of Cals over the range of 30-3000 ng/ml and QCs at low, medium and high 
levels (QCL = 90 ng/ml, QCM = 1500 ng/ml, QCH = 2400 ng/ml) were prepared in BSA 
solution (60 g/l) by serial dilution of the WS1 (200 µg/ml). For 3-HPAA, two sets of Cals 
over the range of 20-2000 ng/ml and QCs (QCL = 60 ng/ml, QCM = 1000 ng/ml, QCH = 
1600 ng/ml) were prepared in BSA solution by serial dilution of the WS1 (100 µg/ml). All 
samples were stored below -65°C until analysis. 
2.4. Sample processing 
2.4.1. Extraction of DOPAC and 3-HPAA from BSA solution  
An aliquot of 75 µl of sample was mixed in 1.5 ml tubes with 150 µl of WS2 of the 
corresponding IS (250 ng/ml) and 300 µl of acetonitrile. Samples were mixed for 10 min at 
1400 rpm on a Mixmate (Eppendorf, Schönenbuch, Switzerland), and then centrifuged for 15 
min at 13200 rpm at 10ºC (Centrifuge 5415R, Eppendorf, Schönenbuch, Switzerland). Clear 
supernatant (400 µl) was transferred into a 96-deepwell plate. The samples were dried by a 
nitrogen evaporator (Evaporex EVX-96, Apricots Designs Inc, USA) with upper temperature 
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of 30°C and lower temperature of 50°C, and reconstituted with 50% solvent A (5 mM acetic 
acid) and 50% solvent B (acetonitrile + 5 mM acetic acid) (V = 100 µl for DOPAC and V = 
200 µl for 3-HPAA). The plate was shaken on a Mixmate for 30 min at 2000 rpm before 
UHPLC-MS/MS analysis.  
2.5. LC-MS/MS instrument and chromatographic conditions 
2.5.1. Mass spectrometry conditions 
UHPLC-MS/MS analysis was performed with an UHPLC 1290 system consisting of a binary 
pump G4220A and autosampler G4226A set at 10ºC, coupled with an 6460 triple quadrupole 
mass spectrometer (all Agilent Technologies, Waldbronn, Germany). An Agilent Jet Stream 
ionization source was used for DOPAC, and an electrospray ionization source for 3-HPAA. 
The instrument was controlled by MassHunter software (Version 7.0; Agilent Technologies, 
Waldbronn, Germany). Nitrogen, generated by a nitrogen generator N2-Mistral (Schmidlin 
AG, Neuheim, Switzerland), was used for both desolvation and nebulization, and as collision 
gas. MS parameters for each compound and their corresponding ISs are summarized in Table 
1. 
The following instrument parameters were used for quantification of DOPAC: nitrogen 
drying gas temperature of 150ºC at a flow rate of 13 l/min, nebulizer pressure of 60 psi, 
sheath gas temperature of 400ºC at a flow rate of 12 l/min, capillary voltage of 2000 V, 
nozzle voltage of 0 V, delta EMV(-) 200 V. 
The following instrument parameters were applied for quantification of 3-HPAA: nitrogen 
drying gas temperature of 325ºC at a flow rate of 13 l/min, nebulizer pressure of 60 psi, 
capillary voltage of 4000 V, delta EMV (-) 300 V. 
2.5.2. Chromatographic conditions 
Analysis of DOPAC and IS was performed on an Acquity HSS T3 column (1.8 µm,  2.1 × 
100 mm; Waters Corp., Milford, MA, USA) heated at 45ºC. The mobile phase consisted of 
eluent A (5 mM acetic acid) and eluent B (acetonitrile with 5 mM acetic acid), and the 
following gradient was used: 0-1 min, 2% B, 1-3 min, 2-100% B, 3-4 min, 100% B, 4-4.01, 
100-2% B, 4.01-5 min, 2% B. The flow rate was 0.4 ml/min, and the injection volume was 5 
µl .The needle wash solvent consisted of water and methanol (50:50, v/v). 
Analysis of 3-HPAA and IS was performed on a Kinetex XB column (1.7 µm, 2.1×100 mm; 
Phenomenex, Torrance, CA, USA) heated at 55ºC. The following gradient was used: 0-1 min, 
5% B, 1-4 min, 5-100% B, 4-5 min, 100% B, 5-5.1, 100-5% B, 5.1-6 min, 5% B. The flow 
rate was 0.6 ml/min, and the injection volume was 5 µl. The needle wash solvent consisted of 
water/methanol/isopropanol/acetonitrile (1:1:1:1, v/v/v/v).  
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2.6. Method validation 
Following EMA/FDA validation guidelines for industry, imprecision in analytical runs was 
calculated by the coefficient of variation (CV%), and had to be < 15% (< 20% at the LLOQ) 
of the nominal values at all concentration levels. Inaccuracy was represented by the relative 
error (RE%), and had to be within ± 15% (within ± 20% at the LLOQ) of the nominal values 
at all concentration levels (U.S. Food and Drug Administration, 2013; European Medicines 
Agency, 2011). 
2.6.1. Chromatographic performance 
A seven-point calibration curve was generated over the range 30-3000 ng/ml for DOPAC, 
and 20-2000 ng/ml for 3-HPAA.  
2.6.2. Carryover 
Carryover for both analytes was assessed by two extracted blank BSA solutions injected 
immediately after the two ULOQ levels. 
2.6.3. Selectivity 
Six QC samples of DOPAC and 3-HPAA at the LLOQ level were prepared in three different 
lots of BSA. 
2.6.4. Specificity 
Six BSA blanks were analyzed, and a peak area measured in the blank samples were less than 
20% of the analyte peak area at LLOQ. 
2.6.5. Intra-run repeatability and Inter-run reproducibility 
The intra-day imprecision and inaccuracy were estimated by injecting six replicates of QC 
samples at five different levels (LLOQ, QCL, QCM, QCH and ULOQ), and expressed as 
CV% and RE%, respectively. The inter-run CV% and RE% were assessed by the same QCs 
on three different days. 
2.6.6. Extraction yield 
Extraction yields of analytes and ISs were evaluated at three levels (QCL, QCM and QCH) 
before extraction, and spiked with the IS after extraction, in comparison to six blank samples 
spiked after extraction (representing 100% of recovery). 
2.6.7. Dilution test 
The dilution QC samples (15000 ng/ml for DOPAC and 10000 ng/ml for 3-HPAA) were 
prepared and diluted with the BSA solution in a ratio of 1:10 and 1:100. 
2.6.8. Short-term stabilities of DOPAC and 3-HPAA in BSA 
One to three overnight freeze-thaw cycles below -65ºC were performed on six replicates of 
each analyte at low and high concentrations. Sample stability at room temperature was 
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assessed with six replicates of each analyte at low and high concentrations, kept on the bench 
at RT for 2 to 4 h. For assessment of processed sample stability in the autosampler at 10ºC, 
six replicates of each analyte at low and high concentrations were analyzed and then stored 
for 24 h and 48 h in the autosampler at 10ºC. Afterwards, these QCs were re-analyzed 
together with freshly prepared Cals and QCs. 
2.6.9. Long-term stability of DOPAC in lithium heparin rat plasma, and of 3-HPAA in BSA 
below -65ºC 
Lithium heparin Sprague Dawley rat plasma was supplemented with 1% of ascorbic acid to 
prevent oxidation of DOPAC. Three replicates of QCL, QCM and QCH were prepared in 
stabilized rat plasma for DOPAC, or in BSA for 3-HPAA, and analyzed the next day after 
preparation (t0). Additional triplicates of QCs at the same concentrations were stored below -
65°C (up to 3 months for DOPAC and up to 12 months for 3-HPAA). After each storage 
interval, the long-term stability samples were compared to freshly prepared Cals and QCs. 
Linear regression analysis was used to assess long-term stability data. Stability of the samples 
was verified by the slope deviation within 1 ± 0.15. 
2.6.10. Stock solution stability test 
Stock solutions of analytes and corresponding ISs, stored below -65ºC over time, were 
compared with freshly prepared stock solutions. The eventual degradation should not exceed 
5% for all compounds. 
2.7. PK studies 
2.7.1. Animals 
Male Sprague Dawley rats (body weight 320-350 g) were purchased from Charles River 
(Wilmington, MA, USA). The animals were individually housed in plastic cages and 
maintained under a 12 h/12 h light/dark cycle. The rats received water ad libitum and a 
standard chow. Before being used in experiments, animals were allowed to acclimate to their 
environment for one week. The rats were maintained on a 12 h/12 h light/dark cycle. All 
animal experiments were performed according to the policies and guidelines of the 
Institutional Animal Care and Use Committee (IACUC) of the University of Florida, 
Gainesville, USA, study protocol #200903448. 
2.7.2. Design of PK studies in rats 
The rats (n = 8 per group) were randomly divided into six groups. DOPAC was given by the 
intravenous bolus injection in the doses of 1, 2 and 4 mg/kg body weight (b.w.). A pilot study 
on the PK of 3-HPAA was performed with doses of 2 and 4 mg/kg b.w. Both compounds 
were dissolved in a vehicle composition consisting of Cremophor/Tween-
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80/PEG/ethanol/water (2:1:1:1:5, v/v/v/v/v). Blood samples (500 μl) were collected from the 
sublingual vein into heparinized tubes at 0 (prior to dosing), 2, 5, 10, 20, 30 min, 1, 2, 4, 6, 8 
and 12 h. The loss of blood volume was replaced with 1 ml normal saline. Plasma samples 
were obtained by centrifugation at 4000 rpm for 15 min at 4ºC, then transferred into 1.5 ml 
tubes and stored at below -65ºC until analysis. 
2.8. PK data analysis 
Mean plasma concentrations of DOPAC and 3-HPAA versus time were generated in 
Graphpad Prism (version 5.01; San Diego, CA, USA). PK parameters were determined by 
non-compartmental and compartmental analyses using WinNonlin software (version 5.2.1; 
Pharsight Corporation, St. Louis, MO, USA). 
2.8.1. Non-compartmental analysis (NCA) 
The PK parameters included the extrapolated concentration at time 0 (C0), terminal 
elimination rate constant (ke), terminal half-life (t½), area under the concentration-time curve 
(AUC), area under the first moment curve (AUMC), mean residence time (MRT), apparent 
volume of distribution (Vd), and plasma clearance (CL). The slope of the terminal phase was 
estimated by log-linear regression using the “best fit” method and uniform weighting. The ke 
was derived from the slope. The t½ was calculated as 0.693/ke. The linear trapezoidal rule was 
applied for determination of the area under the curve from time 0 to the last measurable 
concentration (AUC0-last) and then extrapolated to infinity (AUC0-). The CL following the 
intravenous dosing was calculated as Dose/AUC0-. The Vd was calculated as CL/ke. 
2.8.2. Compartmental analysis (CA) 
A two-compartment body model with different weighting factors was fitted to the DOPAC 
and 3-HPAA data. The goodness of fit was estimated by Akaike's information criterion 
(AIC), Schwarz's Bayesian criterion (SBC), and weighted sum of squared residuals (WSSR). 
The equation for the intravenous bolus two-compartment model was as follows: Cp(t)=A × 
exp
-×t
 + B × exp
-×t
, where Cp(t) is a concentration of a drug in plasma at time t; A and B are 
the Y-axis intercepts;  and  are the initial and terminal slopes. 
2.9. Statistics 
Analytical values were calculated in Excel and presented as mean ± SD with CV% and RE%. 
 
3. Results 
3.1. Validation of the bioanalytical methods for DOPAC and 3-HPAA 
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Quantification of DOPAC and 3-HPAA were performed by UHPLC-MS/MS. Figures 2 and 3 
show extracted multiple reaction monitoring (MRM) chromatograms of the analytes and their 
corresponding ISs in BSA solution. Since DOPAC and 3-HPAA are also endogenous 
metabolites of neurotransmitters, BSA solution as an analyte-free (surrogate) matrix was 
chosen for the preparation of CALs and QCs (Jones et al., 2012). The developed UHPLC-
MS/MS methods were fully validated in terms of accuracy, precision, selectivity, recovery, 
reproducibility and stability according to international regulatory guidelines (U.S. Food and 
Drug Administration, 2013; European Medicines Agency, 2011). The calibration curves were 
quadratic in the range of 30-3000 ng/ml for DOPAC, and 20-2000 ng/ml for 3-HPAA, with a 
1/X weighting factor. Mean coefficients of determination for DOPAC and 3-HPAA were 
0.9994 and 0.9991, respectively (Supporting information Tables 1 and 2). Carryover for 
DOPAC (12%) was within the acceptance criteria (Fig. 2, and Supporting information Table 
3). No carryover was detected for 3-HPAA (Fig. 3, and Supporting information Table 4). 
Both methods were shown to be selective, with CV% and RE% < 20% (Supporting 
information Tables 5 and 6). In the blank BSA samples, no peaks were observed at the 
retention time of the analytes, confirming that both methods were specific for DOPAC and 3-
HPAA (data not shown). Results from the intra- and inter-day imprecision and inaccuracy for 
both compounds are summarized in Table 2. The mean extraction recovery of DOPAC from 
BSA solution ranged from 57.2% to 77.4%, and recovery of the IS was 82.4% (Supporting 
information Table 7). The mean extraction recovery of 3-HPAA was from 106% to 114%, 
and recovery of the IS was 104% (Supporting information Table 8). No impact of dilution 
(10- and 100-fold) on the results was observed (Supporting information Tables 9 and 10). 
DOPAC was stable after one freeze and thaw cycle (after two and three cycles the stability of 
DOPAC could not be confirmed; data not shown), after 2 h storage at RT, and after 48 h 
storage in the autosampler at 10°C (Supporting information Table 11). 3-HPAA was stable 
after three freeze and thaw cycles, after 4 h storage at RT, and after 24 h storage in the 
autosampler at 10°C (Supporting information Table 12). DOPAC in plasma spiked with 1% 
ascorbic acid was stable for 89 days (Supporting information Figure 1). 3-HPAA in BSA 
solution was stable for 378 days of storage below -65°C (Supporting information Figure 2). 
Since degradation was less than 5%, SSs of DOPAC and 3-HPAA were stable below -65°C 
for 204 and 431 days, respectively (Supporting information Tables 13 and 14). The 
degradation of SSs of the IS [
2
H]5-DOPAC and [
2
H]2-3-HPAA was -1.45% and -0.39%, 
respectively (Supporting information Table 15 and 16). In conclusion, both bioanalytical 
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methods were precise, accurate, and reliable for the quantification of DOPAC and 3-HPAA 
in rat plasma. 
 
3.2. Pharmacokinetics of DOPAC 
PK profiles were characterized by a biphasic decline in plasma concentrations (Figure 4). 
DOPAC plasma concentrations fell below the LLOQ 2 h after injection for the doses of 2 and 
4 mg/kg, whereas for the dose of 1 mg/kg the concentration of DOPAC in plasma was below 
the LLOQ already 1 h after administration (Fig. 4B). Dose proportionality for DOPAC was 
evaluated by a linear regression approach. A statistical linear relationship between dose-
dependent PK parameters (C0 and AUC0-) and doses was demonstrated (Fig. 5). The main 
PK parameters of DOPAC calculated by NCA are summarized in Table 3. The compound 
showed fast elimination (ke = 1.32-2.96 h
-1
), with a short terminal t1/2 of 16.8-31.7 min. 
DOPAC had a moderate Vd (0.64-1.14 l/kg), and a high CL of 1.5-1.98 l/h/kg. 
A two-compartment intravenous bolus model with first-order elimination and 1/Ŷ2 as a 
weighting factor was fitted to the DOPAC data. The goodness of fit was confirmed by the 
AIC, SBC, WSSR (Supporting information Table 17). The goodness of fit was also assessed 
by a comparison of simulated and observed concentrations vs. time profiles with a two-
compartment body model (Figure 6). PK parameters calculated for the compartmental model 
are summarized in Table 4. After administration of DOPAC, a rapid distribution to peripheral 
tissues (t1/2 = 3.27-5.26 min) was observed, followed by a slower elimination phase (t1/2 = 
18.4-33.3 min). The values of AUC, MRT, Vd and CL of the compartmental analysis were 
close to those obtained by NCA analysis.  
 
3.3. Pharmacokinetics of 3-HPAA 
A PK pilot study of intravenous 3-HPAA was performed in rats at the doses of 2 and 4 
mg/kg. Plasma concentrations versus time profiles (linear and semi-log plots) are shown in 
Figure 7. At the dose of 4 mg/kg, 3-HPAA was detected for up to 4 h after administration 
(Fig. 7B). In contrast, the plasma concentration of 3-HPAA at the dose of 2 mg/kg dropped 
below the LLOQ after 2 h. The PK parameters obtained by NCA are given in Table 5. 3-
HPAA showed a rapid rate of elimination (ke = 2.1-2.39 h
-1
), resulting in a short terminal t1/2 
of 19.9-26.2 min. 3-HPAA had a moderate Vd of 0.73-0.94 l/kg, and a high CL of 1.46-1.57 
l/h/kg. 
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A two-compartment intravenous bolus model with first-order elimination and 1/Ŷ2 as a 
weighting factor was fitted to the 3-HPAA data. The goodness of fit was confirmed by the 
AIC, SBC, WSSR (Supporting information Table 18). A comparison of simulated and 
observed concentrations vs. time profiles with a two-compartment body model also 
confirmed goodness of fit (Fig. 8). PK parameters of the two-compartment body model are 
summarized in Table 6. After administration of 3-HPAA, a rapid distribution to peripheral 
tissues (t1/2 = 4.3-4.66 min) was observed, followed by a slower elimination phase (t1/2 = 
22- 31.2 min). The values of AUC, MRT, Vd and CL of the compartmental analysis were 
close to those obtained by NCA analysis. 
 
4. Discussion 
PK of DOPAC and 3-HPAA after intravenous injection can be best described by a two-
compartment model with first-order elimination. The plasma levels of DOPAC and 3-HPAA 
were low 60 min after the injection, demonstrating a rapid disappearance of the compounds 
from the circulation. Our findings are in agreement with a recent study that found high 
concentrations of DOPAC and 3-HPAA in urine and kidneys after intravenous administration 
in rats (Gasperotti et al., 2015). 
To exert a direct anxiolytic the compounds have to cross the blood-brain barrier (BBB). 
However, results from a screening with an in vitro ECV304/C6 co-culture BBB model 
suggest that DOPAC and 3-HPAA may not cross the BBB (Youdim et al., 2003). In contrast, 
a recent study in rats reported that after intravenous injection of DOPAC an approx. 2-fold 
increased concentration was found in the brain as compared to basal concentrations in the 
control group (Gasperotti et al., 2015). However, the above studies suffered from some 
methodological limitations, such as non-specific and non-selective detection by HPLC-UV 
(Youdim et al., 2003), or from possible interactions due to a simultaneous injection of 23 
different metabolites (Gasperotti et al., 2015). Acidic compounds like DOPAC and 3-HPAA 
tend to bind to a large extent to albumin, and thus may have a limited brain penetration. Also, 
metabolism in the brain needs to be taken into account, considering that CYP and UGT 
enzymatic activities in the brain have been reported (King et al., 1999; Gervasini et al., 2004). 
Taken together, pharmacologically relevant concentrations of these metabolites in the brain 
are unlikely to be achieved. Thus, it is not clear at this moment how the anxiolytic-like 
properties reported for DOPAC can be explained. Further investigations are needed to 
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identify pharmacologically active metabolites of flavonoids that are BBB penetrant and thus 
could exert anxiolytic-like effects. 
 
5. Conclusions 
UHPLC-MS/MS methods for quantification of DOPAC and 3-HPAA in lithium heparin 
Sprague Dawley rat plasma were developed and validated according to international 
regulatory guidelines. After intravenous bolus injection in rats PK profiles of DOPAC and 3-
HPAA followed a two-compartment model, with fast distribution to peripheral tissues, and 
rapid elimination from the body. At present, the anxiolytic-like properties reported for 
DOPAC cannot be explained. 
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Legends for Figures 
Figure 1. Chemical structures of DOPAC (1), [
2
H]5-DOPAC (2), 3-HPAA (3), and (4) [
2
H]2-
3-HPAA. 
Figure 2. Typical MRM chromatograms of the BSA blank spiked with DOPAC at 3000 
ng/ml (ULOQ) and IS at 250 ng/ml (A), the BSA blank (B), the BSA blank spiked with 
DOPAC at 30 ng/ml (LLOQ) and IS at 250 ng/ml (C). 
Figure 3. Typical MRM chromatograms of the BSA blank spiked with 3-HPAA (quantifier 
only) at 2000 ng/ml (ULOQ) and IS at 250 ng/ml (A), the BSA blank (B), the BSA blank 
spiked with 3-HPAA (quantifier only) at 20 ng/ml (LLOQ) and IS at 250 ng/ml (C). 
Figure 4. Plasma concentrations of DOPAC (mean ± S.D.) after a single intravenous 
administration of 1, 2 and 4 mg/kg b.w., shown as linear (A) and semi-logarithmic (B) plots. 
Figure 5. C0 and AUC0-inf (mean ± S.D.) of DOPAC vs. dosing group (solid line) and fitted 
simple linear regression (dashed line, for visual comparison). 
Figure 6. Observed (mean ± S.D.) and simulated concentrations vs. time profiles of DOPAC 
in rats after a single intravenous dose of 1 (A), 2 (B), and 4 (C) mg/kg b.w. 
Figure 7. Plasma concentrations of 3-HPAA (mean ± S.D.) after a single intravenous 
administration of 2 and 4 mg/kg b.w., shown as linear (A) and semi-logarithmic (B) plots. 
Figure 8. Observed (mean ± S.D.) and simulated concentrations vs. time profiles of 3-HPAA 
in rats after a single intravenous dose of 2 (A) and 4 (B) mg/kg b.w. 
 
 
127
 
 
TABLES 
 
Table 1: MS/MS parameters of analytes and corresponding internal standards. An Agilent Jet 
Stream ionization source (AJS) was used for analysis of DOPAC, and an electrospray 
ionization source (ESI) was used for 3-HPAA. 
Compound Precursor 
ion (m/z) 
Product 
ion (m/z) 
Fragmentor 
(V) 
Dwell 
time 
(ms) 
Collision 
energy (V) 
AJS/ESI 
polarity 
DOPAC 167.03 123 52 400 6 negative 
[
2
H]5-DOPAC 172.1 128.1 67 400 6 negative 
3-HPAA 
quantifier 
151.04 107 55 250 6 negative 
3-HPAA qualifier 151.04 65.1 55 250 26 negative 
[
2
H2]-3-HPAA 153.05 109.0 65 250 6 negative 
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Table 2: Intra- (n = 6) and inter- (n = 18) run imprecision (expressed as CV %) and 
inaccuracy (expressed as RE %) of DOPAC QC samples in BSA, and 3-HPAA QC samples in 
BSA solution, based on 3 series at 5 different levels. 
 DOPAC 3-HPAA 
Nominal level 
(ng/ml) 
30 90 1500 2400 3000 20 60 1000 1600 2000 
Intra-run 
mean 
32.8 100 1657 2485 2926 21.2 64.4 1011 1613 1942 
Intra-run S.D. 
0.47 1.04 24.4 14.2 21.9 1.94 2.68 14.8 28.0 33.8 
Intra-run CV 
% 1.42 1.04 1.48 0.57 0.75 9.16 4.16 1.46 1.73 1.74 
Intra-run RE 
% 9.2 11.1 10.4 3.54 -2.47 5.94 7.35 1.12 0.8 -2.92 
Inter-run 
mean 32.3 100 1653 2496 2969 21.0 60.8 969 1547 1914 
Inter-run S.D. 
0.38 0.8 18.8 20.4 17.5 1.8 3.24 19.6 33.3 75.4 
Inter-run 
CV% 1.18 0.8 1.14 0.82 0.59 8.55 5.31 2.03 2.16 4.04 
Inter-run RE 
% 7.6 11.3 10.2 4 -1.05 5.2 1.32 -3.11 -3.33 -4.28 
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Table 3: PK parameters of DOPAC after a single intravenous administration of 1, 2 and 4 
mg/kg b.w., calculated by non-compartmental analysis (mean ± S.D.). 
Dosing group (mg/kg) 1 2 4 
n 4 7 6 
C0 (µg/l) 3698 ± 392 12023 ± 2111 22748 ± 4938 
ke (1/h) 2.52 ± 0.4 2.96 ± 1.8 1.32 ± 0.14 
t1/2 (min) 16.8 ± 2.9 18.1 ± 8.9 31.7 ± 3.2 
AUC0-last (h×µg/l) 485 ± 49.3 1288 ± 236 2741 ± 585 
AUC0- (h×µg/l) 511 ± 63.9 1322 ± 243 2776 ± 591 
AUMC0-last (h×h×µg/l) 91.8 ± 20.4 197 ± 75.1 534 ± 107 
AUMC0- (h×h×µg/l) 129 ± 44.8 251 ± 104 629 ± 126 
CL (l/h/kg) 1.98 ± 0.24 1.57 ± 0.34 1.50 ± 0.34 
Vd (l/kg) 0.790 ± 0.06 0.639 ± 0.26 1.14 ± 0.24 
MRT (min) 14.8 ± 3.2 11.0 ± 3.1 13.7 ± 0.64 
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Table 4: PK parameters of DOPAC after a single intravenous dose of 1, 2 and 4 mg/kg b.w., 
calculated by compartmental analysis (mean ± S.D.). A two-compartment model with 1/Ŷ2 as 
a weighting factor was fitted to the data. 
Dosing group 
(mg/kg) 
1 2 4 
n 4 7 6 
Cmax (µg/l) 3500 ± 532 10445 ± 1885 16896 ± 3020 
A (µg/l) 2892 ± 567 9803 ± 1521 16196 ± 3035 
B (µg/l) 608 ± 140 642 ± 451 700 ± 352 
 (1/h) 13.2 ± 2.5 11.1 ± 1.7 8.14 ± 1.6 
 (1/h) 2.36 ± 0.51 1.73 ± 0.97 1.35 ± 0.28 
t1/2 (min) 3.27 ± 0.67 3.82 ± 0.6 5.26 ± 0.88 
t1/2 (min) 18.4 ± 4.9 33.3 ± 23.2 31.9 ± 6.2 
k 10 (1/h) 7.35 ± 1.6 8.37 ± 1.4 6.67 ± 0.75 
k 12 (1/h) 3.89 ± 0.75 2.19 ± 0.54 1.16 ± 0.68 
k 21 (1/h) 4.27 ± 1.1 2.28 ± 1.3 1.66 ± 0.5 
AUC0- (h×µg/l) 485 ± 68.0 1254 ± 171 2559 ± 551 
AUMC (h×h×µg/l) 136 ± 55.1 371 ± 208 635 ± 132 
CL (l/h/kg) 2.09 ± 0.28 1.62 ± 0.21 1.63 ± 0.36 
Vc (l/kg) 0.291 ± 0.04 0.197 ± 0.04 0.244 ± 0.05 
Vp (l/kg) 0.268 ± 0.04 0.299± 0.33 0.163 ± 0.06 
MRT (min) 16.4 ± 4.2 18.1 ± 11.4 14.9 ± 0.53 
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Table 5: PK parameters of 3-HPAA after a single intravenous administration of 1, 2 and 4 
mg/kg b.w., calculated by non-compartmental analysis (mean ± S.D.). 
Dosing group (mg/kg) 2 4 
n 8 6 
C0 (µg/l) 6739 ± 1277 17522 ± 1989 
ke (1/h) 2.39 ± 0.72 2.10 ± 0.9 
t1/2 (min) 19.9 ± 10.2 26.2 ± 17.5 
AUC0-last (h×µg/l) 1243 ± 171 2735 ± 514 
AUC0- (h×µg/l) 1300 ± 191 2804 ± 479 
AUMC0-last (h×h×µg/l) 322 ± 110 778± 375 
AUMC0- (h×h×µg/l) 436 ± 240 909 ± 340 
CL (l/h/kg) 1.57 ± 0.21 1.46 ± 0.24 
Vd (l/kg) 0.732 ± 0.31 0.941 ± 0.8 
MRT (min) 19.7 ± 8 19.2 ± 4.8 
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Table 6: PK parameters of 3-HPAA after a single intravenous dose of 2 and 4 mg/kg b.w., 
calculated by compartmental analysis (mean ± S.D.). A two-compartment model with 1/Ŷ2 as 
a weighting factor was fitted to the data. 
Dosing group 
(mg/kg) 
2 4 
n 8 6 
Cmax (µg/l) 6442 ± 1360 16106± 5942 
A (µg/l) 4671 ± 855 12798 ± 3852 
B (µg/l) 1770 ± 843 3308 ± 2337 
 (1/h) 10.9 ± 4 14.4 ± 10.6 
 (1/h) 2.26 ± 0.77 1.99 ± 1 
t1/2 (min) 4.30 ± 1.6 4.66 ± 3.5 
t1/2 (min) 22.0 ± 13.1 31.2 ± 26 
k 10 (1/h) 5.29 ± 1.2 6.21 ± 2.4 
k 12 (1/h) 3.26 ± 2 3.25 ± 2.4 
k 21 (1/h) 4.65 ± 2 4.76 ± 3.5 
AUC0- (h×µg/l) 1232 ± 182 2642 ± 439 
AUMC (h×h×µg/l) 453 ± 285 923 ± 348 
CL (l/h/kg) 1.65 ± 0.23 1.55 ± 0.25 
Vc (l/kg) 0.322 ± 0.07 0.277 ± 0.1 
Vp (l/kg) 0.253 ± 0.2 0.255 ± 0.1 
MRT (min) 21.5 ± 10.9 20.8 ± 5.8 
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FIGURES 
 
Figure 1: Chemical structures of DOPAC (A), [
2
H]5-DOPAC (B), 3-HPAA (C), and (D) 
[
2
H]2-3-HPAA. 
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Figure 2: Typical MRM chromatograms of the BSA blank spiked with DOPAC at 3000 
ng/ml (ULOQ) and IS at 250 ng/ml (A), the BSA blank (B), the BSA blank spiked with 
DOPAC at 30 ng/ml (LLOQ) and IS at 250 ng/ml (C). 
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Figure 3: Typical MRM chromatograms of the BSA blank spiked with 3-HPAA (quantifier 
only) at 2000 ng/ml (ULOQ) and IS at 250 ng/ml (A), the BSA blank (B), the BSA blank 
spiked with 3-HPAA (quantifier only) at 20 ng/ml (LLOQ) and IS at 250 ng/ml (C). 
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Figure 4: Plasma concentrations of DOPAC (mean ± S.D.) after a single intravenous administration of 1, 2 and 4 mg/kg b.w., shown as linear 
(A) and semi-logarithmic (B) plots. 
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Figure 5: C0 and AUC0-inf (mean ± S.D.) of DOPAC vs. dosing group (solid line) and fitted simple linear regression (dashed line, for visual 
comparison). 
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Figure 6: Observed (mean ± S.D.) and simulated concentrations vs. time profiles of DOPAC 
in rats after a single intravenous dose of 1 (A), 2 (B), and 4 (C) mg/kg b.w. 
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Figure 7: Plasma concentrations of 3-HPAA (mean ± S.D.) after a single intravenous administration of 2 and 4 mg/kg b.w., shown as linear (A) 
and semi-logarithmic (B) plots. 
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Figure 8: Observed (mean ± S.D.) and simulated concentrations vs. time profiles of 3-HPAA 
in rats after a single intravenous dose of 2 (A) and 4 (B) mg/kg b.w. 
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Supporting information Figure 1: Long-term stability of DOPAC in rat plasma with 1% 
ascorbic acid, stored for 89 days below -65°C (n = 3). 
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Supporting information Figure 2: Long-term stability of 3-HPAA in BSA solution (60 g/l), 
stored for 378 days below -65°C (n = 3). 
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Supporting information Table 1: Calibrators and calibration curve parameters of DOPAC (n = 14). 
Response: A × Conc.
2
 + B × Conc. + C, Quadratic regression, 1/X weighting. 
 
 
 
 
 
 
 
 
 
 
 
Supporting information Table 2: Calibrators and calibration curve parameters of 3-HPAA (n = 14). 
Response: A × Conc.
2 
+ B × Conc. + C, Quadratic regression, 1/X weighting. 
 
 
 
 
 
 
 
 
 
Concentration (ng/ml) Regression parameters 
 30 100 200 500 1000 2000 3000 A B C r
2
 
Mean 32.7 92.9 192 505 970 1990 2962 0.0067 0.59 0.1 0.9994 
S.D. 1.1 3.06 5.63 12.3 132 27.8 154 0.01 0.73  
CV% 3.37 3.3 2.94 2.44 13.6 1.4 5.2 
RE% 9.09 -7.11 -4.1 0.92 -3.02 -0.48 -1.26 
Concentration (ng/ml) Regression parameters 
 20 50 100 250 500 1000 2000 A B C r
2
 
Mean 19.5 50.6 100 252 502 992 2003 -0.0000000029 0.0034 0.022 0.9991 
S.D. 1.65 3.11 4.15 7.42 11 27.9 55.2 0.00000074 0.00021  
CV% 8.48 6.15 4.14 2.94 2.19 2.81 2.76 
RE% -2.54 1.3 0.34 0.88 0.37 -0.76 0.16 
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Supporting information Table 3: Carry-over assessment of the analyte DOPAC and [
2
H]5-
DOPAC as IS (n = 14). 
 
*: contamination 
  
Run 
No. 
Replicate Peak response (counts) Carry-over (%) Mean Carry-over 
(%) 
  Blank sample LLOQ 
  Analyte IS Analyte IS Analyte IS Analyte IS 
1 1 79.9 0.00 341 5760 23.4 0.00 24 0.00 
 2 550 0.00 2232 41312 24.7 0.00 
2 1 131 0.00 1295 24438 10.1 0.00 12.2 0.00 
 2 314 0.00 2192 43038 14.3 0.00 
3 1 353 0.00 4803 50564 7.35 0.00 7.35 0.00 
 2 *38040 0.00 6613 81322 - 0.00 
4 1 470 0.00 10975 125820 4.28 0.00 5.96 0.00 
 2 1421 0.00 18589 201847 7.65 0.00 
5 1 322 0.00 3608 40423 8.91 0.00 11.1 0.00 
 2 714 0.00 5399 61315 13.2 0.00 
6 1 383 0.00 3991 40772 9.61 0.00 10.7 0.00 
 2 887 0.00 7470 70479 11.9 0.00 
7 1 513 0.00 4998 37418 10.3 0.00 10.1 0.00 
 2 963 0.00 9722 65313 9.9 0.00 
 Mean 12 0.00 
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Supporting information Table 4: Carry-over assessment of the analyte 3-HPAA and [
2
H]2-3-
HPAA as IS (n = 14). 
 
*: LLOQ is outside the acceptance criteria (± 20%), carryover cannot be calculated. 
 
 
 
 
  
Run 
No. 
Replicate Peak response (counts) Carry-over (%) Mean Carry-over 
(%) 
  Blank sample LLOQ 
  Analyte IS Analyte IS Analyte IS Analyte IS 
1 1 0.00 0.00 272 3325 0.00 0.00 0.00 0.00 
 2 0.00 0.00 504 6347 0.00 0.00 
2 1 0.00 0.00 448 5354 0.00 0.00 0.00 0.00 
 2 0.00 0.00 656 7828 0.00 0.00 
3 1 0.00 0.00 334 2899 0.00 0.00 0.00 0.00 
 2 0.00 0.00 *872 3962 - - 
4 1 0.00 0.00 196 2408 0.00 0.00 0.00 0.00 
 2 0.00 0.00 215 3057 0.00 0.00 
5 1 0.00 0.00 152 2431 0.00 0.00 0.00 0.00 
 2 0.00 0.00 219 2831 0.00 0.00 
6 1 0.00 0.00 *179 2544 - - 0.00 0.00 
 2 0.00 0.00 265 2870 0.00 0.00 
7 1 0.00 0.00 317 2889 0.00 0.00 0.00 0.00 
 2 0.00 0.00 309 3064 0.00 0.00 
 Mean 0.00 0.00 
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Supporting information Table 5: Selectivity test of DOPAC, based on three different lots of 
BSA solution (60 g/l), spiked at LLOQ (n = 6). 
 
 
 
 
Supporting information Table 6: Selectivity test of 3-HPAA, based on three different lots of 
BSA solution (60 g/l), spiked at LLOQ (n = 6). 
 
 
 
 
 
Nominal level (ng/ml) 30 
Mean 28.6 
S.D. 3.65 
CV% 12.7 
RE% 10.7 
Nominal level (ng/ml) 20 
Mean 18.7 
S.D. 1.94 
CV% 10.4 
RE% -6.54 
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Supporting information Table 7: Absolute recovery of DOPAC and [
2
H]5-DOPAC (IS) from 
BSA solution (60 g/l) (n = 6). 
 
DOPAC nominal level (ng/ml) 90 1500 2400 
Absolute recovery (%) 57.2 75.4 77.4 
CV% 2.21 1.23 1.22 
SD 1.26 0.93 0.94 
 
 
IS nominal level (ng/ml) 286 
Absolute recovery (%) 82.4 
CV% 1.87 
SD 1.54 
 
 
 
 
Supporting information Table 8: Absolute recovery of 3-HPAA and [
2
H]2-3-HPAA (IS) from 
BSA solution (60 g/l) (n = 6). 
 
3-HPAA nominal level (ng/ml) 60 1000 1600 
Absolute recovery (%) 113 114 106 
CV% 8.94 3.88 8.04 
SD 10.1 4.42 8.53 
 
 
IS nominal level (ng/ml) 143 
Absolute recovery (%) 104 
CV% 4.12 
SD 4.29 
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Supporting information Table 9: Dilution test of DOPAC in BSA solution (60 g/l) at nominal 
concentration of 15000 ng/ml (n = 6). 
 
Nominal level (ng/ml) 15000 
Dilution factor 10X 100X 
Mean 16675 17102 
S.D. 198 201 
CV% 1.19 1.18 
RE% 11.2 14 
 
 
 
 
Supporting information Table 10: Dilution test of 3-HPAA in BSA solution (60 g/l) at 
nominal concentration of 10000 ng/ml (n = 6). 
 
Nominal level (ng/ml) 10000 
Dilution factor 10X 100X 
Mean 10793 11332 
S.D. 207 116 
CV% 1.92 1.03 
RE% 7.93 13.3 
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Supporting information Table 11: Short-term stabilities of DOPAC, expressed as RE% (n = 
6). 
 
Nominal level (ng/ml) 90 2400 
One freeze/thaw cycles below -65°C -0.89 -2.29 
Benchtop at RT for 2 h -8.2 -6.98 
Autosampler at 10°C for 48 h 10.2 4.94 
 
 
 
 
Supporting information Table 12: Short-term stabilities of 3-HPAA, expressed as RE% (n = 
6). 
 
Nominal level (ng/ml) 60 1600 
Three freeze/thaw cycles below -65°C 5.15 7.41 
Benchtop at RT for 4 h -7.43 -3.48 
Autosampler at 10°C for 24 h -0.75 1.57 
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Supporting information Table 13: Stock solution (SS) stability of DOPAC in DMSO, stored 
below -65°C for 204 days and for 6 hours at RT (n = 6). 
 
 
DOPAC SS stored below -65°C for 
204 days with freshly prepared IS 
SS 
DOPAC SS freshly prepared with 
freshly prepared IS SS 
Mean peak  
area ratio 
4.73 4.78 
S.D. 0.017 0.017 
CV% 0.37 0.35 
Difference% -0.99 
 
 
 
 
Supporting information Table 14: Stock solution (SS) stability of 3-HPAA in DMSO, stored 
below -65°C for 431 days and for 4 hours at RT (n = 6). 
 
 
3-HPAA SS stored below -65°C for 
431 days with freshly prepared IS SS 
3-HPAA SS freshly prepared with 
freshly prepared IS SS 
Mean peak 
area ratio 
1.36 1.42 
S.D. 0.01 0.0028 
CV% 0.66 0.19 
Difference% -3.91 
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Supporting information Table 15: Stock solution (SS) stability of [
2
H]5-DOPAC (IS) in 
DMSO, stored below -65°C for 168 days and for 4 hours at RT (n = 6). 
 
 
[
2
H]5-DOPAC SS stored below -65°C 
for 168 days with freshly prepared 
DOPAC SS 
Freshly prepared [
2
H]5-DOPAC SS 
with freshly prepared DOPAC SS 
Mean peak 
area ratio 
0.21 0.21 
S.D. 0.0013 0.00074 
CV% 0.64 0.35 
Difference% -1.45 
 
 
 
 
Supporting information Table 16: Stock solution (SS) stability of [
2
H]2-3-HPAA (IS) in 
DMSO, stored below -65°C for 431 days and for 4 hours at RT (n = 6). 
 
 
[
2
H]2-3-HPAA SS stored below -
65°C for 431 days with freshly 
prepared 3-HPAA SS 
Freshly prepared [
2
H]2-3-HPAA SS 
with freshly prepared 3-HPAA SS 
Mean peak 
area ratio 
0.76 0.76 
S.D. 0.0021 0.002 
CV% 0.27 0.26 
Difference% -0.39 
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Supporting information Table 17: Diagnostic table for a two-compartment model with 1/Ŷ2 as 
a weighting factor fitted to the DOPAC data. 
 
Dosing group (mg/kg) Goodness of fit 
AIC SBC WSSR 
1 -15 -15.8 0.026 
2 -12.8 -13.6 0.039 
4 -6.54 -6.76 0.13 
 
 
 
 
Supporting information Table 18: Diagnostic table for a two-compartment model with 1/Ŷ2 as 
a weighting factor fitted to the 3-HPAA data. 
 
Dosing group (mg/kg) Goodness of fit 
AIC SBC WSSR 
2 -20.9 -21.6 0.018 
4 -15.3 -15.6 0.078 
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3.3 GABAA receptor activity modulating piperine analogs: In vitro metabolic stability, 
metabolite identification, CYP450 reaction phenotyping, and protein binding 
 
Volha Zabela, Timm Hettich, Götz Schlotterbeck, Laurin Wimmer, Marko D. Mihovilovic, 
Fabrice Guillet, Belkacem Bouaita, Bénédicte Shevchenko, Matthias Hamburger, and 
Mouhssin Oufir 
 
Submitted to: European Journal of Pharmaceutical Sciences 
The alkaloid piperine and analogs (SCT-29, LAU 397, and LAU 399) have been previously 
identified as positive allosteric modulators of γ-aminobutyric acid type A (GABAA) 
receptors. We investigated metabolism of piperine and analogs to guide further cycles of lead 
optimization. Metabolic stability of compounds was tested in the presence of pooled human 
liver microsomes. Metabolites were analyzed by UHPLC-Q-TOF-MS, and with the aid of 
metabolite identification software Mass-MetaSite. Unbound fraction in whole blood was 
determined by rapid equilibrium dialysis. CYP450 reaction phenotyping studies were carried 
out with Silensomes
™
. Piperine was the metabolically most stable compound. Aliphatic 
hydroxylation, and N- and O-dealkylation were the major routes of oxidative metabolism. 
Piperine was exclusively metabolized by CYP1A2, whereas CYP2C9 contributed 
significantly in the oxidative metabolism of all analogs. Extensive binding to blood 
constituents was observed for all compounds. 
 
 
 
 
 
My contributions to this publication: development of UHPLC-MS/MS methods for 
quantification of piperine and analogs in potassium phosphate buffer, development of 
UHPLC-Q-TOF-MS methods for qualitative analysis of metabolites, design and performance 
of microsomal stability assays, CYP450 reaction phenotyping, unbound fraction 
determination in whole blood, and metabolite identification, writing the manuscript draft, 
and preparation of figures and tables. 
Volha Zabela 
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 Abbreviations 
au, arbitrary units 
BBB, blood brain barrier 
CYP450, cytochrome P450 
DMSO, dimethyl sulfoxide 
ESI, electrospray ionization 
GABAA, γ-aminobutyric acid type A receptor 
HPLC, high performance liquid chromatography 
HR, high resolution 
IS, internal standard 
MetID, metabolite identification 
MS, mass spectrometry 
MRM, multiple reaction monitoring 
PPB, potassium phosphate buffer 
Q-TOF, quadrupole time-of-flight 
RED, rapid equilibrium dialysis 
TRPV1, transient receptor potential vanilloid type 1 
UHPLC, ultra-high performance liquid chromatography 
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 Abstract 
In a screening of natural products for allosteric modulators of GABAA (γ-aminobutyric acid 
type A receptor), piperine was identified as a compound targeting a benzodiazepine-
independent allosteric binding site. Given that piperine is also an activator of TRPV1 
(transient receptor potential vanilloid type 1) receptors involved in pain signaling and 
thermoregulation, a series of piperine analogs were prepared in several cycles of structural 
optimization, with the aim of separating GABAA and TRPV1 activating properties. We here 
investigated the metabolism of piperine and selected analogs in view of further cycles of lead 
optimization. 
Metabolic stability of the compounds was evaluated by incubation with pooled human liver 
microsomes, and metabolites were analyzed by UHPLC-Q-TOF-MS. CYP450 isoenzymes 
involved in metabolism of compounds were identified by reaction phenotyping with 
Silensomes
™
. Unbound fraction in whole blood was determined by rapid equilibrium 
dialysis. 
Piperine was the metabolically most stable compound. Aliphatic hydroxylation, and N- and 
O-dealkylation were the major routes of oxidative metabolism. Piperine was exclusively 
metabolized by CYP1A2, whereas CYP2C9 contributed significantly in the oxidative 
metabolism of all analogs. Extensive binding to blood constituents was observed for all 
compounds. 
 
Keywords: GABAA, in vitro metabolism, piperine analogs, UHPLC-Q-TOF-MS, 
Silensomes
™
. 
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 1 Introduction 
In a screening of natural products for GABAA (γ-aminobutyric acid type A receptor) 
modulatory properties, the alkaloid piperine was identified as a positive allosteric modulator 
targeting a benzodiazepine-independent binding site (Zaugg et al., 2010). Given that piperine 
is also an activator of TRPV1 (transient receptor potential vanilloid type 1) receptors 
involved in pain signaling and thermoregulation (McNamara et al., 2005), systematic 
structural modifications were carried out in several cycles of optimization, aiming at 
separating GABAA modulatory from TRPV1 activity. A first analog, SCT-66 (Fig. 1), did not 
activate TRPV1 receptors while maintaining GABAA receptor modulatory properties in vitro 
and in vivo (Khom et al., 2013). Subsequently, a library of 76 piperine analogs was prepared. 
Among these, SCT-64 and SCT-29 showed the highest potency and efficacy at GABAA 
receptors, and anxiolytic activity in mice‎ (Schöffmann‎ et‎ al.,‎ 2014).‎ Based on snapshot 
pharmacokinetic data, SCT-29 was selected for the next cycle of medicinal chemistry 
optimization (Schöffmann‎et‎al.,‎2014).‎All analogs synthesized up to this point contained a 
1,3-benzodioxole moiety which is susceptible to metabolic degradation to an ortho-catechol 
that can be oxidized to a reactive ortho-quinone (Attia, 2010; Erve et al., 2013). Therefore, a 
library of 15 aryl-modified analogs was synthesized, of which LAU 397 and LAU 399 
showed the highest efficacy and potency in vitro (Wimmer et al., 2015). Given that to this 
point no experimental drug metabolism data had been recorded, we here evaluated metabolic 
stability and metabolite formation in microsomal incubations of piperine and selected 
compounds from the three cycles of optimization (SCT-29, LAU 397 and LAU 399) to guide 
further cycles of structural modifications. In addition, reaction phenotyping was carried out to 
identify major CYP450 isoenzymes involved in oxidative metabolism of these compounds, 
and unbound fraction in blood was determined with the aid of rapid equilibrium dialysis. 
 
160
 2 Materials and Methods 
2.1 Chemicals and reagents 
Piperine analogs (2E,4E)-5-(benzo[d][1,3]dioxol-5-yl)-N,N-dibutylpenta-2,4-dienamide 
(SCT-29), (2E,4E)-N,N-dibutyl-5-(4-methoxyphenyl)penta-2,4-dienamide (LAU 397), 
(2E,4E)-N,N-dibutyl-5-(thiophen-3-yl)penta-2,4-dienamide (LAU 399) and (2E,4E)-5-
(benzo[d][1,3]dioxol-5-yl)-N,N-dipropylpenta-2,4-dienamide (SCT-64), were synthesized at 
the Vienna University of Technology as described elsewhere (Schöffmann‎ et‎ al.,‎ 2014; 
Wimmer et al., 2015). Piperine‎(≥97.0%),‎Trizma® HCl‎(≥99.0%),‎NaOH‎(≥98.0%),‎MgCl2 
(≥98.0%),‎ EDTA‎ (99.9%),‎ KH2PO4 (≥98.0%),‎ K2HPO4 (≥99.0%),‎ NaH2PO4 (≥99.0%), 
Na2HPO4 (≥99.0%), amodiaquine dihydrochloride‎ (≥99.0%),‎ N-desethylamodiaquine 
dihydrochloride solution (1 mg/ml), 
2
H5-N-desethylamodiaquine dihydrochloride solution 
(100 µg/ml), diclofenac‎ sodium‎salt‎ (≥98.5%),‎ 4′-hydroxy-diclofenac‎ (≥98.0%),‎phenacetin 
(≥98.0%),‎ paracetamol‎ (≥99.0%),‎ 2H4-paracetamol‎ (≥97.0%),‎ dextromethorphan 
hydrobromide‎ monohydrate‎ (≥99.0%),‎ dextrorphan (≥98%),2H3-dextrorphan solution (100 
µg/ml), coumarin‎ (≥99.0%),‎ 7-hydroxycoumarin (≥99.0%), testosterone‎ (≥98.0%),‎ 6--
hydroxytestosterone‎ (≥97.0%),‎ 2H3-6--hydroxy-testosterone solution (100 µg/ml) were 
purchased from Sigma-Aldrich (Steinheim, Germany). Pooled human liver microsomes (50 
donors) were purchased from BioreclamationIVT (Baltimore, USA). NADPH regenerating 
system containing solution A (26 mM NADP
+
, 66 mM glucose-6-phosphate, and 66 mM 
MgCl2 in H2O) and solution B (40 U/ml glucose-6-phosphate dehydrogenase in 5mM sodium 
citrate) was supplied by Corning (Woburn, MA, USA). Silensomes
™
 (>60 donors) and 
homologous controls were from Biopredic International (Rennes, France). Lithium heparin 
human blood (3 donors) was purchased from Blutspendezentrum SRK (Basel, Switzerland). 
Acetonitrile, methanol, formic acid, phosphoric acid, trifluoroacetic acid, and ammonium 
formate and acetate (all HPLC grade) were from BioSolve (Valkenswaard, the Netherlands). 
Dimethyl sulfoxide (DMSO) was from Scharlau (Barcelona, Spain). HPLC grade water was 
obtained by a Milli-Q integral water purification system (Millipore Merck, Darmstadt, 
Germany). A 100 mM potassium phosphate buffer (PPB) consisting of 0.1M KH2PO4 and 
0.1M K2HPO4, sample dilution buffer (PPB with 0.5M EDTA), and a 0.1M Tris/HCl buffer 
supplemented with MgCl2 (5mM) were prepared in-house, adjusted to pH 7.4, filtered, and 
stored at 4°C. 
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 2.2 Microsomal incubations 
Due to non-specific adsorption of piperine and analogs to plastic containers, all incubations 
were conducted in glass vials. Daily working solutions of test compounds were prepared in 
sample dilution buffer from the stock solutions in DMSO, with a final DMSO concentration 
of 0.1-0.2% (v/v) in the incubation mixture. The incubation mixture, with a total volume of 
500 µl, contained PPB, a substrate (1 µM), liver microsomes (0.5 mg proteins/ml), and a 
NADPH regenerating system which initiated the reaction. Reactions were quenched at 0, 15, 
30, 60 min by adding 500 µl of ice-cold acetonitrile with the corresponding internal standard 
(IS): LAU 399 for LAU 397 and SCT-64 for piperine, SCT-29, and LAU 399. Control 
incubations were performed without microsomes, without NADPH, and without both 
microsomes and NADPH to detect possible chemical instability or non-NADPH dependent 
enzymatic degradation. After incubation, samples were centrifuged (11688 g, 4°C) for 10 
min, and 900 µl of supernatant were collected and dried under nitrogen flow (Evaporex EVX-
96, Apricots Designs Inc, USA). Dried residues were redissolved in 200 µl of DMSO by 
shaking on a mixmate (1100 rpm) for 30 min prior to UHPLC-MS/MS analysis. All 
microsomal incubations were performed in triplicate, and the results were expressed as mean 
± S.D. 
2.2.1 Calculations of in vitro half-life and apparent intrinsic clearance 
Typical depletion profiles of the test compounds were obtained from microsomal incubations. 
The percentage of remaining substrates (on a log scale) was plotted against incubation time. 
A linear regression analysis was applied to estimate a slope. Elimination rate constant (ke, 
min
-1
) was calculated using equation 1: 
ke = -slope*2.3     (Eq.1) 
In vitro half-life (t1/2, min) was determined as follows: 
t1/2 = 
0.693
𝑘𝑒
       (Eq.2) 
Apparent intrinsic clearance (CLin,a, µl/min/mg protein) was calculated according to: 
Clin,a = 
𝑉𝑖𝑛𝑐𝑢𝑏∗0.693
𝐴𝑃∗𝑡1/2
      (Eq.3) 
whereby Vincub was the volume of incubation mixture, and AP was the amount of protein in 
the incubation mixture. 
2.3 Microsomal incubations for metabolite identification (MetID) studies 
Microsomal incubations were performed as described above, with a substrate concentration 
of 5 µM. Reactions were terminated after 120 min by adding 500 µl of ice-cold methanol 
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 without internal standard. The same extraction procedure as above was used, but residues 
were reconstituted in 100 µl of methanol. 
2.4 MetID data processing 
MS and MS/MS data were analyzed with Mass-MetaSite version 5.1.1 (Molecular Discovery, 
Pinner, Middlesex, UK) and ACD/Labs MetID (ACD/Labs, Toronto, ON, Canada) 
metabolite identification software packages. 
2.5 Microsomal binding assay 
The extent of non-specific binding of test compounds to human microsomes was determined 
by using rapid equilibrium dialysis (RED) plates with inserts (Thermo Scientific, Waltham, 
MA, USA). Each insert consisted of two chambers separated by a dialysis membrane with a 8 
kDa cut-off. The mixture (500 µl) containing PPB, microsomes (0.5 mg/ml) and test 
compound (1 µM) was loaded into the sample chamber, and 750 µl of PPB were loaded into 
the buffer chamber. The RED plate was sealed with an aluminum foil, and incubated on an 
orbital shaker at 250 rpm, 37°C for 8 h (the time was defined experimentally). After 
incubation, 100 µl of both chambers were collected. Before extraction, 100 µl of PPB were 
added to the microsomal post-dialysis sample, and 100 µl of microsomes (0.5 mg/ml) were 
added to the buffer post-dialysis sample in order to obtain similar matrix effects in LC-
MS/MS analysis. 600 µl of the corresponding IS in ice-cold acetonitrile were added to 
precipitate proteins. Samples were centrifuged (11688 g, 4°C) for 10 min, and 700 µl of 
supernatant were taken and dried under nitrogen flow. The residues were reconstituted in 200 
µl of DMSO, and shaken on a mixmate (1100 rpm) for 30 min prior to UHPLC-MS/MS 
analysis. Microsomal fraction unbound (fu (mic)) was calculated by equation 4. The assay was 
performed in triplicate, and results were expressed as mean ± S.D. 
fu (mic) = 1 – (
𝑃𝐴𝑅𝑚𝑖𝑐−𝑃𝐴𝑅𝑏𝑢𝑓
𝑃𝐴𝑅𝑚𝑖𝑐
)    (Eq.4) 
PARmic is the peak area ratio in microsomal post-dialysis sample, PARbuf is the peak area 
ratio in buffer post-dialysis sample. PAR was calculated from the following equation: 
PAR = 
𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑎𝑛𝑎𝑙𝑦𝑡𝑒
𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝐼𝑆
     (Eq.5) 
The unbound intrinsic clearance (Cin,u, µl/min/mg protein) was calculated according to 
equation 6 (Giuliano et al., 2005). 
Clin,u = 
𝐶𝑙𝑖,𝑎
𝑓𝑢 (𝑚𝑖𝑐)
      (Eq.6) 
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 2.6 Whole blood binding assay 
Pooled human blood (2 males and 1 female) was diluted with PPB (1:1, v/v) to avoid 
clogging of the dialysis membrane. Diluted blood was spiked with the test compound (1 µM), 
and 500 µl were loaded into the sample chamber of a RED plate. 750 µl of PPB were loaded 
into the buffer chamber. The assay was carried out in the same way as described above. The 
unbound fraction was initially calculated in diluted (50%) blood (Eq.7), and then scaled to 
100% using equation 8. The assay was done in triplicate, and the results were expressed as 
mean ± S.D. 
fu50% = 1 – (
𝑃𝐴𝑅𝑏𝑙𝑜𝑜𝑑−𝑃𝐴𝑅𝑏𝑢𝑓
𝑃𝐴𝑅𝑏𝑙𝑜𝑜𝑑
)    (Eq.7) 
PARblood is the peak area ratio in blood post-dialysis sample; PARbuf is the peak area ratio in 
buffer post-dialysis sample. 
fu,blood 100% = 
𝑓𝑢50%
2−𝑓𝑢50%
     (Eq.8) 
2.7 Prediction of human hepatic clearance and extraction ratio from in vitro data 
Physiological scaling factors were used to convert in vitro Clin,u into in vivo Clin (ml/min/kg) 
(Obach, 1999): 
Clin, in vivo = Clin,u* 
45 𝑚𝑔 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠
1 𝑔𝑚 𝑙𝑖𝑣𝑒𝑟
 * 
20 𝑔 𝑙𝑖𝑣𝑒𝑟
1 𝑘𝑔 𝑏𝑜𝑑𝑦 𝑤𝑒𝑖𝑔ℎ𝑡
  (Eq.9) 
The well-stirred liver model was used to predict hepatic metabolic clearance (ClH, ml/min/kg) 
in humans (Gillette, 1971; Rowland et al., 1973; Wilkinson and Shand, 1975): 
ClH = 
𝑄𝐻∗𝑓𝑢,𝑏𝑙𝑜𝑜𝑑∗𝐶𝑙𝑖𝑛,𝑖𝑛 𝑣𝑖𝑣𝑜
𝑄𝐻+𝑓𝑢,𝑏𝑙𝑜𝑜𝑑∗𝐶𝑙𝑖𝑛,𝑖𝑛 𝑣𝑖𝑣𝑜
    (Eq.10) 
QH is the liver blood flow for a healthy adult, and equals 20 ml/min/kg, fu,blood is the unbound 
fraction of the test compound in blood. 
Hepatic extraction ratio was calculated from the following expression (Lau et al., 2002): 
ER = 
𝐶𝑙𝐻
𝑄𝐻
      (Eq.11) 
2.8 In silico prediction of cytochrome P450 (CYP450)-mediated metabolism 
Prediction of CYP450 isoforms involved in the oxidative metabolism of compounds was 
performed with Percepta software (ACD/Labs, Toronto, ON, Canada). The prediction 
outcome was then used to select CYP isoforms for reaction phenotyping (Fig S1). 
2.9 CYP450 reaction phenotyping with Silensomes
™
 
Silensomes
™
 are human pooled liver microsomes in which one given CYP450 isoenzyme has 
been irreversibly inactivated using mechanism based inhibitors (Parmentier et al., 2016). 
Each CYP-Silensome
™
 is associated with a homologous control that is produced under the 
same conditions but without the inhibitor. The following Silensomes
™
 were used: CYP3A4, 
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 CYP2D6, CYP2C9, CYP1A2, CYP2A6, CYP2C8. Control experiments with homologous 
microsomes were performed at the same time as Silensome
™
 incubation. Incubations were 
performed in the same way as microsomal incubations, but Tris/HCl buffer supplemented 
with MgCl2 was used. The metabolized fraction was calculated as follows: 
fm = 1-( 
𝐶𝑙𝑖𝑛 𝑆𝑖𝑙𝑒𝑛𝑠𝑜𝑚𝑒𝑠™
𝐶𝑙𝑖𝑛 𝐶𝑜𝑛𝑡𝑟𝑜𝑙
)    (Eq.12) 
The relative contribution of the CYP of interest was estimated as follows: 
Contribution = (1-(
𝐶𝑙𝑖𝑛 𝑆𝑖𝑙𝑒𝑛𝑠𝑜𝑚𝑒𝑠™
𝐶𝑙𝑖𝑛 𝐶𝑜𝑛𝑡𝑟𝑜𝑙
))*100%  (Eq.13) 
2.9.1 Incubation of CYP-specific substrates with Silensomes
™
 
Silensomes
™
 and control microsomes (0.5 mg/ml) were incubated for 30 min at 37°C with 
200 µM phenacetin (CYP1A2), 100 µM dextromethorphan (CYP2D6), 20 µM amodiaquine 
(CYP2C8), 75 µM testosterone (CYP3A4), 20 µM coumarin (CYP2A6) and 200µM 
diclofenac (CYP2C9). Metabolisation was initiated by addition of 1 mM of NADPH, and the 
reaction was stopped by adding phosphoric acid (0.15M) (v/v). All samples were centrifuged 
at +4°C at 2500 g for 15min. Supernatants were diluted with corresponding ISs (1:1, v/v), 
and analyzed by HPLC-MS/MS to quantify the metabolites formed. The assay was done in 
triplicate, and the results were expressed as mean ± S.D. 
2.10 HPLC-MS/MS analysis 
A 1200SL HPLC system (Agilent, Santa Clara, CA, USA) coupled to an API3200 tandem 
mass spectrometer (AB Sciex, Framingham, MA, USA) was used for the analysis of CYP-
specific substrate incubations with Silensomes
™
. Separation was performed on a Waters 
XSelect HSS T3 C18 column (2.5µm, 4.6 × 75 mm; Waters Corp., Milford, MA, USA) 
heated at 50°C. Quantification was done with electrospray ionization (ESI) in negative or 
positive modes by multiple reaction monitoring (MRM). The ESI source was operated with 
the following settings: curtain gas 50 arbitrary units (au), source temperature 550°C, 
nebulizer gas 50 au, and auxiliary gas 30 au. Ion spray voltage, declustering potential, and 
collision energy were adapted for each analyte and corresponding ISs. The system was 
controlled by Analyst software (version 1.5.2; AB Sciex, ON, Canada). For the positive ion 
mode, the mobile phase consisted of 5mM ammonium acetate in water (A), and 0.3% formic 
acid in a mixture of methanol and acetonitrile (1:1, v/v) (B). For the negative ion mode, the 
mobile phase consisted of 0.01% formic acid in water (A), and acetonitrile (B). The flow rate 
was 1.5 ml/min, and the injection volumes ranged from 5 to 20 µl. 
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 2.11 UHPLC-MS/MS analysis 
An UHPLC 1290 system coupled to a 6460 tandem mass spectrometer (all Agilent 
Technologies, Waldbronn, Germany) was used to analyze the samples from microsomal 
stability, reaction phenotyping, and binding assays. Separation was achieved on a Kinetex 
PFP column (1.7 µm, 2.1 x 50 mm; Phenomenex, Torrance, CA, USA) heated at 55°C. The 
flow rate was 0.5 ml/min, and the injection volume was 5 µl. Quantification was done in 
MRM utilizing an Agilent Jet Stream electrospray ionization source in positive mode. The 
mobile phase consisted of 10 mM ammonium formate with 0.05% formic acid (A), and 
acetonitrile with 0.05% formic acid (B). The gradient started at 1 min with 40% of B and 
increased to 70% of B within 3.00 min, followed by a column washing step with 100% of B 
for 1 min. The source was operated with the following settings: nebulizer pressure 20 psi, 
nozzle voltage 0 V, sheath gas flow 11 l/min, sheath gas temperature 300°C, drying gas flow 
10 l/min, drying gas temperature 320°C, capillary voltage 2500 V. Fragmentor voltage and 
collision energy for each analyte and corresponding IS were as described elsewhere 
(Eigenmann et al., 2016). The system was controlled by MassHunter software (version 7.0; 
Agilent Technologies, Santa Clara, CA, USA). 
2.12 UHPLC-Q-TOF-MS analysis 
An UHPLC 1290 system coupled to a 6540 quadrupole time-of-flight (Q-TOF) mass 
spectrometer (all Agilent Technologies, Santa Clara, CA, USA) was used for high-resolution 
accurate mass measurements. Separation of parent compounds and metabolites was 
performed on a Kinetex PFP column (1.7 µm, 2.1 x 50 mm; Phenomenex, Torrance, CA, 
USA) heated at 55°C. The flow rate was 0.4 ml/min, and the injection volume was 5 µl. Data 
acquisition was performed in MS scan and in targeted MS/MS modes: MS scan 100-1000 m/z 
at 1 Hz, and MS/MS 50-350 m/z also at 1 Hz. The mobile phase consisted of 10 mM 
ammonium formate with 0.05% formic acid (A), and acetonitrile with 0.05% formic acid (B). 
The gradient started at 1 min with 2% of B, from 1-8 min, 25% B, from 8-12 min, 35% B, 
from 12-16 min, 100% B, followed by a column washing step with 100% of B for 1 min, and 
re-equilibration for 3 min. The ESI source was operated in positive mode with the following 
settings: nebulizer pressure 30 psi, nozzle voltage 0 V, sheath gas flow 12 l/min, sheath gas 
temperature 400°C, drying gas flow 12 l/min, drying gas temperature 330°C, capillary 
voltage 2500 V, and fragmentor voltage 175 V. For the collision induced dissociation (CID) 
experiments the fragmentation was performed with two different collision energies of 20 and 
40 V. The precursor isolation mass window of the quadrupole was set to 1.3 m/z at full width 
half maximum. The acquired spectra were automatically recalibrated on-line by reference 
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 ions with exact masses of 121.0509 and 922.0098 m/z. The Q-TOF mass spectrometer was 
operated at 4 GHz analog-to-digital converter rate in dual channel mode at a resolving power 
of 19 000 (measured at m/z 322). The system was controlled by MassHunter Acquisition and 
Qualitative Analysis (version 6.0; Agilent Technologies, Santa Clara, CA, USA). 
 
3 Results 
Metabolic stability of compounds was studied by incubation with pooled human liver 
microsomes. Piperine was the metabolically most stable compound, with a t1/2 of 141 min 
(Fig. 2, and Table 1). SCT-29 and LAU 397 showed t1/2 of approx. 45 min, whereas a t1/2 of 
only 24.9 min was found for LAU 399 (Fig. 2, and Table 1). Apparent intrinsic clearance was 
calculated (Table 1) and used to categorize compounds into low, medium, or high clearance  
(Nassar, 2009). Piperine was thus a low clearance compound, SCT-29 and LAU 397 were 
medium clearance, and LAU 399 was a high clearance compound. However, due to non-
specific binding of substrates to microsomes, the unbound fractions were determined and 
employed to determine unbound intrinsic clearance of each molecule (Table 1). It appeared 
that all analogs had high unbound intrinsic clearance (267-411 µl/min/mg protein). Human 
hepatic clearance and extraction ratio were predicted from in vitro microsomal stability data 
using the liver well-stirred model. In vitro unbound intrinsic clearance of each compound was 
converted into in vivo by applying physiological scaling factors (Table 2). 
Binding of piperine and analogs in whole blood was determined since extensive binding 
negatively affects distribution of the compounds into deeper compartments and hence, 
concentrations at the target site. Unbound fractions of compounds in whole blood were 
determined, and used for the prediction of human hepatic clearance (Table 2). In addition, the 
hepatic extraction ratio was calculated (Table 2) to classify the compounds into low, medium, 
or high extraction categories (Lau et al., 2002). Based on these criteria, all compounds were 
low extraction ratio compounds. 
Metabolite profiles of compounds after incubation with human microsomes were analyzed by 
high resolution (HR)-MS, and the acquired data were further processed by metabolite 
identification software. The presence of a diagnostic product ion from the parent compound 
in the MS spectra of metabolites supported metabolite identification. The fragmentation 
patterns of parent compounds are summarized in Figure S2. For piperine, extracted ion 
chromatograms of the blank, t0, and t120 samples are shown for m/z 201.0547 (diagnostic 
product ion) (Fig. S3). Extracted ion chromatograms of the t120 sample for m/z 201.0547 
(diagnostic product ion), and for m/z 302.1387 and 304.1544 (metabolites) are given in 
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 Figure 3. Microsomal incubation of piperine yielded four metabolites M1-M4 (Table 3). 
Metabolites M1-M3, all with m/z of 302.1387, were formed by hydroxylation of the 
piperidine ring (Fig. 4). M4 (m/z 304.1544) was likely formed via opening of the piperidine 
ring by N-dealkylation, and reduction of the aldehyde (Fig. 4). MS spectra of piperine and 
metabolites are shown in Figure S4. 
For SCT-29, extracted ion chromatograms of the blank, t0, and t120 samples are shown for m/z 
201.0545 (diagnostic product ion) (Fig. S5). Extracted ion chromatograms of the t120 sample 
for m/z 201.0545 (diagnostic product ion), and for m/z 346.2013 (metabolites) are given in 
Figure 5. Microsomal incubation of SCT-29 yielded three metabolites M1-M3 (Table 3) with 
m/z of 346.2013 that was indicative of aliphatic hydroxylation (Fig. 4). MS spectra of SCT-
29 and metabolites are provided in Figure S6. 
For LAU 397, extracted ion chromatograms of the blank, t0, and t120 samples for two 
diagnostic product ions at m/z 187.0752 and 173.0602 are given in Figures S2, S7, and S8. 
Figure 6 shows extracted ion chromatograms of the t120 sample for m/z 187.0752 (diagnostic 
product ion), and for m/z 332.2220 (metabolites), and extracted ion chromatograms of the t120 
sample for m/z 173.0602 (diagnostic product ion), and m/z 318.2061 and 302.2118 
(metabolites) are given in Figure 7. Microsomal incubation of LAU 397 yielded seven 
metabolites M1-M7 (Table 3). Metabolites M1 and M2 with m/z of 318.2061 were formed 
through via O-dealkylation and aliphatic hydroxylation (Fig. 4). Metabolites M3-M5 with m/z 
of 332.2220 were formed by aliphatic hydroxylation, whereas metabolites M6 and M7 with 
m/z of 302.2118 were produced via O-dealkylation (Fig. 4). MS spectra of LAU 397 and 
metabolites are provided in Figures S9 and S10, respectively. 
For LAU 399, extracted ion chromatograms of the blank, t0, and t120 samples for the 
diagnostic product ion m/z 163.0216 are provided in Figure S11, and extracted ion 
chromatograms of the t120 sample for m/z 163.0216 (diagnostic product ion), and m/z 
308.1677 and 306.1522 (metabolites) are shown in Figure 8. Microsomal incubation of LAU 
399 yielded three metabolites M1-M3 (Table 3). M1-2 with m/z of 308.1677 were formed by 
aliphatic hydroxylation, whereas M3 with m/z of 306.1522 was formed through aliphatic 
hydroxylation followed by oxidation of the alcohol (Fig. 4). MS spectra of LAU 399 and 
metabolites are provided in Figure S12. 
CYP450 reaction phenotyping studies were performed with Silensomes
™
. The types of 
Silensomes
™
 for the studies were selected based on the prediction from the CYP450 
substrates module of ACD/labs Percepta 14.0 (Fig. S1), and further validated with CYP450-
specific substrates (Fig. S13). Examples of typical CYP3A4 Silensomes
™
 profiles 
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 with/without enzyme contribution are provided in Figure S14, and results of the reaction 
phenotyping for piperine and analogs are summarized in Figure 9. Piperine and SCT-29 were 
metabolized exclusively by one CYP450 isoenzyme, CYP1A2 and CYP2C9, respectively. 
Metabolism of LAU 397 involved CYP3A4 and CYP2C9, and LAU 399 was metabolized by 
CYP2C9 and CYP1A2. 
 
4 Discussion 
In vitro metabolic stability is routinely assessed in early drug discovery to evaluate stability 
of leads, and to identify metabolically labile sites to guide lead optimization. We here 
investigated the metabolic stability of piperine and selected analogs in the presence of pooled 
human liver microsomes, and calculated in vitro unbound intrinsic clearance for each 
compound. Piperine was identified as the metabolically most stable compound, whereas the 
tested analogs were rapidly metabolized. Metabolites formed by microsomal incubation were 
analyzed. Interestingly, hydroxylation of piperine and analogs preferentially occurred on the 
aliphatic portion of the molecule. However, the exact position of hydroxylation could not be 
established due to a low abundance of metabolites. 
CYP450 reaction phenotyping showed that piperine and SCT-29 are cleared by a single 
enzyme, CYP1A2 and CYP2C9, respectively, and thus are more sensitive to drug-drug 
interactions. CYP2C9 (Zhou et al., 2009) contributed significantly in the oxidative 
metabolism of all analogs. Genetic polymorphism of CYP2C9 may lead to individual 
variations in drug response (Tomalik-Scharte et al., 2008). 
Piperine and all tested analogs exhibited extensive binding to blood constituents, which in 
turn resulted in a low hepatic extraction ratio calculated for all compounds. The strong 
protein binding can be explained by the lipophilicity of piperine (cLogP 3.27) and analogs 
(cLogP 4.70-5.21) (Eigenmann et al., 2016). Highly lipophilic compounds tend to bind 
strongly to plasma proteins, and high lipophilicity also leads to higher metabolic clearance 
(Tsaioun and Kates, 2011). 
 
5 Conclusions 
Piperine analogs (SCT-29, LAU 397, and LAU 399) were rapidly metabolized and showed 
strong binding to blood constituents due to increased lipophilicity. The next cycle of 
medicinal chemistry optimizations should, therefore, focus on reducing lipophilicity, in order 
to decrease metabolic liabilities and extensive protein binding. 
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 Legends for Figures 
Figure 1: Chemical structures of piperine and selected analogs from three cycles of 
optimization. 
Figure 2: Metabolic stability of piperine and selected analogs SCT-29, LAU 397 and LAU 
399 analogs in incubations with pooled human liver microsomes (n = 3). 
Figure 3: Phase I metabolites of piperine produced by microsomal incubation. Extracted ion 
chromatograms of the t120 sample are shown for m/z 201.0547 (diagnostic product ion), and 
for m/z 302.1387 and 304.1544 (metabolites). 
Figure 4: Phase I metabolites of piperine and analogs, as proposed by Mass-MetaSite. 
Figure 5: Phase I metabolites of SCT-29 produced by microsomal incubation. Extracted ion 
chromatograms of the t120 sample are shown for m/z 201.0545 (diagnostic product ion), and 
for m/z 346.2013 (metabolites). 
Figure 6: Phase I metabolites of LAU 397 produced by microsomal incubation. Extracted ion 
chromatograms of the t120 sample are shown for m/z 187.0752 (diagnostic product ion), and 
for m/z 332.2220 (metabolites). 
Figure 7: Phase I metabolites of LAU 397 produced by microsomal incubation. Extracted ion 
chromatograms of the t120 sample are shown for m/z 173.0602 (diagnostic product ion), and 
for m/z 318.2061 and 302.2118 (metabolites). 
Figure 8: Phase I metabolites of LAU 399 produced by microsomal incubation. Extracted ion 
chromatograms of the t120 sample are shown for m/z 163.0216 (diagnostic product ion), and 
for m/z 308.1677 and 306.1522 (metabolites). 
Figure 9. CYP450 reaction phenotyping with Silensomes
™
. The graphs show the relative 
contribution of CYP450 isoenzymes to the oxidative metabolism of compounds. 
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 TABLES 
 
Table 1: Metabolic stability of piperine and analogs in the presence of human liver microsomes (n = 3). Values are expressed as mean ± S.D. 
 
Compound t1/2 (min) Clin,a 
(µl/min/mg protein) 
fu (mic) 
 
Clin,u 
(µl/min/mg protein) 
Piperine 141 ± 33.2 10.3 ± 2.41 0.863 ± 0.213 12.0 ± 2.79 
SCT-29 43.1 ± 5.31 32.6 ± 3.28 0.101 ± 0.0232 322 ± 35.6 
LAU 397 45.7 ± 15.8 32.9 ± 9.00 0.0796 ± 0.0159 411 ± 113 
LAU 399 24.9 ± 5.03 57.6 ± 10.2 0.216 ± 0.0252 267 ± 50.3 
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 Table 2: Prediction of human hepatic clearance and extraction ratio from in vitro microsomal stability data. Values are expressed as mean ± S.D. 
 
Compound Clin,in vivo 
(ml/min/kg) 
fu, blood 
 
ClH 
(ml/min/kg) 
ER 
Piperine 10.8 ± 2.51 0.0303 ± 0.00239 0.317 ± 0.0729 0.0159 ± 0.00364 
SCT-29 290 ± 32.1 0.000344 ± 0.0000598 0.0866 ± 0.00954 0.00433 ± 0.000477 
LAU 397 370 ± 101 0.000245 ± 0.0000763 0.0737 ± 0.0201 0.00368 ± 0.00101 
LAU 399 240 ± 45.3 0.00156 ± 0.000287 0.468 ± 0.0865 0.0234 ± 0.00432 
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 Table 3: Observed phase I metabolites of piperine and analogs. 
 
Compound RT (min) Mass shift Chemical 
structure 
Calculated 
m/z [M+H]
+
 
Observed 
m/z [M+H]
+
 
Mass error 
(ppm) 
Diagnostic 
product ions 
Piperine 13.22 - C17H19NO3 286.1438 286.1440 -0.70 201.0547 
M1 9.17 +15.9949 C17H19NO4 302.1387 302.1386 0.33 201.1029 
M2 9.44 +15.9949 C17H19NO4 302.1387 302.1387 -0.12 201.0547 
M3 9.54 +15.9949 C17H19NO4 302.1387 302.1387 -0.12 201.1026 
M4 9.83 +18.0106 C17H21NO4 304.1543 304.1544 -0.33 201.0551 
SCT-29 13.97 - C20H27NO3 330.2064 330.2065 -0.30 201.0545 
M1 13.30 +15.9949 C20H27NO4 346.2013 346.2014 -0.28 201.0544 
M2 13.45 +15.9949 C20H27NO4 346.2013 346.2015 -0.52 201.0546 
M3 13.57 +15.9949 C20H27NO4 346.2013 346.2017 -1.15 201.0547 
LAU 397 14.00 - C20H29NO2 316.2271 316.2272 -0.43 187.0752 
M1 11.49 +1.9792 C19H27NO3 318.2064 318.2061 0.94 173.0602 
M2 12.03 +1.9792 C19H27NO3 318.2064 318.2062 0.55 173.0601 
M3 13.37 +15.9949 C20H29NO3 332.2220 332.2217 0.90 187.0752 
M4 13.51 +15.9949 C20H29NO3 332.2220 332.2217 0.90 187.0752 
M5 13.61 +15.9949 C20H29NO3 332.2220 332.2220 -0.74 187.0762 
M6 13.63 -14.0157 C19H27NO2 302.2115 302.2118 -0.99 173.0602 
M7 13.71 -14.0157 C19H27NO2 302.2115 302.2113 0.66 173.0596 
LAU 399 13.96 - C17H25NOS 292.1730 292.1736 -2.05 163.0216 
M1 13.11 +15.9949 C17H25NO2S 308.1679 308.1677 0.65 163.0209 
M2 13.34 +15.9949 C17H25NO2S 308.1679 308.1682 -0.97 163.0212 
135.0337 
M3 13.49 +13.9792 C17H23NO2S 306.1522 306.1522 0.02 163.0212 
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FIGURES 
 
Figure 1: Chemical structures of piperine and selected analogs from three cycles of 
optimization. 
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Figure 2: Metabolic stability of piperine and selected analogs SCT-29, LAU 397 and LAU 
399 in incubations with pooled human liver microsomes (n = 3). 
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Figure 3: Phase I metabolites of piperine produced by microsomal incubation. Extracted ion 
chromatograms of the t120 sample are shown for m/z 201.0547 (diagnostic product ion), and 
for m/z 302.1387 and 304.1544 (metabolites). 
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Figure 4: Phase I metabolites of piperine and analogs, as proposed by Mass-MetaSite. 
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Figure 5: Phase I metabolites of SCT-29 produced by microsomal incubation. Extracted ion 
chromatograms of the t120 sample are shown for m/z 201.0545 (diagnostic product ion), and 
for m/z 346.2013 (metabolites). 
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Figure 6: Phase I metabolites of LAU 397 produced by microsomal incubation. Extracted ion 
chromatograms of the t120 sample are shown for m/z 187.0752 (diagnostic product ion), and 
for m/z 332.2220 (metabolites). 
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Figure 7: Phase I metabolites of LAU 397 produced by microsomal incubation. Extracted ion 
chromatograms of the t120 sample are shown for m/z 173.0602 (diagnostic product ion), and 
for m/z 318.2061 and 302.2118 (metabolites). 
 
 
 
182
Figure 8: Phase I metabolites of LAU 399 produced by microsomal incubation. Extracted ion 
chromatograms of the t120 sample are shown for m/z 163.0216 (diagnostic product ion), and 
for m/z 308.1677 and 306.1522 (metabolites). 
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Figure 9: CYP450 reaction phenotyping with Silensomes
™
. The graphs show the relative 
contribution of individual CYP450 isoenzymes to the oxidative metabolism of compounds. 
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Figure S1: Prediction of CYP450 isoenzymes involved in the oxidative metabolism of 
piperine and analogs by ACD/Labs Percepta. Green – confident non-substrate; gray – 
uncertain prediction. 
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Figure S2: Fragmentation patterns of piperine and analogs. 
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Figure S3: Phase I metabolites of piperine produced by microsomal incubation. Extracted ion 
chromatograms of the blank, t0, and t120 samples are shown for diagnostic product ion m/z 
201.0547. 
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Figure S4: MS spectra of piperine and phase I metabolites M1-M4 processed with Mass-
MetaSite. 
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Figure S5: Phase I metabolites of SCT-29 produced by microsomal incubation. Extracted ion 
chromatograms of the blank, t0, and t120 samples are shown for diagnostic product ion m/z 
201.0545. 
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Figure S6: MS spectra of SCT-29 and phase I metabolites M1-M3 processed with Mass-
MetaSite. 
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Figure S7: Phase I metabolites of LAU 397 produced by microsomal incubation. Extracted 
ion chromatograms of the blank, t0, and t120 samples are shown for diagnostic product ion m/z 
187.0752. 
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Figure S8: Phase I metabolites of LAU 397 produced by microsomal incubation. Extracted 
ion chromatograms of the blank, t0, and t120 samples are shown for diagnostic product ion m/z 
173.0602. 
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Figure S9: MS spectra of LAU 397 and phase I metabolites M3-M5 for diagnostic product 
ion m/z 187.0752 processed with Mass-MetaSite. 
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Figure S10: MS spectra of LAU 397 and phase I metabolites M1-M7 for diagnostic product 
ion m/z 173.0602 processed with Mass-MetaSite. 
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Figure S11: Phase I metabolites of LAU 399 produced by microsomal incubation. Extracted 
ion chromatograms of the blank, t0, and t120 samples are shown for diagnostic product ion m/z 
163.0216. 
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Figure S12: MS spectra of LAU 399 and phase I metabolites M1-M3 processed with Mass-
MetaSite. 
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Figure S13: Validation of Silensomes
™
 with CYP450-specific substrates (n = 3): testosterone 
(CYP3A4), dextromethorphan (CYP2D6), diclofenac (CYP2C9), phenacetin (CYP1A2), 
amodiaquine (CYP2C8), coumarin (CYP2A6). The graph shows inhibition of metabolite 
formation in Silensomes
™
 compared to homologous controls. 
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Figure S14: Example of typical CYP3A4 Silensome
™
 profiles for two piperine analogs, showing that LAU 397 (A) is a substrate, whereas SCT-
29 (B) is not metabolized by this isoenzyme. 
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Quantitative UHPLC-MS/MS methods were developed and validated in compliance to 
international regulatory guidelines for industry (1, 2) to support PK studies of kaempferol and 
the metabolites 4-HPAA, 3-HPAA, and DOPAC in rats. Several bioanalytical issues during 
UHPLC-MS/MS method development for DOPAC were encountered, and solved to reach 
acceptance criteria of the regulatory guidelines. Since DOPAC is an endogenous compound 
mainly originating from the neurotransmitter dopamine (3), the use of a surrogate matrix, 
which devoid of the target analyte (4), was mandatory. Bovine serum albumin solution at 60 
g/l was used in this case (5). To prevent non-specific adsorption of DOPAC to plastic 
surfaces, pre-treatment of polypropylene tubes with 0.2% Tween-20 solution was done before 
the preparation of calibrators and quality controls (5). The example of DOPAC demonstrated 
the importance of bioanalytical method development and validation prior to a study sample 
analysis. 
 
Upon intravenous application, PK of kaempferol followed a one-compartment model, with a 
rapid clearance (4-6 l/h/kg) and an extremely short t1/2 (3-4 min) (6). Upon oral dosing, low 
bioavailability for kaempferol was observed. In plasma the compound was present as phase II 
conjugates (6). Our findings were supported by the results from in vitro intestinal 
permeability assays which showed extensive metabolism of kaempferol in a Caco-2 cell 
model (7). Given that kaempferol undergoes extensive first-pass metabolism, it is more likely 
that the anxiolytic effect reported for this flavonoid is rather attributed to its metabolites. 
 
PK profiles of the major colonic metabolites 4-HPAA, 3-HPAA, and DOPAC were obtained 
after intravenous application. PK of the metabolites followed two-compartment model, with a 
quick distribution (t1/2 = 3-6 min) into peripheral tissues as well as a rapid elimination (t1/2  
= 18-33 min) from the body (5, 6). With such a rapid elimination, pharmacologically relevant 
concentrations of these metabolites in the brain are unlikely to be achieved. Furthermore, 
acidic compounds like 4-HPAA, 3-HPAA, and DOPAC tend to bind, in a large extent, to 
albumin, and thus may have a limited brain penetration. Also, metabolism in the brain needs 
to be taken into account, considering that CYP and UGT enzymatic activities in the brain 
have been reported (8, 9). Taken together, it is not clear at this moment how the anxiolytic-
like properties reported for the metabolites can be explained. 
Further investigations are thus needed to identify pharmacologically active metabolites that 
are brain penetrant. Brain microdialysis experiments complemented with high resolution MS-
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based untargeted metabolomics are planned for the future. Microdialysis technique will be 
employed for sampling the brain interstitial fluid to obtain metabolic profiles of control and 
test groups (10). High resolution MS-based untargeted metabolomics will be applied to 
compare metabolite levels in the brain between the groups (11). Afterwards, metabolomics 
data will be processed with the aid of the statistical software Agilent Mass Profiler 
Professional to uncover significant abundance differences of brain metabolites in control and 
test animals. The metabolites will be identified with the aid of MetID software Mass-
MetaSite. 
 
Specific and robust UHPLC-MS/MS methods for quantification of piperine and its analogs 
were developed to support in vitro metabolism studies of these compounds. Metabolic 
stability of piperine and its analogs was investigated in the presence of pooled human liver 
microsomes. Microsomal stability assays revealed piperine as the metabolically most stable 
compound with a t1/2 of 141 min (12). Analogs SCT-29 and LAU 397 demonstrated similar 
metabolic stability with a t1/2 of around 45 min, whereas analog LAU 399 was shown to be 
the metabolically most unstable compound with a t1/2 of 25 min (12). To obtain metabolite 
profiles of the test compounds after incubation with microsomes, UHPLC-Q-TOF-MS 
methods were developed. The high resolution accurate mass data were further processed with 
the aid of MetID software Mass-MetaSite. The principal routes of oxidative metabolism were 
found to be aliphatic hydroxylation, and N- and O-dealkylation (12). Additionally, CYP450 
reaction phenotyping was performed to determine which CYP isozymes are involved in the 
metabolism of piperine and analogs. It appeared that piperine was exclusively metabolized by 
CYP1A2, whereas CYP2C9 contributed significantly in the oxidative metabolism of all 
analogs (12). Binding characteristics of piperine and analogs in whole blood were examined 
since extensive binding may impact their distribution into tissues. In fact, extensive binding 
to blood constituents was observed for all compounds (12). Summing up the results, it can be 
concluded that analogs were rapidly metabolized and showed strong binding to blood 
constituents due to increased lipophilicity. For analogs LogP values were in the range of 
4.70-5.21 compared to piperine with a LogP 3.27 (13). The next cycle of medicinal chemistry 
optimizations should, therefore, be focused on reducing lipophilicity to lower metabolic 
liability and extensive binding of analogs. Adding polar groups such as hydroxyl, sulfhydryl 
or carbonyl in the molecule can be a solution to reduce lipophilicity (14). 
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